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ABSTRACT
Longitudinal growth of endochondral bones is controlled by the cartilage growth
plate. Chondrocyte proliferation and hypertrophy, vascular invasion, formation of
ossification centers and cartilage replacement by bone tissue are all important processes
required for normal growth. These biological processes have to be tightly regulated or
disturbances will lead to skeletal diseases. A large number of genes, growth factors and
hormones have been implicated in the regulation of growth plate biology, however, less
is known about the intracellular signaling pathways involved. Nitric oxide (NO) has been
identified as a regulator of cellular proliferation, differentiation, migration, survival and
metabolism in multiple cell types. In bone biology, it has been implicated in bone
remodeling and the pathogenesis of osteoarthritis, but the roles of specific nitric oxide
synthase (NOS) enzymes in chondrocyte physiology and cartilage development are
unclear. The goal of this thesis was to analyze the roles of NOS/NO signaling in specific
stages of endochondral bone formation.
We had shown recently that chondrocyte-specific deletion of the Rac1 gene
results in severe dwarfism due to reduced chondrocyte proliferation in mice, but the
molecular pathways involved remained unknown. Employing a Rac1-deficient
monolayer chondrocyte culture, we showed that loss of Rac1 results in severely reduced
levels of inducible nitric oxide synthase (iNOS) protein and NO production. Additionally,
reduced iNOS expression was found in Rac1-decifient mice in vivo. Using a tibia organ
culture system, we showed that NO donors rescued the antiproliferative effects of Rac1
inhibition. Examination of the growth plate of iNOS-deficient mice revealed reduced
chondrocyte proliferation and decreased expression of cyclin D1, while ATF3, a
iii

suppressor of cyclin D1 transcription, showed increased expression. Thus, we identified
iNOS/NO as a novel mediator of Rac1 signaling and ATF3 as a link between iNOS and
chondrocyte cell cycle.
Doe to the skeletal phenotypes we observed in iNOS-deficient mice, my next study
investigated effects of inactivation of endothelial nitric oxide synthase (eNOS) on
cartilage development in mice. eNOS-deficient mice showed increased lethality and
reduced bone growth, delayed ossification and a marked reduction in the number of
proliferating chondrocytes. The mechanisms leading to these bone phenotypes appear to
be caused by decreased cyclin D1 and increased p57 expressions in mutants, resulting in
slower cell cycle progression and earlier cell cycle exit. Additionally, expression of early
chondrocyte markers such as Sox9 was reduced and prehypertrophic markers were
upregulated in mutant mice.
Because my studies had shown upregulation of nNOS in eNOS-null cartilage, next
I analyzed the skeletal phenotype of nNOS-deficient mice. Transient growth retardation,
reduced length of long bones, less trabecular bone and decreased mineralization were
shown in nNOS KO mice. Reduced proliferating chondrocyte numbers in mutants may in
part be due to premature cell cycle exit, shown by reduced cyclin D1 and upregulated p57
expressions. Similar to the other two mutant strains, ATF3 was a link between nNOS and
reduced cyclin D1 expression. In addition, I demonstrated increased apoptosis, reduced
early chondrocyte markers such as Sox genes and increased prehypertrophic markers
RORα and c-Fos in mutant mice. Together, these data suggest that NOS/NO presents a
core signaling pathway to regulate chondrocyte proliferation and differentiation through
control of cell cycle protein.
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CHAPTER ONE

INTRODUCTION AND LITERATURE REVIEW

2

1.1 Introduction
1.1.1 The function of bones
The skeletal system is one of the major organ systems in the human body and made
up of 206 bones (Docherty, 2007a). The most obvious and one of the most important
skeletal functions is to provide a framework that supports the human body and protects
internal organs such as brain, spinal cord, heart, lungs, liver, and kidneys. There are also
many other functions of the skeletal system that are essential for other processes in the
human body. The bones in our body are joined and facilitate muscle contractions to move
and perform our daily work. The skeleton is also a regulator of metabolism and acts as a
reservoir of minerals such as calcium and phosphorous (Karsenty et al., 2009).
Additionally, bone marrow is a place for hematopoiesis, where the formation of new
blood cells takes place.
1.1.2 The organization of the human skeletal system
The human skeletal system is perpendicularly symmetrical in nature. It consists of
the axial and the appendicular skeletons. The axial skeleton includes bones of the
vertebral column, thoracic and rib cages, sternum and skull. It is made up of 80 bones
(Docherty, 2007b). The main function of the axial skeleton is the protection of organs,
like heart, brain and lungs, and maintaining the upright position of the body. The
appendicular skeleton is attached to the axial skeleton, including pectoral girdles
(shoulder portion), upper limbs, pelvic girdle (hip portion) and lower limbs. Body
movements are possible because of these bones (Docherty, 2007b).
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1.1.3 Skeletogenesis
The process by which bones are formed is called ossification. Ossification is an
extremely complex, life-long process (Docherty, 2007a). Formation of the adult skeleton
is achieved through two independent mechanisms: intramembranous and endochondral
ossification (Beier, 2005; Olsen et al., 2000). In intramembranous bone formation,
mesenchymal cells directly differentiate into osteoblasts. Some of the craniofacial bones
are formed this way. Endochondral ossification (EO) is the process responsible for
formation of the majority of bones in the vertebrate skeleton (Teixeira et al., 2008;
Wagner and Karsenty, 2001). EO starts from mesenchymal cells that condense at the
position of future bone, through a complex process of chondrogenesis to form a highly
controlled and precisely shaped cartilage template (Ballock and O'Keefe, 2003). The
cartilage template grows through chondrocyte proliferation and differentiation to
establish the cartilage growth plate that ultimately drives the longitudinal growth of the
bone. This process eventually determines the adult height (Fig. 1.1). Long bones such as
femur are formed through this process. Finally, a process of growth and remodeling after
birth (in a growth and maintenance phase) results in a skeleton which is well adapted to
its function as an organ not only for support and protection of internal organs, but also for
movement , blood cell formation and regulation of calcium homeostasis.

1.2 Endochondral bone formation
1.2.1 Chondrogenesis
Endochondral ossification is initiated by aggregation of mesenchymal cells,
followed by cell differentiation into chondrocytes through the process of chondrogenesis.

4

Figure 1.1 Overview of endochondral ossification.
During embryogenesis, mesenchymal cells start to aggregate and condense at the location
of future bone. They then differentiate into chondrocyte in the center of these
condensations through chondrogenesis. Chondrocytes proliferate and differentiate within
these condensations leading to the formation of cartilage anlagen. At the periphery of the
condensations, cells flatten, elongate and form the perichondrium. These chondrocytes
also keep proliferating to expand the cartilage template. Eventually, cells at the center of
this template terminally differentiate into hypertrophic cells. Perichondral cells adjacent
to hypertrophic chondrocyte become osteoblasts, forming a bone collar. Hypertrophic
chondrocyte direct mineralization of the surrounding cartilage matrix, attract blood vessel
invasion, and then undergo apoptosis. Osteoblasts form early trabecular bone adjacent to
the hypertrophic chondrocytes, forming the primary spongiosa. Epiphyseal growth plates
form at the both ends of the long bone with unique organization of the chondrocytes. At
the end of the bone, the secondary ossification center forms through cycles of
chondrocyte hypertrophy, vascular invasion and osteoblast activity.
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Chondrogenesis is a highly complex process leading to the formation of a cartilage
template (Provot and Schipani, 2005). Early condensations can be found in the human
fetus at 6.5 week of gestation and at 10.5 days (E10.5) of embryonic mouse development
(Kaufman, 1992). At this time point in development, the shape, number and position of
future skeletal elements are decided (Goldring et al., 2006). Members of the Sox family
of transcription factors (Sox9, Sox5 and Sox6) are required for this early differentiation
(Wagner and Karsenty, 2001). Sox9 is one of the earliest markers expressed in cells
undergoing condensation. Sox9 transcript is detected in all prechondrogenic
mesenchymal condensation as early as 8.5-9.5 days of mouse embryonic development
(Kaufman, 1992), and the expression peaks in cartilage at E11.5-14.5 days (Asou et al.,
2002). Sox5 and 6 are not found in condensations, but they are co-expressed with Sox9
during differentiation (Wagner and Karsenty, 2001). Cells in the condensations
differentiate to chondrocytes and deposit an extracellular matrix specific for cartilage,
consisting of molecules such as collagens II, IX, and XI and proteoglycans (e.g.
aggrecan). At the border of the condensations, chondrocytes differentiate to flattened
elongated cells to form the perichondrium (Kronenberg, 2003).

All these events

contribute to the establishment of cartilage anlagen for the future bone elements (Fig.
1.1). Cartilage anlagen can be observed at 7 weeks of human and 11.5 days of mouse
embryonic development (Olsen et al., 2000; Kaufman, 1992).
1.2.2 Epiphyseal growth plate
Once mesenchymal cells commit to the chondrogenic lineage, the subsequent
events of EO occur through the epiphyseal growth plate. Longitudinal bone growth
dictates the final height of human bodies and is dependent on the activity of the growth
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plates (Provot and Schipani, 2005). The growth plate is established around the end of the
first trimester in human fetal development and around embryonic day 15 in mice
(Kaufman, 1992). The growth plate is a unique structure where specific chondrocyte
populations are organized in distinct zones (e.g. zones of resting, proliferating, and
hypertrophic chondrocytes) based on their morphology, cellular activities and gene
expression patterns (Ballock and O'Keefe, 2003) (Fig. 1.1). Within these zones, the
chondrocytes are organized in distinguishable columnar arrays and express different
matrix proteins (Olsen et al., 2000).
The resting chondrocytes are small round cells in a relatively quiescent state and
located furthest away from the primary ossification center. It is believed that some of
these cells have stem-like properties, and can give rise to the neighboring proliferative
zone (Ballock and O'Keefe, 2003). Within this zone of the growth plate, flattened
proliferating chondrocytes are organized in a columnar array, and proliferation of
chondrocytes occurs in a unidirectional manner, resulting in longitudinal growth of the
bone (Hunziker, 1994). Both resting and proliferating chondrocytes express extracellular
matrix (ECM) molecules, such as collagen II and aggrecan (Kronenberg, 2003).
Throughout chondrogenesis, the balance of signaling by growth factors such as bone
morphogenetic proteins (BMPs) and fibroblast growth factors (FGFs) determines the rate
of proliferation (Hoffmann and Gross, 2001). Chondrocyte proliferation is also under
control of cell-cycle proteins, such as cyclin D1 and A (Beier, 2005; Karsenty and
Wagner, 2002; Kronenberg, 2003).
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1.2.3 Chondrocyte hypertrophy and extracellular matrix production
Chondrocytes in the center of the cartilage mould then stop proliferating, start to
differentiate into prehypertrophic cells, and eventually enlarge to terminally differentiated
hypertrophic chondrocytes under the control of several cell cycle genes and different
transcription factors (Colnot, 2005; Karsenty and Wagner, 2002; Kronenberg, 2003). The
transcription factor RUNX2 (runt related transcript factor 2) is required for this terminal
chondrocyte differentiation (Olsen et al., 2000; Provot and Schipani, 2005). It has been
shown that chondrocyte hypertrophy is responsible for 60% of long bone growth, and the
rest is due to both matrix synthesis and chondrocyte proliferation (Hunziker, 1994;
Hunziker and Schenk, 1989; Nilsson et al., 1994).
Hypertrophic chondrocytes are the principle regulators of the subsequent events of
bone growth (Karsenty and Wagner, 2002; van der Eerden et al., 2003). They change
their gene expression pattern to synthesize type X collagen, direct the mineralization of
their extracellullar matrix, attract blood vessel invasion through the production of
vascular endothelial growth factor (VEGF), activate osteoclasts to digest the matrix, and
direct adjacent perichondral cells to become osteoblasts, which then secret a matrix rich
in type I collagen and form a bone collar around the center of the cartilage template
(Goldring et al., 2006; Kronenberg, 2003) (Fig. 1.1). Hypertrophic chondrocytes then
undergo apoptotic cell death (Shum and Nuckolls, 2002). The cartilage matrix provides a
scaffold for osteoblasts to lay down bone matrix within it (Ballock and O'Keefe, 2003;
Kronenberg, 2003; Lefebvre and Smits, 2005; Lotz et al., 1999; Olsen et al., 2000).
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1.2.4 Blood vessel invasion and ossification centers
VEGF and other angiogenic factors secreted by hypertrophic chondrocytes recruit
endothelial cells from the surrounding blood circulation, and trigger vascular invasion
from the periosteum (once vascularized, the perichondrium becomes the periosteum)
(Hunziker, 1994). This invasion brings osteoclasts and hematopoietic cells into the
mineralized cartilage. The newly recruited osteoclasts start to degrade the mineralized
matrix (Drissi et al., 2005; Hunziker, 1994). Osteoblasts are also recruited from the
periosteum, and lay down a new bone-specific matrix on the remains of the hypertrophic
cartilaginous matrix. With the formation of the early trabecular bone, the primary
spongiosa is established from the middle of the growth plates and eventually develops
into a primary ossification center (POC) (Fig. 1.1). Another step in endochondral bone
formation is the formation of secondary ossification centers (SOCs), which initiate at a
late stage of the development. They start to appear at postnatal day 5 or 6 in mice (Olsen
et al., 2000; van der Eerden et al., 2003). These centers form in the middle of epiphyseal
cartilage after establishment of the growth plates. After formation of the secondary
ossification center, the epiphyseal cartilage is now separated from the growth plate by the
SOC and will eventually develop into articular cartilage at the far end of bone, which
provides an important cushion during the whole adult life (Hunziker and Schenk, 1989)
(Fig. 1.2). The longitudinal growth of the bone continues to depend on the activity of the
epiphyseal growth plates between primary and secondary ossification centers (Ballock
and O'Keefe, 2003). In humans, it closes during puberty (when primary and secondary
ossification centers fuse) and eventually determines adult height (Shum and Nuckolls,
2002).
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Figure 1.2 The formation of secondary ossification centers.
The secondary ossification centers (SOC) form in the middle of the epiphyseal cartilage
after establishment of growth plates. At this point, the epiphyseal cartilage that is now
separated from the growth plate by the SOC will eventually develop into articular
cartilage at the far end of bone, which provides an important cushion during the whole
adult life. The longitudinal growth of the bone continues to depend on the activity of the
epiphyseal growth plates between primary and secondary ossification centers. In humans,
the growth plates close during puberty and eventually determine adult height. The
mechanisms leading to the formation of the secondary ossification centers are similar to
the formation of primary ossification centers. (POC: primary ossification center).
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The mechanisms leading to the formation of the secondary ossification centers are
similar to the formation of primary ossification centers. The formation of secondary
ossification centers is delayed in cartilage disease, such as spondyloepiphyseal dysplasia
(Zelzer and Olsen, 2003).
1.2.5 Bone modeling and remodeling
The last step in bone development is the tissue modeling and remodeling. Bone
tissues experience consistent modeling and remodeling during development and in adult
life, through the coordinated activity of bone-forming osteoblasts and bone-resorbing
osteoclasts (Docherty, 2007a; Karsenty and Wagner, 2002; Olsen et al., 2000; Ortega et
al., 2004). Cytokines released from bone resorption by osteoclasts activate osteoblast
precursors to lay down cyclically shaped osteoid that is then mineralized to form new
osteon (Holmbeck and Szabova, 2006; Olsen et al., 2000). Communication between
bone-forming osteoblasts, bone-resorbing osteoclasts and other bone cells regulates bone
turnover in balancing the normal remodeling sequence under control of local and
systemic bone remodeling pathways (Holmbeck and Szabova, 2006).

1.3 Systemic control and local regulators of longitudinal growth
1.3.1 Endocrine factors
The process of longitudinal bone growth is governed by a complex network of
endocrine

signals,

including

growth

hormone,

insulin-like

growth

factor

I,

glucocorticoids, thyroid hormone, estrogen, androgen, vitamin D, and leptin (Nilsson et
al., 2005). Many of these signals regulate growth plate function, both by acting locally on
growth plate chondrocytes and indirectly by modulating other endocrine signals in the
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network (Nilsson et al., 1994). Some of the local effects of hormones are mediated by
changes in paracrine factors that control chondrocyte proliferation and differentiation
(Nilsson et al., 1994). Many human skeletal growth disorders are caused by abnormalities
in the endocrine regulation of the growth plate (Nilsson et al., 1994; van der Eerden et al.,
2003; Zelzer and Olsen, 2003), some of which are discussed below.
1.3.1.1 Growth Hormone (GH) and insulin-like growth factors (Igfs)
GH is a peptide hormone secreted by the pituitary gland that stimulates growth and
cell reproduction. Igfs are peptide hormones secreted from many different cells (Nilsson
et al., 2005). GH and Igfs are potent stimulators of longitudinal bone growth (Mushtaq et
al., 2004). GH excess, due to pituitary adenomas in childhood, results in gigantism.
Conversely, GH deficiency or insensitivity due to GH-receptor mutations or defects in
GH signaling pathways markedly impairs postnatal growth (Osafo et al., 2005). Mice
lacking the GH gene exhibit normal birth weight, but a reduction in postnatal growth
(Osafo et al., 2005). Mice lacking either the Igf-1 or Igf-2 genes show intrauterine growth
retardation with birth weights approximately 60% that of wild-type littermates (Wang et
al., 2006). The original somatomedin hypothesis stipulates that the effects of GH on
linear growth are mediated by stimulating Igf-1 expression, including in chondrocytes
(Hunziker, 1994; Nilsson et al., 1994; Nilsson et al., 2005).
1.3.1.2 Glucocorticoids
Glucocorticoids are widely used as anti-inflammatory and immunosuppressive
drugs in children (Silvestrini et al., 2000). Long-term, high-dose glucocorticoid treatment
often leads to growth failure and osteoporosis (Silvestrini et al., 2000). Similarly,
systemic administration of glucocorticoids in mice, rats, and rabbits decreases the rate of
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longitudinal bone growth, by inhibiting growth plate chondrocyte proliferation
(Silvestrini et al., 2000). In addition, glucocorticoids may stimulate apoptosis of growth
plate chondrocytes (Nilsson et al., 1994). The local effects of glucocorticoids on growth
plate chondrocyte proliferation may be mediated, in part, by changes in the local Igf-I
system (Nilsson et al., 2005; Silvestrini et al., 2000).
1.3.1.3 Thyroid hormone
The thyroid hormones, thyroxine (T4) and triiodothyronine (T3), are tyrosinebased hormones produced by the thyroid gland and primarily responsible for regulation
of metabolism. Thyroid hormone is necessary for normal skeletal growth and maturation
(Stevens et al., 2000). Hypothyroidism slows longitudinal bone growth and endochondral
ossification, while hyperthyroidism accelerates both processes (Nilsson et al., 1994). In
hypothyroid animals, there is a decrease in the heights of the proliferative and
hypertrophic zones, and a decrease in chondrocyte proliferation, hypertrophy, and
vascular/bone cell invasion (Stevens et al., 2000). Additionally, the normal columnar
organization of the growth plate is disrupted (Stevens et al., 2000). Some of the skeletal
effects of thyroid hormone appear to be due to a direct action on the growth plate
(Nilsson et al., 1994).
1.3.2 Local regulatory mechanisms in the growth plate
Proliferation and hypertrophy of growth plate chondrocytes and ECM production
drive the longitudinal growth of endochondral bones and eventually determine body
length in mammals (Beier, 2005; Kronenberg, 2003; Okazaki and Iwamoto, 2006). Many
growth factors and transcription factors control these processes. Bone morphogenetic
proteins (BMPs) and the central transcription factor Sox 9 regulate early chondrocyte
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differentiation (Beier, 2005; Karsenty and Wagner, 2002). Chondrocyte proliferation is
under control of Indian hedgehog (Ihh), parathyroid hormone-related protein (PTHrP)
and Fibroblast growth factor (FGF) signaling, and cell-cycle genes, such as Cyclin D1
and A (Beier, 2005; Kronenberg, 2003). Eventually, chondrocytes differentiate to mature
hypertrophic cells under control of the transcription factor RUNX2 among others
(Karsenty and Wagner, 2002; Kronenberg, 2003; Shum and Nuckolls, 2002) (Fig. 1.3).
VEGF and RANKL mediate angiogenesis and osteoclast activation respectively along
with other growth factors (Olsen et al., 2000). Other local factors include transforming
growth factor β, and Wnt families (Beier, 2005; Nilsson et al., 2005; Olsen et al., 2000;
Teixeira et al., 2008).
1.3.2.1 The Ihh/PTHrP negative feed-back loop
Ihh is a master regulator of bone development, coordinating chondrocyte
proliferation, chondrocyte differentiation and osteoblast differentiation (Kronenberg,
2003). During endochondral ossification, Ihh is synthesized by prehypertrophic and early
hypertrophic chondrocytes within the growth plates. It binds to its receptor Patched-1
(Ptc-1), causing activation of Smoothened (Smo), which then triggers a cascade leading
to gene activation (Kronenberg, 2003; Wagner and Karsenty, 2001). PTHrP is secreted
from perichondral cells and resting chondrocytes at the ends of long bone. It acts on
receptors on proliferating chondrocytes to keep them in the proliferative pool (Nilsson et
al., 2005). The interaction of Ihh and PTHrP leads to the hypothesis that these two
paracrine factors together control the number of chondrocytes in the proliferative pool
through a feed-back loop (Karp et al., 2000; Kronenberg, 2003). When chondrocytes
close to the hypertrophic zone are no longer sufficiently stimulated by PTHrP, they stop
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Figure 1.3 Local regulators of growth plate and life cycle of chondrocyte.
Longitudinal growth of the cartilage growth plate is under control of many secreted
factors and endogenous regulators such as transcription factors. Each stage of
chondrocyte is characterized by express specific molecular markers and matrix proteins
(in red): the aggregates of mesenchymal cells express BMPs and Sox family proteins;
resting cells express Sox proteins, PTH/PTHrP, FGFR2 and collagen II; proliferative
chondrocytes express FGFR3, cell cycle proteins such as Cyclins D1 and A, and collagen
II and aggrecan;

prehypertrophic cells are under control of the transcription factor

RUNX2, and express Ihh and FGFs; hypertrophic cells express collagen X, MMP13 and
ALP in bone matrix.
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proliferating and start to synthesize Ihh. Ihh then acts on its receptor on chondrocyte to
increase the rate of proliferation and also stimulates the production of PTHrP at the ends
of growth plates through an unknown mechanism (Wagner and Karsenty, 2001). Ihh also
acts on perichondrial cells to convert these cells into osteoblasts of the bone collar (Karp
et al., 2000).
1.3.2.2 Opposing actions of BMPs and FGFs
FGFs are secreted proteins that act through tyrosine kinase receptors. The FGF
family of proteins consists of at least 23 structurally related polypeptides that play a
critical role in a variety of biological processes. FGF1, 2, 4, 8, 9, and particularly 18
(Provot and Schipani, 2005), and their four receptors are expressed during endochondral
bone formation (Ornitz and Marie, 2002). It has been shown that FGF signaling regulates
chondrocyte proliferation and differentiation (Karsenty and Wagner, 2002; Kronenberg,
2003; Ornitz and Marie, 2002). FGF receptor 3 (FGFR3) is expressed in proliferating
chondrocytes; FGFR1 is expressed in prehypertrophic and hypertrophic chondrocytes and
perichondrium; and FGFR2 is expressed in the perichondrium and primary spongiosa
(Kronenberg, 2003). FGF18 is expressed in the perichondrium, and acts on FGFR 3 to
decrease chondrocyte proliferation, to increase the production of Ihh, and to accelerate
the differentiation of hypertrophic chondrocyte into terminal differentiated chondrocytes
(Ornitz and Marie, 2002). BMPs are members of the TGF-β family of paracrine factors,
which have essential roles at every stage of endochondral bone development (Hoffmann
and Gross, 2001). They act on each of these steps, sometimes in a manner opposite to the
effects of FGFs (Kronenberg, 2003). They accelerate chondrocyte proliferation, increase
Ihh production and stimulate terminal chondrocyte differentiation, as shown by the

19

expression of osteopontin and other molecular markers (Kronenberg, 2003; Ornitz and
Marie, 2002).
1.3.2.3 CNP regulation of endochondral bone growth
The natriuretic peptide family consists of three structurally related peptides: atrial
natriuretic peptide (ANP); brain natriuretic peptide (BNP); and c-type natriuretic peptide
(CNP) (Pejchalova et al., 2007; Yasoda and Nakao, 2009). These molecules regulate a
number of biological processes through intracellular cGMP pathways, by acting through
two different membrane-bound receptors: GC-A (NPR-A) and GC-B (NPR-B) (Yasoda
and Nakao, 2009). CNP acting through its receptor, NPR-B, plays an important role in
endochondral ossification (Teixeira et al., 2008). A number of recent studies of genetic
mouse models and organ cultures demonstrated its role in vivo and in vitro (Agoston et
al., 2007; Chikuda et al., 2004; Chusho et al., 2001; Miyazawa et al., 2002; Pejchalova et
al., 2007; Teixeira et al., 2008; Yasoda et al., 2004). CNP-deficient mice display
dwarfism due to impaired endochondral bone formation (Chusho et al., 2001; Pejchalova
et al., 2007). The deficient mice have a narrow growth plate with a significant reduction
in the hypertrophic zone (Chusho et al., 2001; Miyazawa et al., 2002). Npr2 (NPR-B) KO
mice have a similar bone phenotype as CNP KO mice (Bartels et al., 2004; Miyazawa et
al., 2002). Metatarsals from fetal rats and tibia isolated from mouse embryos treated with
CNP showed increased bone growth (Agoston et al., 2007; Mericq et al., 2000).
Chondrocyte proliferation was modestly increased. The most significant characteristic of
CNP treatment was increased hypertrophic zone length, due to both increase in size and
number of hypertrophic chondrocytes (Agoston et al., 2007; Teixeira et al., 2008).
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However, while many extracellular regulators of cartilage development and
transcription factors controlling growth plate function have been identified, much less is
known about the intracellular signaling pathways. Over the years, nitric oxide (NO) has
been identified not only in bone cell metabolism (van't Hof and Ralston, 2001) but also
been shown to be involved in endochondral bone formation (Teixeira et al., 2005) and the
communication between different cell types in bone (Ralston et al., 1995; van't Hof and
Ralston, 1997).

1.4 Nitric oxide and Bone
1.4.1 The discovery of NO
Nitric oxide (NO) was first discovered as an endothelial-derived relaxation factor
more than two decades ago (Furchgott, 1999; Ignarro, 1999). NO physiology soon
became one of the most rapidly growing research areas in biology. The importance of the
pioneering work on this small molecule was recognized by the 1998 Nobel Prize in
Physiology and Medicine to Drs. Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad.
1.4.2 The physiological functions of NO
NO can function as an intracellular messenger, an autacoid, a paracrine substance, a
neurotransmitter, or as a hormone that can be carried to distant sites for the effects
(Murad, 1999). The versatile functions of NO come from the chemical properties of the
compound. NO is a gaseous uncharged free radical with an unshared electron that makes
it easy to react with many molecules in order to regulate biological processes (Moncada
et al., 1991). Because it is uncharged, it can freely diffuse to the surrounding cells,
making it ideal as a signaling molecule (Teixeira et al., 2008). In most processes, NO
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activates soluble guanylyl cyclase (sGC) and causes increased levels of the intracellular
secondary messenger cGMP (Moncada et al., 1991; Murad, 1999). However, the reactive
properties of NO and the derivatives of NO were found to play important roles in its
biological functions too (Lundberg et al., 2008; Marshall et al., 2004; Moncada et al.,
1991). For example, NO can interact with superoxide rapidly to form peroxynitrite,
which is known to induce smooth muscle cell lipid peroxidation during inflammation
(Lundberg et al., 2008). The functions of NO cover almost every biological aspect, for
example, in the cardiovascular system it causes vascular relaxation, prevents platelet
aggregation, inhibits leukocyte adhesion and scavenges superoxide anions (Ignarro, 1999;
Moncada and Higgs, 1993). It is also a neurotransmitter at synaptic endplates in the vagal
system (Moncada and Higgs, 1993; Murad, 2006). The ultimate effects of NO are
determined by its level, its origin, and by what else in the microenvironment it will react
to (Moncada et al., 1991).
1.4.3 NO synthesis and regulation
NO is generated through nitric oxide synthase (NOS) enzymes by oxidizing a
guanidino nitrogen of L-arginine to NO and L-citrulline (Moncada and Higgs, 1993;
Murad, 2006) (Fig. 1.4). NOS proteins use complex cosubstrates, including molecular
oxygen, NADPH, FAD, FMN and heme iron groups, and require the cofactors
calmodulin and BH4 to bind the enzyme as a homodimer (Murad, 2006). This reaction
has to occur at adequate oxygen and cofactor levels (BH4, NADPH), or the uncoupling of
the electron will form superoxide instead of NO (Moncada and Higgs, 1993; Murad,
2006). The enzyme activity can be inhibited by substituted arginine analogues such as
LNMMA and LNAME. NO can also be generated non-enzymatically from nitrite in the
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Figure 1.4 Generation of NO from NOS.
NO is formed by NOS enzymes through oxidizing a guanidino nitrogen of L-arginine to
NO and L-citrulline. This reaction usually occurs at adequate oxygen and cofactor levels
(BH4, NADPH). The enzyme activity can be inhibited by substituted arginine analogues
such as L-NAME, and NO can also be generated pharmacologically by compounds in
vitro such as organic nitrates, sodium nitroprusside or nitroglycerin. There are three NOS
proteins, nNOS, iNOS and eNOS. nNOS and eNOS activities are regulated by
intracellular calcium and calmodulin. Cytokines can induce iNOS to produce NO at a
high level for a prolong time period.
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acid environment of the stomach (van't Hof and Ralston, 2001) and pharmacologically by
compounds such as organic nitrates, sodium nitroprusside or nitroglycerin, which have
been used clinically for treatment of angina pectoris for over two centuries (Murad,
1999).
Three different NOS proteins have been identified so far. The neuronal form of
NOS (nNOS or NOS1) was first identified in brain (Moncada and Higgs, 1993), then
found to be expressed in many cell types. The endothelial form of NOS (eNOS or NOS3)
was first discovered in endothelial cells (Ignarro, 1999), but most cell types express
eNOS. The inducible form of NOS (iNOS or NOS2) can be induced by LPS or many
inflammatory cytokines in almost every cell type and plays an important role in
inflammatory diseases (Furchgott, 1999) (Tab. 1.1). These proteins are encoded by three
different genes on different chromosomes and have about 50-60% homology with each
other and the cytochrome P450 enzymes (Murad, 2006).
Both eNOS and nNOS (collectively called cNOS) constitutively produce NO at
low levels (picomolar range) in many cell types. Their activity is mainly regulated by
changes in intracellular Ca2+ concentration and activities of calmodulin (Ignarro, 1999;
Moncada et al., 1991; Scher et al., 2007). Expression of eNOS has been shown to be
activated by phosphorylation at serine 1177 by many signaling pathways, such as heatshock protein (HSP90), Akt or acetylcholine (Ach) (Feelisch, 2008; Forstermann and
Kleinert, 1995). Additionally, eNOS gene promoter activity is enhanced by shear stress
and changes in estrogen levels (Armour et al., 2001a; Klein-Nulend et al., 1998; van't
Hof and Ralston, 2001). Consistent with this, eNOS mRNA level has been found to be
increased in endothelial cells after exposure to physiological concentration of estrogen
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(Armour et al., 2001a) and in response to shear stress (Klein-Nulend et al., 1998). nNOS
protein is found in the synaptic endplates, scarcoplasic reticulum, and mitochondria
(Feelisch, 2008) and is upregulated upon activation of synaptic endplates in the central
nervous system (Moncada et al., 1991). The regulation of nNOS expression seems to be
very complex as reflected by at least eight different promoters transcribing eight different
exon sequences in different cell types (Forstermann and Kleinert, 1995).
In contrast, iNOS is capable of generating large quantities of NO (nanomolar
range) over a prolonged time period. However, because iNOS activity depends on
transcription, response to external stimuli is not as rapid as that of cNOS. Properties of
these three NOS are summarized in Table 1. (Tab. 1.1). Activation of the transcription
factor NF-κB seems to be an essential step for iNOS induction in most cells (Feelisch,
2008). iNOS can be activated by the endotoxin LPS and by pro-inflammatory cytokines,
such as interleukin 1 (IL-1), tumor necrosis factor alpha (TNFα) and interferon γ (INFγ)
through NF-κB pathways, whereas glucocorticoids and the anti-inflammatory cytokines
IL-4, IL-10 and TGFβ are inhibitory (van't Hof and Ralston, 2001). It is now clear that
the iNOS promoter is markedly upregulated by several cytokines and endotoxins
(Forstermann and Kleinert, 1995). Interestingly, different combinations of cytokines
differ in their abilities to produce NO in different cell types. For example, human
chondrocytes can be induced by single cytokines such as IL-1β or TNFα to produce NO,
whereas human primary osteoblasts require two or three cytokines for significant
induction of NO production (Ralston, 1997).
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Table 1.1 Sumary table of Nitric Oxide Synthases (NOS)

Constitutive
NOS

Inducible
NOS

Isoforms

Examples of
source

Calcium/
Calmodulin

Characters

Examples of
Function

nNOS, NOS1

Brain

Dependent

eNOS, NOS3

Macrophage

Dependent

Picomole NO Learning
fast release;
Short lasting;
Signaling
molecule;
Vasodilation
Stimulated
by Ach

iNOS, NOS2

Endothelium Independent Nanomole
NO slow
release;
Long lasting;
Induced by
cytokines

Cytotoxicity
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Additionally, high levels of NO produced by iNOS actually inhibit NF-κB activity
itself, thus limiting iNOS and NO production in a negative feed-back loop (Moncada et
al., 1991). Recently, cNOS were also found to be inducible by cytokines while iNOS was
found constitutively expressed in many cell types (Feelisch, 2008) including
chondrocytes (Rosa et al., 2008).

1.4.4 Molecular pathways of NO action
NO is a gaseous uncharged free radical with an unshared electron, making it very
reactive. Because it is uncharged, it can freely diffuse to surrounding cells once it’s
formed (Murad, 1999). In most processes, NO from cNOS serves as a messenger
molecular and its physiological functions are mediated by its direct activation of the
heme-containing moiety of sGC in target cells (Collin-Osdoby et al., 1995). Activation
of sGC causes an increase in the intracellular cGMP levels (Moncada and Higgs, 1993;
Moncada et al., 1991). cGMP is a very important second messenger in many cell types
and interacts with specific binding sites in target proteins, including cGMP-dependent
protein kinases (PKG), cGMP-binding proteins (e.g. phosphodiesterases, PDEs) and
cGMP-dependent ion channels (e.g. ICH) (Feelisch, 2008; Murad, 2006) (Fig. 1.5).
Activation of PKG triggers a cascade of phosphorylation events that culminate in the
alteration of various cellular processes, e.g. cell proliferation, smooth muscle relaxation,
cytotoxicity and neurotransmission (Collin-Osdoby et al., 1995).
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Figure 1.5 Molecular pathways of NO in cartilage.
Once NO is produced, it can freely diffuse to surrounding cells and activates sGC, which
causes an increase in the intracellular secondary messenger cGMP levels. cGMP is a very
important second messenger in many cell types and interacts with specific binding sites
in target proteins, including cGMP-dependent protein kinases (PKG), cGMP-binding
proteins (e.g. phosphodiesterases, PDEs) and cGMP-dependent ion channels (e.g. ICH).
An important role of cGMP-dependent protein kinase II (PKGII) in bone formation has
been identified. Mice lacking PKGII or its upstream activator C-type natriuretic peptide
(CNP) demonstrated severe skeletal phenotypes and dwarfism. Possible downstream
pathways of cGKII include the inhibition of nuclear translocation of transcription factor
SOX9, suppression of FGF signaling, and activation of MAPK (p38 and ERK). (Adapted
from Teixeira et al., 2008)
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In contrast, high concentrations of NO, for example from iNOS, can bind to tyrosine or
cysteine residues of many thiol containing proteins and lead to nitration and nitrosylation
of the proteins (Lundberg et al., 2008; Marshall and Stamler, 2001; Stamler et al., 2001).
For example, S-nitrosylation of glutathione, leads to inhibition of glutathione and other
redox-signaling regulation pathways (Stamler et al., 2001).
1.4.5 Mechanisms of nitrite, nitrate, peroxynitrite
The half life of NO is only a few seconds because it converts to nitrite and nitrate
shortly after it is formed (Furchgott, 1999). These products have been used as markers of
NO formation for a long time. It is clear now that these derivatives of nitrogen are
responsible for many biological effects of NO. For example, nitrite has been shown to
protect tissues against ischemia/reperfusion-related injuries in several organs (Feelisch,
2008). This is particularly important for cartilage, because cartilage is an avascular tissue,
and the oxygen level is only about 1-6% in deeper articular chondrocytes (Hirao et al.,
2006; Schipani et al., 2001). NO formation by NOS requires abundant oxygen levels,
while nitrite formation is independent of oxygen. Therefore, when oxygen levels fall
below a critical threshold, nitrite and nitrate react to mediate indirect effects of NO, and
nitrite reduction to NO may serve to prevent a drop in NO concentration (Feelisch, 2008).
At the same time, NO can interact with superoxide to form the very reactive
peroxynitrite and hydroxyl radicals that are responsible for tissue damage during
inflammatory process by inducing lipid peroxidation (Feelisch, 2008). Peroxynitrite
becomes a marker for inflammation and formation of NO in many cell types (Stamler et
al., 2001).
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1.4.6 Expression of NOS proteins in cartilage
All three NOS proteins are expressed in chicken, and NO derivatives accumulate in
the calcified region of the chicken cartilage (Teixeira et al., 2005), suggesting a role of
NOS genes in cartilage development. iNOS was found spontaneously expressed in
normal human articular cartilage, but at a higher level in chondrocytes from osteoarthritis
(OA) (Rosa et al., 2008). This implies an important role of iNOS in articular cartilage,
and indeed iNOS is speculated to participate in almost every aspect of

OA

pathophysiology (Abramson, 2008; Abramson et al., 2001; Amin and Abramson, 1998;
Feelisch, 2008; van den Berg, 2001).
Over years NO has been known to regulate bone cell metabolism and bone
remodeling (Abramson, 2008; Teixeira et al., 2008; van't Hof and Ralston, 2001).
Recently, with the reported roles of cGKII and CNP as regulators of endochondral bone
formation, the biological role of NO in bone formation has been investigated further.
1.4.7 NO in cartilage development and endochondral bone formation
In vitro studies suggest that NO signaling is required for chondrocyte maturation
(Teixeira et al., 2005). In chicken cartilage, NO synthesis is required for development of
the mature chondrocyte phenotype by upregulating alkaline phosphatase (ALP) and type
X collagen expression (Teixeira et al., 2005). Inhibition of NOS, sGC, or cGK blocked
retinoic-acid induced chondrocyte maturation in vitro (Kirimoto et al., 2005). High levels
of NO, whether from nitric oxide donors or endogenously induced by cytokines, has been
shown to induce chondrocyte apoptosis, and recently this apoptosis has been linked to
generation of reactive oxygen species in chondrocyte (Lotz et al., 1999). Interestingly, a
study showed that low levels of NO protect chondrocytes from cell death through
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upregulation of heme oxygenase 1 (HO-1) and NF-κB, and concomitant downregulation
of both extracellular signaling regulated protein kinases ERK 1/2 and p38 activation
(Kim et al., 2005).
In recent years, a study of genetically altered mice discovered that eNOS gene
knockout mice display reduced bone volume and bone formation at 6 weeks of age, but a
normal bone phenotype was restored at 12-18 weeks (Aguirre et al., 2001). Another study
showed that eNOS knockout mice present limb deficiencies with short digits, reduced
weight and delayed growth (Hefler et al., 2001). It was proposed that these abnormities
were caused by insufficient blood flow to the limbs and hemorrhage. However, the exact
mechanism and role of eNOS in earlier stages of skeletal development is not well
understood. Other groups demonstrated that nNOS knockout mice present higher bone
mineral density in 10-week old female mice, particularly in trabecular bone (van't Hof et
al., 2004). Moreover, administration of NOS inhibitors to drinking water of pregnant rats
induced fetal growth retardation and hindlimb disruptions in pups (Diket et al., 1994).
However, because of potential compensatory mechanism between the three NOS proteins
and the possibility of non-specific actions of NOS inhibitors, the in vivo role of NO and
NOS genes in endochondral ossification still waits to be elucidated.
Interestingly, double knockout mice for two NOS genes do not display significant
growth defects as also shown for triply knockout mice of all three NOS genes (Sabanai
et al., 2008; Teixeira et al., 2008). However, the double and triple knockout mice present
high frequency of embryonic lethality and very low survival rates postnatally (15% in
triple knockout mice) (Sabanai et al., 2008; Teixeira et al., 2008).

This suggests

occurrence of major abnormalities during development in most embryos. Postnatal death
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of triple knockout mice is mostly due to spontaneous myocardial infarction accompanied
by severe coronary arteriosclerotic lesions (Nakata et al., 2008), but the surviving
knockout mice surprisingly live a normal life. This suggests that other effects may
compensate for loss of all three NOS genes. One study of triple knockout mice showed
increased bone mineral density in 12-20 week-old mice, but these parameters were
normal in younger (4 week-old) mice (Sabanai et al., 2008). This study also demonstrated
increases in bone formation rate, mineral apposition rate, and serum alkaline phosphatase
concentration in triple knockout mice (Sabanai et al., 2008). These results further confirm
the role of NOS in bone homeostasis. More generally, analyses of mice with inactivation
of two or all three NOS genes suggest that the phenotypes of these mice are variable,
ranging from very mild phenotypes to lethality (Teixeira et al., 2008). More detailed
studies on the knockout mice and other compensatory mechanisms need to be completed.
1.4.8 Effects of NO on bone remodeling, osteoblasts and osteoclasts
NO appears to have biphasic effects on osteoblasts and osteoclasts. The constitutive
production of NO at low concentrations promotes the proliferation and differentiation of
osteoblasts and modulates osteoblast function. Some investigators have shown that slow
release of NO donors stimulates osteoblast proliferation and differentiation in vitro, while
NOS inhibitors had little effects on them (MacPherson et al., 1999). eNOS signaling was
found to be important for the osteoblast lineage (Grassi et al., 2006). Several studies
showed reduced bone formation in eNOS knockout mice accompanied by reduced
osteoblast number and mineralization (alkaine phosphatase, ALP and mineral deposition)
in vivo and in vitro (Aguirre et al., 2001). Additionally, eNOS signaling was shown to be
essential for estrogen and mechanical loading induced bone formation (Armour et al.,
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2001a; Furchgott, 1999). Another study revealed that eNOS may act to mitigate an
exaggerated state of estrogen-deficiency-induced bone remodeling (Aguirre et al., 2001).
nNOS knockout mice present reduced bone remodeling with reduced remodeling surface
and a reduction in osteoblast numbers in vivo (van't Hof et al., 2004). In contrast, high
concentrations of NO are also inhibitory for the osteoblast lineage, and NO production
induced by IL-1β, TNF-α, and IFN-γ appears to be partly responsible for the inhibitory
effects on osteoblast proliferation (Evans and Ralston, 1996) and on the promotion of
osteoblast differentiation and apoptosis (Lotz et al., 1999). As a result, high levels of NO
and iNOS regulate osteoblast function and inhibit bone formation with important
implications for the pathogenesis of inflammation-mediated osteoporosis (Armour et al.,
2001b).
These results also support the idea that moderate induction of NO potentiates bone
resorption. NO therefore appears to be an important regulatory molecule for both
osteoblast and osteoclast lineages and represents one of the molecules produced by
osteoblasts which directly regulate osteoclastic activity (Evans and Ralston, 1996).
It is now well-established that a high concentration of NO is a potent inhibitor of
osteoclast-mediated bone resorption. When combined with other cytokines, IFN-γ
markedly induces NO production, which suppresses osteoclast formation and activity of
mature osteoclasts (Brandi et al., 1995). This high concentration of NO is largely
responsible for the selective inhibitory effect of IFN-γ on cytokine-induced bone
resorption. It is suggested that the inhibitory effects of NO on bone resorption are partly
explained by induction of apoptosis in osteoclast progenitors rather than osteoclast
formation (Ralston, 1997). Therefore, it is of interest to study the selectivity of NO-
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induced bone cell apoptosis and the communication between bone cells, and it is of
clinical relevance that modulating NO concentrations may have therapeutical potential.
There is no evidence to support a role of eNOS for normal osteoclast formation
and activity under physiological conditions in knockout mice (van't Hof and Ralston,
2001). nNOS knockout mice present reduced bone remodeling and a reduction in
osteoclast numbers in vivo, suggesting a role of nNOS in stimulation of bone turnover
(van't Hof et al., 2004).
1.4.9 Downstream targets of NO in bone
The cellular pathways downstream of NO in skeletal cells are complex and poorly
understood. As discussed above, an important role of cGMP-dependent protein kinase II
(PKGII) in bone formation has been identified (Chikuda et al., 2004; Pfeifer et al., 1996).
Mice lacking PKGII or its upstream activator C-type natriuretic peptide (CNP)
demonstrated severe skeletal phenotypes and dwarfism (Chusho et al., 2001; Miyazawa
et al., 2002; Pejchalova et al., 2007; Pfeifer et al., 1996). Because both NO and CNP
stimulate the production of cGMP via soluble or particulate guanylyl cyclases (GC)
(Chusho et al., 2001), the cGMP/cGKII pathway would be a likely mediator of NO
signaling in cartilage. Identification of the downstream targets of cGKII in bone
formation is under investigation by several groups. Some studies of CNP signaling
suggested that possible downstream pathways of cGKII include the inhibition of nuclear
translocation of transcription factor SOX9 (Miyazawa et al., 2002), suppression of FGF
signaling, and activation of MAPK (p38 and ERK) (Agoston et al., 2007; Teixeira et al.,
2008; Yasoda et al., 2004) (Fig. 1.5). In agreement with these models, IL-1 caused a
release of FGF in rabbit articular chondrocyte and stimulated cell proliferation, which
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was blocked by NOS inhibition (Jang and Murrell, 1998). However, cGKII is not the
only downstream target of NO (Feelisch, 2008; Kim et al., 2005). The role of cGKI and
the indirect effects of the NO derivatives nitrite, nitrate, and peroxynitrite in individual
bone cells need to be studied further.

1.5 Overall objectives and hypotheses
1.5.1 Rational
Endochondral ossification is controlled by a process of chondrogenesis,
chondrocyte proliferation, differentiation and eventually hypertrophy. During postnatal
development, proliferation and hypertrophy occur in a controlled fashion in the cartilage
growth plate, regulating the full length of adult bone. As we discussed above, NO
promotes chondrocyte maturation and apoptosis in vitro, and NOS genes play an
important role in bone formation and remodeling. However, little is known about the role
of these genes in the cartilage growth plate and in early endochondral bone formation.
The recent identification of CNP/cGMP/cGKII as important regulators of endochondral
bone formation provides further motivation to study the role of NO/NOS in growth plate
development and endochondral ossification. The overall objective of this study was to
identify the effects of the NO/NOS pathways on specific events during the endochondral
ossification

process,

differentiation.

in

particular

chondrocyte

proliferation

and

hypertrophic
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1.5.2 Overall hypothesis
NOS/NO controls endochondral ossification by regulating chondrocyte
proliferation and differentiation.

1.5.3 Research plan and specific aims
1.5.3.1 Aim 1: Analyze the roles of iNOS/NO in growth plate physiology and its
interaction with the Rac1 gene in vivo
Objective: We had shown recently that chondrocyte-specific deletion of the Rac1 gene in
mice leads to severe dwarfism due to reduced chondrocyte proliferation, but the
molecular pathways involved remained unclear. Our study examined the iNOS/NO
pathway as a novel mediator of mitogenic Rac1 signaling and implicated it as a target for
therapies for growth disorders.
Hypothesis: iNOS/NO signaling mediates mitogenic signaling of Rac1 gene in cartilage
Main findings:
1. Rac1-deficient chondrocytes display severely reduced levels of iNOS protein and
NO production. NO donors reversed the proliferative effects induced by Rac1
deficiency, whereas inhibition of NO production mimicks the effects of Rac1 loss
of function.
2. Examination of the growth plate of iNOS-deficient mice revealed reduced
chondrocyte proliferation and lower expression of cyclin D1, a key regulator of
chondrocyte proliferation.
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3. Rac1-NO signaling inhibits the expression of ATF3, a known suppressor of cyclin
D1 expression in chondrocytes, identifying ATF3 as a link between Rac1/iNOS
and the chondrocyte cell cycle.

1.5.3.2 Aim 2: Characterize the roles of eNOS/NO pathway in growth plate
physiology in vivo
Objective: NO has been implicated both in the bone remodeling and pathogenesis of
osteoarthritis, but the role of specific NOS enzymes in chondrocyte physiology is unclear.
The objective of this study was to examine the effects of inactivation of eNOS on
cartilage development using genetically modified mice.
Hypothesis: eNOS/NO signaling promotes endochdondral bone growth through direct
effects in growth plate chondrocytes.
Main findings:
1. eNOS-deficient mice show increased lethality and reduced bone growth, with
hypocellular growth plates and a marked reduction in the number of proliferating
chondrocytes.
2. In vitro studies demonstrated lower chondrocyte numbers and reduced
endochondral bone growth in mutants, suggesting that the role of eNOS signaling
in chondrocyte proliferation is cell-autonomous.
3. Reduced chondrocyte numbers appear to be caused by decreased cyclin D1 and
increased p57 expression in mutants, resulting in slower cell cycle progression
and earlier cell cycle exit.
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4. The prehypertrophic markers P57, RORα and Hif-1α were expressed prematurely
in mutant mice.

1.5.3.3 Aim 3: Determine the roles of nNOS/NO pathway in cartilage growth plate in
vivo
Objective: We recently described the effects of eNOS deficiency on cartilage
development. Interestingly we found an upregulation of nNOS transcription levels in
eNOS-deficient cartilage. Therefore, now we extended these studies to mice deficient for
nNOS.
Hypothesis: nNOS/NO signaling promotes chondrocyte proliferation and inhibits
differentiation in the cartilage growth plate in vivo.
Main findings:
1. nNOS-null mice show transient growth retardation and shorter long bones. nNOSdeficient growth plates display a marked reduction in replicating proliferating
chondrocytes.
2. Histological sections also demonstrated thinner cortical bone and fewer trabeculae
in mutant mice.
3. Reduced chondrocyte numbers may in part be due to premature cell-cycle exit
because of decreased cyclin D1 and increased p57 expression in mutants.
4. Increased chondrocyte apoptosis was shown by increased cleaved-caspase 3
staning in mutants.
5. Expressions of prehypertrophic markers p57, RORα, and c-Fos were increased,
while the expression of Hif1α was not changed in mutants.
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CHAPTER TWO

iNOS/NITRIC OXIDE SIGNALING MEDIATES THE MITOGENIC
ACTIVITY OF RAC1 DURING ENDOCHONDRAL BONE GROWTH*

*This chapter has been reproduced from:
Wang, G.*, Yan, Q. *, Woods, A., Feng, Q. and Beier, F. iNOS/nitric oxide signaling
mediates the mitogenic activity of Rac1 during endochondral bone growth. (*contributed
equally). We are currently revising this manuscript for J. of Cell Science.
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2.1 Chapter summary
Coordinated proliferation and differentiation of growth plate chondrocytes controls
endochondral bone growth and final height in humans, and disruption of this process
results in diseases of the growing and adult skeleton such as chondrodysplasias or
osteoarthritis. We had shown recently that chondrocyte-specific deletion of the Rac1 gene
in mice leads to severe dwarfism due to reduced chondrocyte proliferation, but the
molecular pathways involved remained unclear. Here, we demonstrate that Rac1deficient chondrocytes display severely reduced levels of iNOS protein and NO
production. NO donors reversed the proliferative effects induced by Rac1 deficiency,
whereas inhibition of NO production mimicks the effects of Rac1 loss of function.
Examination of the growth plate of iNOS-deficient mice revealed reduced chondrocyte
proliferation and expression of cyclin D1, a key regulator of chondrocyte proliferation.
Finally, we demonstrate that Rac1-NO signaling inhibits the expression of ATF3, a
known suppressor of cyclin D1 expression in chondrocytes, identifying ATF3 as a link
between Rac1/iNOS and the chondrocyte cell cycle. In conclusion, our studies identify
the iNOS/NO pathway as a novel mediator of mitogenic Rac1 signaling and implicate it
as a target for therapies for growth disorders.
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2.2 Introduction
Growth of endochondral bones is regulated by the coordinated proliferation and
differentiation of growth plate chondrocytes (Kronenberg, 2003; Olsen et al., 2000). Cell
volume increase during hypertrophy provides one driving force for bone growth, while
ordered proliferation is required for generation of sufficient cell numbers for subsequent
hypertrophy (Beier, 2005). Thus, inhibition of either proliferation or hypertrophy can
both result in dwarfism. Numerous diseases are caused by disruption of these processes,
for example by gene mutations, endocrine imbalances and mechanical or nutritional
influences. Many growth factors and hormones have been shown to regulate chondrocyte
proliferation, including fibroblast growth factors, parathyroid hormone-related peptide,
and Indian hedgehog (Ballock, 2003; van der Eerden et al., 2003). However, the
intracellular mechanisms controlling chondrocyte proliferation and hypertrophy are much
less understood.
We have previously reported that chondrocyte-specific inactivation of the Rac1
gene, encoding a Rho family GTPase with a central role in cellular signaling pathways,
causes dwarfism and numerous skeletal abnormalities (Wang et al., 2007). A similar
phenotype of reduced long bone growth was observed upon limb-specific inactivation of
the Rac1 gene (Morita et al., 2007). Rho family GTPases act as molecular switches that
become activated in response to specific extracellular stimuli through the activity of
guanine nucleotide exchange factors (GEFs) that load GTP onto the GTPase (Heasman
and Ridley, 2008; Vega and Ridley, 2007; Vega and Ridley, 2008). Activated Rho
proteins then interact with a large variety of downstream effectors, including cytoskeletal
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regulators and various kinases, to control a number of cellular events such as cell
migration, cell cycle progression and gene expression.
The defects we observed in cartilage-specific Rac1 KO mice appear to be due, at
least to a large part, to reduced chondrocyte proliferation (Wang et al., 2007), but the
downstream mechanisms connecting Rac1 to chondrocyte proliferation are unknown.
Rac1 has been shown to control many cellular processes, including actin dynamics, gene
expression and generation of reactive oxygen species (ROS) (Bustelo et al., 2007;
Hordijk, 2006). There are many interactions between ROS and NO (Thomas et al., 2008);
however, NO or the enzymes involved in its synthesis have not been identified as major
mediators of Rac1 signaling. Three different NOS have been identified, eNOS, iNOS and
nNOS (endothelial, inducible and neuronal NOS, respectively) (Bryan et al., 2009). Here
we identify iNOS as a novel target of Rac1 that mediates the mitogenic activities of this
pathway during endochondral bone growth.
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2.3 Materials and methods
2.3.1 Animals and materials
Timed-pregnant CD1 mice were purchased from Charles River Laboratories at
embryonic day 15.5 mice (E15.5). S-nitroso-N-acetylpenicillamine (SNAP), 2,2'(Hydroxynitrosohydrazino)

bis-ethanamine

(NOC-18),

and

the

Rac1

inhibitor

(NSC23766) were obtained from Calbiochem. N (G)-nitro-L-arginine methyl ester (LNAME), 3-morpholinosydnonimine (SIN-1) and sodium nitroprusside (SNP) were
obtained from Sigma and reconstituted in Dimethyl sulfoxide (DMSO, vehicle) according
to the manufacturer's instructions. Cell culture materials and general chemicals were
obtained from Invitrogen, Sigma or VWR unless otherwise stated.
The following antibodies were employed in this study: iNOS #ab15323-500, and
eNOS #ab3868-100 (abcam); Rac1 #sc-217, Nitrotyrosine #sc-32757, ATF3 #sc-188,
Goat-anti-mouse #sc-2005, and Goat-anti-rabbit #sc-2004 (all from Santa Cruz
Biotechnology); Cyclin D1 (SP4) #9104-S1 (NeoMarkers Inc.); BrdU #03-3900 (Zymed
Laboratories).
2.3.2 Mouse breeding and genotyping
Mice with a deletion of the iNOS gene (NOS2tm1Lau, stock# 002609) (Laubach et al.,
1995) and control mice with C57/BL6 background were obtained from Jackson
Laboratory (Bar Harbor, ME), and exposed to a 12-h light–dark cycle and fed tap water
and regular chow at libitum. All procedures involving animals were approved by the
University of Western Ontario Animal Care and Use Committee. For PCR genotyping,
tail snips were used to prepare DNA for PCR analysis. PCR genotyping was performed
by simultaneous amplification of the wild-type and null iNOS alleles as described
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(Tranguch and Huet-Hudson, 2003). PCR fragments were analyzed by agarose gel
electrophoresis.
2.3.3 Primary cell culture and treatments
Primary chondrocytes were isolated essentially as described (James et al., 2006;
Woods et al., 2009c). Long bones from limbs were isolated from E15.5 mouse embryos
and placed in α-MEM media (Invitrogen) containing 0.2% Bovine Serum Albumin
(BSA), 1 mM β-glycerophosphate, 0.05 mg/ml ascorbic acid and penicillin/streptomycin.
Then the medium was removed and the bones placed in 4 ml of 0.25% trypsin-EDTA
(Invitrogen) for 15 min at 37°C. Trypsin was subsequently replaced with 1 mg/ml
collagenase P (Roche) in DMEM/10% fetal bovine serum (Invitrogen), and cells were
incubated at 37°C with rotation at 100 rpm for 90 min. Following digestion, the cell
suspension was centrifuged for 5 min at 1000 rpm, and the collagenase containing
supernatant was decanted. Chondrocytes were resuspended in medium containing 2:3
DMEM:F12, 10% fetal bovine serum, 0.5 mM L-glutamine, and penicillin/streptomycin
(25 units/ml). Cells were seeded in 6-well NUNC plates at a density of 5 × 104 cells per
ml and incubated overnight. Primary monolayer chondrocytes were treated with 10-3 M
L-NAME, 10-5 M SNAP or NOC-18 or the DMSO control (vehicle) diluted in fresh
media supplemented with 0.25 mM ascorbic acid (Sigma) and 1 mM β-glycerophosphate
(Sigma) and incubated for up to 5 days with replacement of the medium and treatments
every other day.
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2.3.4 Adenoviral infections
Adenovirus expressing Cre Recombinase or GFP (control) was purified using the
Adeno-XTM virus mini-purification kit (Clontech) and incubated with primary
chondrocytes from Rac1fl/fl mice at a multiplicity of infection (MOI) of 50. Four hours
after culturing, medium was changed and cells were cultured as described above.
2.3.5 ROS and NO measurements
Intracellular ROS and NO were measured fluorometrically. The nonfluorescent dye
2′,7′-dichlorofluorescein diacetate (DCF-DA) permeated cells easily and hydrolyzed to
fluorescent 2′,7′-dichlorofluorescein (DCF) upon interaction with intracellular ROS.
Cultured cells were washed twice with PBS. Cells were then incubated with 20 μM of
DCF-DA for 30 min and washed with PBS. The DCF fluorescence was analyzed using a
fluorometer (SAFIRE microplate reader, TECAN, Australia) at an excitation of 485 nm
and an emission of 530 nm. Nitric oxide production in chondrocytes was analyzed using
DAF-FM

DA

(4-amino-5-methylamino-2',7'-difluorofluorescein

diacetate),

a

fluorescence probe specific for NO, that was added (10 μM) to cells. The probe was
diluted in culture medium. Cells were incubated with DAF-FM for 30 min at 37°C and
and then washed with PBS. Measurements were made using the SAFIRE microplate
reader (TECAN, Australia; excitation, 495 nm; emission, 515 nm).
2.3.6 Cell proliferation assay
Cell proliferation assays were performed using CyQUANT NF Cell Proliferation
Assay Kit (Invitrogen) according to manufacturer’s protocol, as described (Yan et al.,
2010). Chondrocytes were isolated as described above and seeded in 96-well NUNC
plates at a density of 1000 cells/100µl/well. After treatment, the medium was discarded
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and replaced with CyQUANT NF dye reagent diluted in HBSS buffer and incubated for
30 min in 37oC incubator. Measurement of the fluorescence intensity of each sample was
done using SAFIRE microplate reader (TECAN, Australia) with excitation at 480 nm and
emission detection at 520 nm with a minimum of 6 individual wells per treatment in
duplicate and three independent cell isolations. Images of primary chondrocyte were
taken after treatments of 1 day in culture using a Nikon SMZ1500 microscope with
Photometric CoolSNAP colour digital camera (Nikon Canada) and PTI Image Master 5
program.
2.3.7 Tibia organ culture
Tibiae were isolated from E15.5 embryos from CD1 timed-pregnant mice (Charles
River Canada) using the Stemi DV4 Stereomicroscope (Zeiss) as described (Agoston et
al., 2007; Wang et al., 2007). Dissection day was considered to be day 0 and tibiae were
allowed to recover from dissection overnight in serum-free α-MEM media containing
0.2% BSA, 0.5 mM L-glutamine, 40 units penicillin/mL and 40 μg streptomycin/mL as
described (Agoston et al., 2007). The following morning, bones in 24-well Falcon plates
were measured using an eyepiece in the Stemi DV4 Stereomicroscope and treated with
10-3 M L-NAME, 10-5 M SNAP or NOC-18 or 5 X 10-5 M Rac1 inhibitor (NSC23766)
with or without 10-5 M SNP, and DMSO as the vehicle. Medium was changed every 48
hrs beginning on day 1, and bones measured on days 1, 3 and 6. Results are expressed as
change in length relative to day 1. Experiments were repeated at least three times, with 4–
6 bones per treatment for each trial.
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2.3.8 Histology, immunohistochemistry and BrdU labeling
Tibia samples from organ cultures or newborn mice were rinsed with PBS and fixed
in 4% paraformaldehyde overnight. Bones were then placed in 10% formalin solution,
and sent for embedding and sectioning in the Pathology lab at the Molecular Pathology
Core Facility at the Robarts Research Institute (London, Ontario, Canada). Following
sectioning, bones were stained with hematoxylin and eosin or safranin O/fast green using
standard protocols (Solomon et al., 2009; Wang et al., 2007; Yan et al., 2010). For
immunohistochemistry, sections were incubated with primary anti-Cyclin D1 antibody
(1:50 dilution, NeoMarkers), anti-ATF3 antibody (1:200 dilution, Santa Cruz), antinitrotyrosine antibody (1:200 dilution, Santa Cruz) or anti-iNOS antibody (1:1000
dilution, abcam) overnight at 4°C. For BrdU labeling, newborn mice were injected 1h
before sacrifice intraperiteally with BrdU (Roche) at a dose of 0.01 ml/g body weight.
BrdU was detected in paraffin sections using anti-BrdU antibody (1:100 dilution, Zymed
Laboratories). Bound antibody was visualized using the UltraVision LPValue detection
system (Lab Vision) with AEC chromogen substrate (Lab Vision).
2.3.9 RNA isolation, and real-time RT-PCR
Total RNA was isolated from epiphyseal cartilage of long bone from newborn mice
or primary cells using TRIzol (Invitrogen), according to the manufacturer's
recommendations. Taqman real-time PCR was performed as described (James et al.,
2006; Woods et al., 2005) with primers and probe sets from Applied Biosystems (ATF3
Mm00476032_m1; Gapdh Mm99999915_g1). Data were normalized to Gapdh mRNA
levels and represent averages and SEM from direct comparison of mutant and control
littermates from three different crosses.
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2.3.10 Statistical analysis
Statistical significance was determined by Student’s T-Test or by one-way
ANOVA with Bonferroni post test using GraphPad Prism version 4.00 for Windows,
GraphPad Software, San Diego California USA, www.graphpad.com. In figures where
values are shown as percentages, data were first log-transformed before applying
ANOVA.

2.4 Results
2.4.1 Rac1 deficiency results in reduced iNOS expression and NO production
We have previously shown hypocellularity and reduced proliferation in Rac1deficient growth plates (Wang et al., 2007). We first examined whether we could
recapitulate this phenotype in vitro to facilitate biochemical studies on the underlying
mechanisms. Primary chondrocytes were isolated from Rac1fl/fl mice, carrying two alleles
of a conditional (floxed) Rac1 allele. Cells in monolayer culture were infected with
adenoviruses expressing green fluorescent protein (GFP, control) or Cre recombinase.
Infection with Ad-Cre resulted in a marked reduction of Rac1 protein (Fig. 2.1A);
densitometry determined that Rac1 proteins levels were reduced by 70 % in Ad-Creinfected cultures (data not shown). Control cells increased their numbers steadily over the
three-day time course of the experiment, whereas cells infected with Ad-Cre multiplied at
a much slower rate (Fig. 2.1B). This was accompanied by reduced expression of cyclin
D1 (Fig. 2.1C), as we had observed in vivo. These data documented that our in vitro
culture
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Figure 2.1 iNOS expression and NO generation are reduced in Rac1-deficient
chondrocytes.
Primary chondrocytes were isolated from Rac1fl/fl mice and infected with adenovirus
expressing green fluorescent protein (GFP, control) or Cre recombinase. Infection with
Ad-Cre resulted in approximately 70 % reduction of Rac1 protein (A). Cell counts
demonstrated that control cells increased their numbers steadily over the three-day time
course of the experiment, whereas cells infected with Ad-Cre multiplied at a much slower
rate (B). This was accompanied by reduced expression of cyclin D1 in mutant cells,
compared to control (C). Rac1 deletion reduced ROS levels, but caused a more
pronounced reduction in NO production (D) in Cre recombinase-infected cells. Western
blotting demonstrated markedly reduced expression of iNOS protein in Cre-expressing
chondrocytes, whereas eNOS expression was similar to control cells (E). By
immunohistochemistry, iNOS staining was notably reduced in growth plates from
cartilage-specific Rac1 KO mice compared to control mice (F). Scalebar: 50µm. A
similar decrease in staining in mutant mice was observed for nitrotyrosine, an indicator of
cellular NO levels (G). Scalebar: 100µm. Figures are representative of 3 independent
trials.
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system provides a good model to study the effects of Rac1 deletion on chondrocyte
proliferation.
Since Rac1 is able to stimulate ROS generation, we measured levels of ROS and
NO. Rac1 deletion caused an approximately 50 % reduction in ROS levels, but NO
production was inhibited to a much larger degree (Fig. 2.1D). We therefore examined the
molecular cause of reduced NO production and showed that expression of iNOS protein
was markedly reduced in Rac1-deficient chondrocytes, whereas eNOS expression was
similar to control cells (Fig. 2.1E). To analyze effects of Rac1 deficiency on iNOS
expression in vivo, we performed immunohistochemistry of paraffin sections from
control and cartilage-specific Rac1 KO mice. In control mice, iNOS protein was found
mostly in late proliferating and prehypertrophic chondrocytes (Fig. 2.1F). iNOS staining
was notably reduced in growth plates from mutant mice that also showed disorganization
of the proliferative zone, as we described earlier (Wang et al., 2007). A similar decrease
in staining in mutant mice was observed using an antibody for nitrotyrosine, an indicator
of cellular NO levels (Fig. 2.1G). Collectively, these data suggest that iNOS expression
and NO generation are severely reduced in Rac1-deficient chondrocytes.

2.4.2 NO promotes chondrocyte proliferation in cell and organ culture
We next examined whether addition of exogenous NO could overcome the effects
of Rac1 deficiency. Addition of SIN-1, which induces both ROS and NO generation,
rescued the numbers of Rac1-deficient chondrocytes in monolayer culture (Fig. 2.2A). In
parallel, we treated cells with the phorbol ester PMA (an inducer of ROS only that did
not change NO levels; data not shown) and observed no effects on chondrocyte numbers,
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Figure 2.2 NO can rescue the effects of Rac1 deficiency.
Primary chondrocytes were isolated from Rac1fl/fl mice and infected with adenoviruses
expressing green fluorescent protein (GFP, control) or Cre recombinase. Addition of
SIN-1, but not PMA, in this culture system increased numbers of Rac1-deficient
chondrocytes (A). Western blotting showed that cyclin D1 expression in primary
chondrocytes was restored by SIN-1, but not PMA (B). Incubation of chondrocytes with
the NOS inhibitor L-NAME reduced chondrocyte cell numbers, while the NO donors
SNAP and NOC18 caused an increase in chondrocyte cell numbers (C and D). Scale bar
for C: 50µm. Figures are representative of 3 independent trials.
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suggesting that the mitogenic defects in Rac1-deficient chondrocytes are not due to lower
ROS production. Similarly, Western blotting demonstrated that cyclin D1 expression in
Rac1-deficient chondrocytes is restored by SIN-1, but not PMA (Fig. 2.2B). These data
suggested that NO production is required for Rac1-induced chondrocyte proliferation and
that inhibition of NO synthesis by other means would result in similar phenotypes as
deletion of Rac1, while NO donors should increase chondrocyte proliferation. To test this
prediction, we incubated chondrocytes with the NOS inhibitor L-NAME and the NO
donors SNAP and NOC18. L-NAME reduced chondrocyte cell numbers, while both
donors increased cell numbers (although only SNAP reached statistical significance; Fig.
2.2C and D). Collectively, these data suggest a model where Rac1 promotes chondrocyte
proliferation through iNOS/NO-mediated induction of cyclin D1 expression.
We next examined how NO regulates chondrocyte proliferation and tissue
architecture in intact growth plates using an organ culture system of embryonic mouse
tibiae (Agoston et al., 2007). Tibiae were grown with DMSO (control) and L-NAME for
six days. Measurement of growth plate zones in H&E-stained tissue sections
demonstrated that L-NAME treatment resulted in a shortened proliferative zone, while
the resting and hypertrophic zones of the growth plate were not affected (Fig. 2.3A and
B). This was accompanied by reduced numbers of BrdU-incorporating cells (Fig. 2.3C
and D).
2.4.3 NO donors rescue the effects of Rac1 inhibition on bone growth
To investigate whether NO donors can rescue effects of Rac1 inhibition in intact
growth plates, tibiae were incubated with the pharmacological Rac1 inhibitor NSC23766
(Gao et al., 2004). Our earlier studies had demonstrated that this compound has similar
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Figure 2.3 Inhibition of NO production results in reduced proliferation in tibia
organ cultures.
Tibiae isolated from E15.5 mice were incubated in organ culture with DMSO or the NOS
inhibitor L-NAME (1mM). After six days, tibiae were fixed, embedded and sectioned,
and sections were stained with hematoxylin and eosin (H&E). Staining and measurement
of zone length demonstrated a shorter proliferative zone in L-NAME treated tibiae (A;
red arrow: proliferating cell zone; blue arrow: hypertrophic cell zone A, B; RZ; resting
zone, PZ: proliferative zone, HZ; hypertrophic zone. Scale bar 250 µm). This was
accompanied by reduced numbers of BrdU-incorporating (C and D; dark brown nuclei;
Scale bar 100 µm). Immunohistochemistry figures are representative of 3 independent
trials.
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effects on early chondrogenesis as genetic inactivation of Rac1, providing evidence for
the specificity of the inhibitor (Woods et al., 2007a). NSC23766 treatment for six days
resulted in drastic reduction of bone growth in our organ culture system (Fig. 2.4A and
B), accompanied by shortening of the proliferative zone (Fig. 2.4C). The NO donor SNP
did not affect bone growth on its own, but completely rescued the effects of Rac
inhibition on overall tibia growth and the length of the proliferative zone (Fig. 2.4A-C).
These data demonstrate that restoration of NO signaling overcomes the effects of Rac1
deficiency in the authentic three-dimensional context of the growth plate.

2.4.4 Reduced chondrocyte proliferation in iNOS-deficient mice
Since our data suggested a role for endogenous Rac1-iNOS signaling in growth
plate chondrocyte proliferation, we next analyzed the cartilage phenotype of iNOSdeficient mice (Laubach et al., 1995). Growth plates from these mice showed normal
zonal and columnar architecture, but appeared slightly hypocellular in their centers (Fig.
2.5A), similar to but more subtle than those of mice with cartilage-specific deletion of the
Rac1 gene (Wang et al., 2007). Cell counts confirmed hypocellularity in the proliferative
zone of mutant mice (Fig. 2.5B). Immunohistochemistry and counts of positive cells
demonstrated lower numbers of chondrocytes incorporating BrdU (Fig. 2.5C and D) and
expressing cyclin D1 (Fig. 2.5E and F) in iNOS-deficient growth plates. Both of these
features had also been observed in cartilage-specific Rac1 KO mice (Wang et al., 2007).
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Figure 2.4 The NO donor SNP rescues the effects of Rac inhibition in organ culture.
E15.5 tibiae were incubated with control medium, the Rac inhibitor NSC23766 (50 µM),
the NO donor SNP (10 µM) or both for six days. Rac inhibition resulted in drastic
reduction of bone growth in our tibia organ culture system (A and B), accompanied by
shortening of the proliferative zone (C). The NO donor SNP (10 µM) did not affect bone
growth on its own, but completely rescued the effects of Rac inhibition on growth and the
length of the proliferative zone (A-C). Scale bar 100 µm. Images are representative of 3
independent trials.
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Figure 2.5 Reduced chondrocyte proliferation in iNOS KO mice.
Growth plates from iNOS mutant mice were hypocellular (A), as shown by Safranine
O/Fast Green staining. Cell counts confirmed hypocellularity in the proliferative zone of
mutant mice (B). Immunohistochemistry and counts of positive cells demonstrated lower
numbers of chondrocytes incorporating BrdU (C and D) and expressing cyclin D1 (E and
F) in iNOS-deficient growth plates. Scalebar for A 250 µm, C and E 100 µm. Images are
representative of 3 independent trials.

68

69

2.4.5 The transcriptional repressor ATF3 is upregulated upon loss of Rac1 or iNOS
We had shown earlier that cyclin D1 expression in chondrocytes is positively
regulated by the transcription factors ATF-2 and CREB and repressed by ATF3 (Beier et
al., 2001; Beier et al., 1999a; James et al., 2006). Immunohistochemistry demonstrated
limited expression of ATF3 protein in chondrocytes of control mice, but markedly
increased numbers of stained cells upon loss of Rac1 (Fig. 2.6A). In agreement with these
data, ATF3 mRNA levels were increased in Rac1-deficient cartilage in vivo (Fig. 2.6B)
and in primary Rac1fl/fl chondrocytes infected with Ad-Cre (Fig. 2.6C). This suggests
premature induction of ATF3 which in turn can repress cyclin D1 transcription and result
in earlier cell cycle withdrawal. SIN-1 treatment reduced ATF3 protein levels both in
control chondrocytes and in Rac1-depleted chondrocytes in cell culture (Fig. 2.6D),
suggesting that NO represses ATF3 expression. Finally, the number of ATF3-expressing
chondrocytes is increased and its expression domain is expanded in iNOS KO growth
plates, similar to Rac1 mutants (Fig. 2.6E). These data suggest that the Rac1-iNOS-NO
pathway acts to suppress ATF3 expression in order to maintain cyclin D1 transcription
and chondrocyte proliferation.
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Figure 2.6 ATF3 suppresses cyclin D1 expression and inhibit chondrocyte
proliferation.
Immunohistochemistry demonstrated relatively little expression of ATF3 protein in
control mice (see also in magnification in right panel), with markedly increased
expression upon loss of Rac1 (A). Scale bar 50 µm. Real-time RT-PCR demonstrated that
ATF3 mRNA levels are increased in Rac1-deficient cartilage in vivo (B) and in primary
Rac1fl/fl chondrocytes infected with Ad-Cre (C). SIN-1 treatment reduced expression of
ATF3 protein in primary wild type and Rac1-deficient chondrocytes, while PMA did not
affect either (D). The number of ATF3-expressing chondrocytes was increased in iNOS
KO growth plates, similar to Rac1 mutants (E). Scale bar 100 µm. Figures are
representative of 3 independent trials.
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2.5 Discussion
Chondrocyte proliferation is one of the main determinants of endochondral bone
growth and thus final height. While many extracellular signals that control these
processes are known, the intracellular signaling pathways connecting cell surface
receptors to specific cell cycle genes are less well understood. We had shown that the
small GTPase Rac1 is essential for normal chondrocyte proliferation and cyclin D1
expression, but the molecular mechanisms involved were not known. Here we
demonstrate that Rac1 controls chondrocyte proliferation by stimulation of iNOS
expression and NO production, which in turn suppresses ATF3 expression and thus
allows increased transcription of the cyclin D1 gene (Fig. 2.7).
While the regulation of ROS generation by Rac1 is well established, there has been
much less attention on interactions between Rac proteins and NO signaling. The
requirement for Rac1 for normal iNOS expression in our study is consistent with an
earlier report showing reduced iNOS mRNA levels upon adenoviral delivery of
dominant-negative Rac to rat livers (Harada et al., 2003). However, Rac1 activation or
inhibition did not alter iNOS induction by interleukin 1β in smooth muscle cells (Finder
et al., 2001), suggesting that the connections between both pathways are stimulus- and/or
cell type-specific. Interestingly, Rac1 deficiency in endothelial cells leads to reduced
expression and activity of eNOS (Sawada et al., 2008), while eNOS protein levels were
not altered in our system. These data suggest that the connections between Rac1 (and
possibly other Rho GTPases) and components of the NO signaling pathway are
connected in a cell type-specific manner. In addition, it appears likely that
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Figure 2.7 Model of Rac1 –iNOS/NO – ATF3 – cyclin D1 signaling in chondrocytes.
Our data show that Rac1 is required for normal levels of iNOS expression and NO
production in chondrocytes. NO suppresses expression of ATF3, which acts as
transcriptional repressor of cyclin D1. In Rac1- or iNOS-deficient chondrocytes, ATF3
levels are increased, resulting in reduced activity of the cyclin D1 promoter which in turn
slows chondrocyte proliferation and induces premature cell cycle exit.
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the Rac1-iNOS interaction demonstrated by us is not exclusive; for example, Rac1
probably acts through additional effectors including ROS and the actin cytoskeleton, and
iNOS activity and expression in chondrocytes is likely controlled by additional upstream
regulators.
NO and NOS genes have been studied extensively in the context of bone
remodeling and arthritis (Scher et al., 2007; van't Hof and Ralston, 2001), but much less
is known about the roles of this pathway in endochondral bone development (Teixeira et
al., 2008). Teixeira and colleagues had shown that excess NO promotes hypertrophic
differentiation and apoptosis of chondrocytes in chicken (Teixeira et al., 2005; Teixeira et
al., 2001), while our data suggest that basal levels of NO are required for chondrocyte
proliferation. Studies from other tissues suggest that the role of iNOS in cellular
proliferation is cell-type and/or context-specific; for example, iNOS is required for
hepatocyte proliferation during liver regeneration (Yasoda et al., 2009) but suppresses
proliferation of smooth muscle cells (Kibbe et al., 2000). However, to our knowledge
neither ATF3 nor cyclin D1 have been implicated in the mitogenic or anti-mitogenic
effects of iNOS. It should be noted that since in vitro data from our and other laboratories
suggest Rac1 functions during chondrocyte hypertrophy (Kerr et al., 2008; Wang and
Beier, 2005), it is quite possible that iNOS or other NOS enzymes also contribute to this
role of Rac1.
Interestingly, we recently demonstrated a similar phenotype as described here (e.g.
reduced proliferation and cyclin D1 expression, increased levels of ATF3 and premature
cell cycle exit) in mice deficient for the eNOS gene (Yan et al., 2010). Together, these
studies suggest a dose-dependent effect of nitric oxide in the growth plate where low
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levels are required for proliferation, but high levels promote terminal differentiation and
ultimately apoptosis. This model is in agreement with suggested dose-dependent effects
of NO (Thomas et al., 2008). The overlap in phenotypes in this and our earlier study (Yan
et al., 2010) also imply partial overlap of iNOS and eNOS function in chondrocytes. NO
generated from either source inhibits the onset of ATF3 expression, allowing continued
expression of cyclin D1 and thus delaying cell cycle exit. However, eNOS expression
was not affected by loss of Rac1, suggesting that the two genes are regulated by different
upstream pathways and mediate mitogenic responses to different external stimuli.
In conclusion, this study identified the iNOS/NO pathway as a central mediator of
the mitogenic activity of Rac1 in growing endochondral bones. Further research into this
will provide us with novel approaches towards the treatment of various skeletal diseases
such as chondrodysplasias.
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CHAPTER THREE

ENDOTHELIAL NITRIC OXIDE SYNTHASE DEFICIENCY RESULTS IN
REDUCED CHONDROCYTE PROLIFERATION AND ENDOCHONDRAL
BONE FORMATION*
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results in reduced chondrocyte proliferation and endochondral bone growth. Arthritis &
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3.1 Chapter summary
Nitric oxide (NO) and aberrant chondrocyte differentiation have both been
implicated in the pathogenesis of osteoarthritis, but whether these processes are
connected is unknown, and the role of specific nitric oxide synthase (NOS) enzymes in
chondrocyte physiology is unclear. The objective of this study was to examine the effects
of inactivation of endothelial nitric oxide synthase (eNOS) on cartilage development in
mice. Skeletal growth and development of mice carrying a null mutation in the eNOS
gene was studied in comparison to control littermates. In situ analyses were
complemented by experiments with primary chondrocytes and tibial explants from these
mice. eNOS-deficient mice show increased lethality and reduced bone growth, with
hypocellular growth plates and a marked reduction in the number of proliferating
chondrocytes. In vitro studies demonstrated lower chondrocyte numbers and reduced
endochondral bone growth in mutants, suggesting that the role of eNOS signaling in
chondrocyte proliferation is cell-autonomous. Reduced chondrocyte numbers appear to
be caused by decreased cyclin D1 and increased p57 expressions in mutants, resulting in
slower cell cycle progression and earlier cell cycle exit. In addition, expression of early
chondrocyte markers such as Sox9 was reduced and prehypertrophic markers were
expressed prematurely in mutant mice. Our data identify a novel and important role of
eNOS in chondrocyte proliferation and endochondral bone growth and demonstrate that
loss of eNOS results in premature cell-cycle exit and prehypertrophic chondrocyte
differentiation during cartilage development.
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3.2 Introduction
Nitric Oxide (NO) plays an important role in the progression of osteoarthritis
(OA), in part by influencing the physiology of chondrocytes (Abramson, 2008). NO is
synthesized through L-arginine by nitric oxid synthases (NOS) in many cell types. Three
different types of NOS have been identified. The neuronal (nNOS or NOS1) and
endothelial (eNOS or NOS3) forms are constitutively expressed, and their activity is
regulated by intracellular signaling and the calcium binding protein calmodulin (van't Hof
and Ralston, 2001). The inducible form (iNOS or NOS2) is stimulated at the level of
expression by factors including lipopolysaccharide and cytokines, such as IL-1, TNFα
and IFNα, and leads to a sustained and high levels of NO, mainly in inflammatory disease
(Abramson, 2008; Mungrue et al., 2003).
Changes in the articular chondrocyte phenotype, such as initiation of hypertrophic
differentiation, are thought to play an important role in the pathogenesis of OA (Appleton
et al., 2007; Drissi et al., 2005; Gauci et al., 2008). Physiologically, chondrocyte
hypertrophy occurs in the process of endochondral ossification that gives rise to most
bones in the vertebrate skeleton, such as the long bones of the limbs (Karsenty and
Wagner, 2002; Zelzer and Olsen, 2003). Endochondral ossification involves the
formation of a highly controlled and precisely shaped cartilage template that is
subsequently replaced by bone tissue and bone marrow (Wagner and Karsenty, 2001).
Once mesenchymal cells commit to the chondrogenic lineage, the subsequent events of
endochondral bone formation occur through the epiphyseal growth plate (Olsen, 1999),
which consists of zones of resting, proliferating, and hypertrophic

chondrocytes

organized in distinguishable columnar arrays (Wagner and Karsenty, 2001). Within the
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growth plate, proliferation of chondrocytes occurs in a unidirectional manner, resulting in
longitudinal bone growth (Goldring et al., 2006; Kronenberg, 2003). After exiting the cell
cycle, chondrocytes start to differentiate into prehypertrophic and eventually hypertrophic
chondrocytes (Hoffmann and Gross, 2001; Mackie et al., 2008; Stanton et al., 2003).
Hypertrophic chondrocytes direct mineralization of the surrounding extracellular matrix,
attract blood vessel invasion, and ultimately undergo apoptosis while being replaced by
bone and bone marrow (Kronenberg, 2003; Olsen et al., 2000). Proliferation and
hypertrophy of growth plate chondrocytes and extracellular matrix production drive the
longitudinal growth of endochondral bones and eventually determine body length in
mammals (Kronenberg, 2003; Okazaki and Iwamoto, 2006).
Since both NO signaling and altered chondrocyte differentiation contribute to OA,
it is important to examine whether both processes are connected. Studies in the chicken
suggest that NO signaling promotes chondrocyte hypertrophy (Teixeira et al., 2008;
Teixeira et al., 2005), but the roles of NO and in particular the individual NOS genes in
mammalian cartilage development are not well understood. In this study, we used a
genetic approach to address the role of eNOS in chondrocyte differentiation and
endochondral ossification in vivo. Inactivation of the eNOS gene resulted in a number of
phenotypes, including reduced proliferation and earlier cell cycle exit of chondrocytes.
Overall, these data provide novel information regarding the importance of eNOS/NO
signalling in chondrocyte development and identify downstream regulators of
endochondral ossification.

90

3.3 Materials and methods
3.3.1 Animals and materials
Timed-pregnant CD1 mice were purchased from Charles River Laboratories. Cell
culture materials and general chemicals were obtained from Invitrogen, Sigma or VWR
unless otherwise stated. The following antibodies were employed in this study: Kip2/p57
#sc8298 (rabbit antibody against human protein), RORα #sc28612 (rabbit antibody
against human protein), ATF3 #sc188 (rabbit antibody against human protein), Goat-antimouse #sc2005, Goat-anti-rabbit #sc2004 (all from Santa Cruz Biotechnology); Cyclin
D1 (SP4) #9104-S1 (rabbit antibody against human, mouse and rat proteins; NeoMarkers
Inc.); PCNA #2586, (mouse antibody against human, mouse and rat proteins; Cell
Signaling Inc.); Hif1α #07-628 (rabbit antibody against human protein; Upstate Inc.);
BrdU #03-3900 (mouse antibody, species-independent; Zymed Laboratories).
3.3.2 Mouse breeding and genotyping
Mice with a deletion of the eNOS gene (Stock #2684) (Shesely et al., 1996) and
control mice in the C57/BL6 background were obtained from Jackson Laboratory (Bar
Harbor, ME), and exposed to a 12-hour light-dark cycle and fed tap water and regular
chow at libitum. All procedures involving animals were approved by the University of
Western Ontario Animal Care and Use Committee. All experiments were done using
crosses of heterozygote mice to compare KO animals to wild type controls within litters.
For PCR genotyping, tail snips were used to prepare DNA for PCR analysis. PCR
genotyping was performed by simultaneous amplification of the eNOS wild type and null
alleles as described (Hefler et al., 2001). PCR fragments were analyzed by agarose gel
electrophoresis.

91

3.3.3 Skeletal staining and histology
Animals were skinned, eviscerated and dehydrated in 95% ethanol overnight and
then in acetone overnight. Skeletons were stained with 0.015% alcian blue, 0.05%
alizarin red and 5% acetic acid in 70% ethanol for several days. Skeletons were then
cleared in 1% KOH, passed through a decreasing KOH series and stored in
glycerol/ethanol (1:1) (Wang et al., 2007). After dissection of mice, bones were rinsed
with PBS, fixed in 4% Paraformaldehyde (PFA) overnight, placed in 10% formalin
solution and sent for embedding and sectioning into 4µm sections at the Molecular
Pathology Core Facility at the Robarts Research Institute (London, Ontario, Canada).
Following sectioning, bones were stained with hematoxylin and eosin or safranin O/fast
green using standard protocols (Solomon et al., 2009; Wang et al., 2007) or used for
immunohistochemistry as described below.
3.3.4 Immunohistochemistry and BrdU labeling
For immunohistochemistry, sections unstained prior to use were incubated in 3%
H2O2 for 15 min at room temperature, following by boiling for 20 min in 10 mM sodium
citrate (pH 6.0) and blocking with 5% goat serum at room temperature for 30 min.
Sections were incubated with primary antibody overnight at 4°C and secondary
antibodies according to the manufacturers’ recommendations. After washing, the sections
were incubated for 1-10 min with DAB substrate solution (Dako North America, Inc.),
washed and mounted. All images were taken at room temperature with a Retiga EX
camera connected to a Leica DMRA2 microscope using OpenLab 4.0.4 software. For cell
counts in sections, all cells and cells positive for staining with primary antibody labeling
were counted from three different areas of one section. Sections from at least three mice
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per genotype, and at least three sections from every mouse, were analyzed, and averages
and standard deviation from all counts/genotype are shown.
For BrdU labeling, newborn mice were injected intraperitoneally with BrdU
(Roche) at a dose of 0.03 mg/g body weight one hour before sacrifice. BrdU was detected
in paraffin sections using anti-BrdU antibody (Zymed Laboratories) as described above.
For all antibodies, negative controls were conducted following the same protocol in the
absence of the primary antibody.
3.3.5 Primary cell culture and MTT assays
Tibiae, femuri and humeri were isolated from embryonic day 15.5 (E15.5) KO
and control mouse using a Stemi DV4 Stereomicroscope (Zeiss). 20 bones from the same
genotype were placed in 2ml α-MEM media (Invitrogen)/well containing 0.2% bovine
serum albumin (BSA), 1 mM β-glycerophosphate, 0.05 mg/ml ascorbic acid and
penicillin/streptomycin in a 6-well culture dish (Falcon), as described (James et al.,
2005). Then medium was removed and every 10-12 bones from each group placed in 1
ml of 0.25% trypsin-EDTA (Invitrogen) for 15 min at 37°C. Trypsin was subsequently
replaced with 1 mg/ml collagenase P (Roche) in DMEM/10% fetal bovine serum
(Invitrogen), and cells were incubated at 37°C with rotation at 100 rpm for 90 min.
Following digestion, the cell suspension was centrifuged for 5 min at 1000 rpm, and the
collagenase containing supernatant was decanted. Chondrocytes were resuspended in
medium containing 2:3 DMEM:F12, 10% fetal bovine serum, 0.5 mM L-glutamine, and
penicillin/streptomycin (25 units/ml) supplemented with 0.25 mM ascorbic acid (Sigma)
and 1 mM β-glycerophosphate (Sigma). Chondrocytes (10000 cell/ml) were seeded in 96well culture dish (Falcon), containing 100 µl of medium per well and cultured in the
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presence of 5 % CO2. Cell numbers were determined by MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide) assay as described (Halawani et al., 2004; Wang et
al., 2004).
3.3.6 Tibia organ culture
Tibiae were isolated from E15.5 embryos from wild type and KO mice as described
above (Agoston et al., 2007; Wang et al., 2007). Dissection day was considered to be day
0 and tibiae were allowed to recover from dissection overnight in serum-free α-MEM
medium 1 ml/well, 1 tibia/well containing 0.2% Bovine Serum Albumin (BSA), 0.5 mM
L-glutamine, 40 units penicillin/mL and 40 μg streptomycin/mL in 24-well Falcon plates
as described (Agoston et al., 2007; Wang et al., 2007). All culture dishes were maintained
in an incubator containing 5% CO2. The following morning, bone length was measured
using an eyepiece in the Stemi DV4 Stereomicroscope. Medium was changed every 48
hrs beginning on day 1, and bones measured on days 2, 4 and 6. Results are expressed as
growth in length relative to day 1. Experiments were repeated at least three times, with 4–
6 bones per treatment for each trial.
3.3.7 Western blotting
Fresh cartilage from limbs of newborn mice was dissected in cold Puck's solution
A (PSA; 80 g/l NaCl, 4.0 g/l KCl, 0.6 g/l KH2PO4, 0.9 g/l Na2HPO4·7H2O, and 10 g/l
glucose, pH 7.4). Modified Radioimmunoprecipitation (RIPA) Buffer extracts of
cartilage were used directly for Western blotting (Appleton et al., 2007; Wang et al.,
2007). Blocking, incubation with antibodies and washing were carried out in accordance
with instructions of the supplier of the primary antibody. Immunoblots were developed
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using the ECL detection system (Amersham). Representative blots from three
independent littermate comparisons are shown.
3.3.8 RNA isolation, and real-time RT-PCR
Total RNA was isolated from epiphyseal cartilage of long bone from newborn mice
using TRIzol (Invitrogen), according to the manufacturer's recommendations. Taqman
real-time PCR was performed as described (James et al., 2005; Woods et al., 2005) with
primers and probe sets from Applied Biosystems (Sox9 Mm00448840_m1; Col2a1
Mm00491889_m1;
Mm00468869_m1;

Col10a1
Nos1

Mm00487041_m1;
Mm00435175_m1;

Rora
Nos2

Mm00443103_m1;

Hif1a

Mm00440485_m1;

Nos3

Mm00435204_m1; Gapdh Mm99999915_g1). Data were normalized to Gapdh mRNA
levels and represent averages and SEM from direct comparison of mutant and control
littermates from three different crosses. Statistical significance of real-time PCR results
was determined by one way ANOVA with Bonferroni post-test using GraphPad Prism
4.00 for Windows.
3.3.9 Statistical analysis
All experiments were performed with at least three independent litters. Statistical
significance was determined by a one-way ANOVA with Bonferroni post test using
GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego, California,
USA.

95

3.4 Results
3.4.1 Inactivation of eNOS gene results in reduced viability and growth
We used eNOS-deficient mice to address the role of this gene in cartilage
development in vivo. Based on our breeding protocol from heterozygote mice, Mendelian
ratio would predict that 50% of newborn mice are heterozygote and 25% are homozygote
eNOS null mice. However, examination of genotype distribution of newborn mice
revealed that only 14% of pups are homozygous for the mutant eNOS allele, and 40% are
heterozygous. Analyses of genotypes at different embryonic stages showed the expected
Mendelian distribution (data not shown). These data suggest that loss of eNOS gene
results in increased lethality at the late prenatal or the perinatal stage. Additionally,
newborn eNOS-/- mice showed 44% neonatal death occurring shortly after birth. Slightly
decreased body weight (86%) and length (92%) were found in eNOS-/- mice at birth.
Analysis of both parameters over the first 42 days of life demonstrated that growth
retardation became more pronounced in surviving eNOS-/- mice as the animals aged (Fig.
3.1A). Growth retardation was similar in female and male mice (data not shown).
However, some eNOS-/- mice demonstrated more severe delays in growth and
development, and some were born with a kinky tail (6 out of 20 KO mice from 9 litters)
(Fig. 3.1B).
We next examined the skeletal phenotype of eNOS-deficient mice. Whole skeletal
staining with alcian blue and alizarin red confirmed that mutant mice have a smaller
skeleton than control littermates at postnatal day 1 (Fig. 3.1C). The majority of mutant
mice showed no obvious morphological changes in the skeleton. Detailed observation of
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Figure 3.1 Loss of eNOS results in reduced growth.
Body length and body weight of mice were determined during the first 42 days of their
life. eNOS null mice show slower increases in both parameters compared to wild type
littermates (A). Mean and standard deviation from at least 8 mice per genotype are
shown for each data point. (*P<0.05) (WT: wild type; KO: knockout). Comparison of an
eNOS knockout (KO) mouse and a wild type (WT) littermate at postnatal day 4
demonstrates delay in growth and development and a kinky tail in the mutant (B). Whole
skeletal staining with alcian blue and alizarin red at postnatal day1 shows no
morphological difference besides reduced size in mutants (C). Measurements of selected
individual bones confirm reduced bone length in humeri and tibiae in neonatal mutant
mice (D). Real-time RT-PCR using RNA extracted directly from neonate cartilage from
eNOS KO mice demonstrated upregulated nNOS transcript levels; iNOS mRNA levels
did not change; and eNOS transcripts could not be detected in KO mice (E). (ND: not
detectable; N = 4, *P<0.05).
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the whole skeleton of mutant mice demonstrated a smaller rib cage and skull and a
shorter appendicular skeleton. Measurement of selected individual bones confirmed
reduced bone length of humeri (76%) and tibiae (80%) in neonatal mutant mice (Fig.
3.1D). Real-time RT-PCR using RNA extracted directly from mutant neonate cartilage
demonstrated upregulated nNOS transcription levels compared with control; iNOS
mRNA levels were unchanged; and eNOS transcripts could not be detected in mutant
mice, as expected (Fig. 3.1E).
3.4.2 eNOS deficiency reduces chondrocyte proliferation in the growth plate
To elucidate the cellular basis for the reduced skeletal growth, we analyzed
growth plate organization. Growth plates from newborn mutant mice displayed a similar
chondrocyte arrangement in proliferative and hypertrophic zones as control animals (Fig.
3.2A). Measurement of the width of the various growth plate zones showed that the
proliferative zone is slightly smaller and the hypertrophic zone is slightly larger in KO
growth plates, but these effects were not statistically significant (Fig. 3.2B). eNOS-/growth plates were hypocellular (Fig. 3.2A). Counts of cell numbers in the proliferative
zone of the growth plate revealed fewer cells per area in mutants (71% of control cell
numbers), while cell counts in the epiphyseal cartilage did not show a significant
difference between genotypes (Fig. 3.2C).
We next asked whether changes in cell proliferation are the cause of
hypocellularity in eNOS-deficient growth plates. BrdU incorporation assays showed a
marked reduction in replicating cells in mutant mice that was confirmed by cell counts
(Fig. 3.3A). Control experiments in these and all subsequent immunohistochemistry
studies were done without primary antibody and showed no staining (data not shown).
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Figure 3.2 eNOS deficiency results in reduced proliferating chondrocyte numbers in
growth plate.
Histological analyses (safranin O/Fast Green staining) demonstrate that growth plates
from newborn mutant mice displayed a similar chondrocyte arrangement into
proliferating and hypertrophic zones as control mice (A). Measurement of the width of
the resting zone (RZ), proliferative zone (PZ) and hypertrophic zone (HZ) in the growth
plates did not show significant changes in the mutant (B). However, cell numbers per
area in the proliferative zone of the mutant growth plate are lower (71%) (C). (EC:
epiphyseal cartilage; PZ: proliferative zone) (Scale bar=500µm) Mean and standard
deviation from at least 8 mice per genotype are shown (*P<0.05).
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Figure 3.3 eNOS deficiency reduces chondrocyte proliferation and endochondral
bone growth in vitro.
BrdU incorporation assays show a remarked reduction in replicating cells in eNOS
mutant mice (A), which is confirmed by counting of labeled cells. Similarly,
immunohistological staining of proliferating cell nuclear antigen (PCNA) showed
reduced positive cell numbers per area in eNOS mutant mice (B). MTT assays
demonstrate a slower increase in cell numbers of eNOS-/- primary chondrocytes than
observed for cells from wild type or heterozygote littermates (C). In organ culture,
mutant tibiae showed reduced bone growth compared with those from control animals at
day 4 and day 6 of culture (D). (Scale bar=200µm) Mean and standard deviation from at
least 4 independent experiments per genotype are shown (*P<0.05).
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demonstrated a similar reduction in mutant mice (Fig. 3.3B). These data demonstrated
reduced proliferation of chondrocytes upon loss of eNOS.
Because our mutant mice are eNOS-deficient in all cells of the body, it was
possible that reduced bone growth and chondrocyte proliferation are secondary to loss of
eNOS in other cell types. We therefore compared proliferation of primary chondrocytes
from control and eNOS-/- mice in culture. MTT assays demonstrated that mutant cells
increased their numbers more slowly than those form control littermates, while
chondrocytes from heterozygote mice did not show any differences to wild type cells
(Fig. 3.3C). In addition, we conducted organ culture experiments by growing tibiae from
E15.5 eNOS-/- and wild type mice for 6 days in culture. While bones from both genotypes
were of similar length at the beginning of the culture, mutant bones showed significantly
reduced growth compared with those from control animals at day 4 and day 6 (Fig. 3.3D).
These data suggest that eNOS is required for normal chondrocyte proliferation and
endochondral bone growth in a cell-autonomous fashion.
3.4.3 eNOS deficiency results in reduced cyclin D1 expression
To elucidate the reason for reduced cell numbers in eNOS-/- mice, we examined cell
cycle protein expression in growth plates. Immunohistochemical staining of cyclin D1,
which is required for normal chondrocyte proliferation (Beier, 2005; Beier et al., 2001),
demonstrated reduced numbers of positive cells in mutant mice (Fig. 3.4A). Reduced
cyclin D1 protein expression in eNOS-deficient cartilage was confirmed by western blot
(Fig. 3.4B). We recently described that the transcription factor ATF3 is upregulated
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Figure 3.4 eNOS deficiency causes reduced cyclin D1 expression.
Immunohistochemical staining for cyclin D1 showed reduced numbers of positive cells in
eNOS null mice (A). Reduced cyclin D1 expression in mutants was confirmed by
Western blot (B). In addition, activating transcript factor 3 (ATF3) was found
upregulated in eNOS null mice by immunohistochemistry (C). Counting of the positive
cells per area confirmed these changes in the mutant (D). (Scale bar=200µm)
Representative pictures from at least 4 independent experiments are shown.
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during chondrocyte hypertrophy and represses activity of the cyclin D1 promoter in
chondrocyte (James et al., 2006). Immunohistochemistry demonstrated increased ATF3
expression in eNOS-deficient growth plates (Fig. 3.4C), suggesting that premature
induction of ATF3 expression in mutant mice leads to repression of cyclin D1
transcription and chondrocyte proliferation.
3.4.4 Premature differentiation of eNOS-deficient chondrocytes
Since reduced chondrocyte proliferation is often associated with premature cell
cycle exit and maturation (Beier, 2005), we examined the expression of additional
markers of prehypertrophic chondrocytes. Expression of the cell-cycle inhibitor p57,
which promotes cell cycle exit and is required for normal chondrocyte differentiation,
was found to be increased by immunohistochemistry (Fig. 3.5A) and Western blot (Fig.
3.5B) in mutant mice. In wild type growth plates, p57 protein is restricted to a small band
of prehypertrophic chondrocytes, while in KOs there is both earlier staining in late
proliferative cells and sustained staining in hypertrophic chondrocytes. The nuclear
receptor RORα is another marker for prehypertrophic and hypertrophic chondrocytes
(Woods et al., 2009b) that showed a similar expansion in expression as p57 in mutant
mice (Fig. 3.5C). Similar upregulation was observed for Hif-1α (Fig. 3.5D), a sensor for
low oxygen tension (Hwang et al., 1988; Koshiji and Huang, 2004) that has been
implicated in cartilage development (Schipani et al., 2001).
3.4.5 eNOS deficiency changes cartilage-specific gene expression
We sought to complement our immunohistochemistry results by quantitative
analyses of gene expression, using real-time RT-PCR of RNA directly extracted from
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Figure 3.5 Premature differentiation of eNOS-deficient chondrocytes.
Immunohistochemistry demonstrates increased expression of the cell-cycle inhibitor
protein p57 in mutant mice (A), which is confirmed by Western blot (B). The expression
of prehypertrophic and hypertrophic markers retinoic acid related orphan receptor alpha
(RORα) and hypoxia inducible factor 1 alpha (Hif-1α) is also upregulated in mutant
growth plates, as shown by immunohistochemistry (C and D). Counting of the positive
cells per area confirmed these changes in the mutant (E). (Scale bar=200µm)
Representative pictures from at least 4 independent experiments are shown.

108

109

cartilage. Our results revealed decreased expression of early chondrocyte markers,
Col2a1 and Sox9 and increased expression of the prehypertrophic markers RORa and
Hif1a (Fig. 3.6). In contrast, transcript levels for Col10a1, a marker of fully hypertrophic
chondrocytes, were only elevated slightly (non-significantly) in mutant cells. These data
suggest that the major phenotype in eNOS-deficient growth plates is the premature exit
from the cell cycle and earlier prehypertrophic differentiation, with fewer effects on
terminal differentiation.
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Figure 3.6 eNOS deficiency promotes prehypertrophic gene expression.
Real-time RT-PCR analyses with RNA extracted directly from neonate cartilage reveals
decreased expression of the early chondrocytes markers Col2a1 and Sox9, and increased
expression of prehypertrophic markers RORα and Hif1a in eNOS-deficient cartilage,
while expression of the hypertrophic marker Col10a1 was not significantly changed.
Mean and standard deviation from at least 4 independent experiments per genotype are
shown (*P<0.05).
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3.5 Discussion
While NO has been shown to play an important role in controlling chondrocyte
physiology in OA, the roles of the three NOS enzymes in cartilage development are less
clear. In this study, we provide evidence for an important function of eNOS in the
regulation of chondrocyte proliferation and differentiation. Our data show that genetic
ablation of the eNOS gene in vivo results in reduced chondrocyte proliferation and
endochondral bone growth. Analyses of the underlying molecular mechanisms suggest
that these effects are likely due to altered expression of several cell-cycle proteins and the
modulation of intracellular pathways with known roles in chondrocyte differentiation,
including Sox 9 and Hif-1α.
Although there were no gross morphological changes in the axial and appendicular
skeleton of mutant mice, staining confirmed smaller rib cages, skull, spine and shorter
long bones. Some KO mice showed more pronounced growth retardation and other
defects such as kinky tails. The reasons for the variability in the phenotype are not
known, but are consistent with earlier reports (Hefler et al., 2001). eNOS-deficient mice
share some similarities to those observed in mice that lack C–type natriuretic peptide
(CNP) (Chusho et al., 2001), especially dwarfism and a reduction in chondrocyte
proliferation. Because both NO and CNP stimulate the production of cGMP via soluble
or particulate guanylyl cyclases (GC) (Teixeira et al., 2008), these similarities are not
surprising and provide further evidence for the importance of cGMP signaling in
endochondral bone formation. However, the phenotype of eNOS null mice does not
exactly resemble that of mice lacking CNP or the main effector of cGMP in cartilage,
cGMP-dependent kinase II (cGKII) (Pfeifer et al., 1996). For example, mice lacking CNP
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have strikingly narrow growth plates and shorter proliferating and hypertrophic zones
(Chusho et al., 2001), which we did not see in our mutant mice. Because NO is produced
through different NOS isoforms, deletion of eNOS might be compensated by the other
two NOS enzymes. Indeed, we found a 2-fold upregulation of nNOS transcript levels in
eNOS deficient mice, suggesting that these two constitutive forms have partially
redundant roles in cartilage. Additionally, cGMP is not the only downstream target of
NO; for example, NO can alter the activity of several proteins though tyrosine
nitrosylation (Foster et al., 2009; Hess et al., 2005), which could account for some of the
observed differences to CNP- and cGKII-deficient mice.
A requirement for eNOS in proliferation has been described for a number of cells,
including endothelial cells and osteoblasts (Aguirre et al., 2001; Beier et al., 1999b). On
the other hand, Teixeira and colleagues had reported that NO signaling stimulates
chondrocyte hypertrophy in chicken chondrocytes (Teixeira et al., 2005), raising the
question whether loss of eNOS would promote proliferation at the expense of
differentiation or result in the opposite phenotype, e.g. reduced proliferation and earlier
onset of maturation. Our results clearly support the latter model. While species-specific
effects or differences in approaches (e.g. in vivo versus in vitro) could explain some of
the differences between our study and Teixeira’s (Teixeira et al., 2005), the more likely
explanation is that NO effects in chondrocytes are differentiation stage- and
concentration-dependent. For example, it is plausible to speculate that loss of only one
NOS protein has different effects as pharmacological inhibition of all three.
eNOS inactivation results in reduced chondrocyte proliferation in vivo and in vitro.
Considering that eNOS was deleted in all cells of the body in our mice, it was unclear
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whether the reduced chondrocyte proliferation is because of loss of eNOS in cartilage or
secondary to defects in other tissues (e.g. in endocrine tissues or endothelial cells).
Therefore, we conducted organ culture and primary cell culture in vitro, thus removing
systemic and endocrine influences. Our organ culture data demonstrated reduced tibia
growth upon loss of eNOS, and mutant chondrocytes showed reduced multiplication of
cells in culture. While these culture systems contain perichondral and periosteal cells that
might be responsible for some of the observed changes, these results are consistent with
the in vivo phenotype of eNOS KO mice and a cell-autonomous role of eNOS in
chondrocyte proliferation.
The progression of the eukaryotic cell cycle is controlled by cyclins and cyclindependent kinases (Beier, 2005). For example, cyclin D1 has been shown to regulate the
G1 phase of the cell cycle, is expressed specifically in the proliferating zone of growth
plates and required for maximal chondrocyte proliferation in vivo and in vitro (Beier,
2005; Beier et al., 2001). Our data showed a decline in cyclin D1 and an increase in p57
expression, presumably resulting in slower cell-cycle progression and early cell-cycle
exit upon loss of eNOS. The earlier cell cycle exit and resulting acceleration in the onset
of prehypertrophic differentiation is also supported by increased expression of
prehypertrophic markers such as RORα and Hif-1α, and by reduced expression of
markers for proliferating chondrocytes, such as collagen II and Sox9. Of note, growth
plate zone measurements and analyses of type X collagen expression suggest that eNOS
deficiency accelerates prehypertrophic differentiation without accompanying acceleration
of terminal hypertrophic differentiation.
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In summary, our data demonstrate a role for eNOS in chondrocyte proliferation
and endochondral bone growth. Loss of eNOS affects numerous aspects of cartilage
physiology, including chondrocyte proliferation and gene expression. Further
investigations into the specific mechanisms involved will result in a better understanding
of physiological and pathological ossification and the role of eNOS in arthritic diseases.
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CHAPTER FOUR

REDUCED CHONDROCYTE PROLIFERATION INCREASED APOPTOSIS
AND PREMATURE DIFFERENTIATION IN NEURONAL NITRIC OXIDE

SYNTHASE DEFICIENT MICE*

*This chapter has been reproduced from:
Yan, Q., Feng, Q. and Beier, F. Reduced chondrocyte proliferation increased apoptosis
and premature differentiation in neuronal nitric oxide synthase-deficient mice.
Submitted to Arthritis Res Ther.
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4.1 Chapter summary
Nitric oxide (NO) has been implicated in the local regulation of bone metabolism.
However, the contribution made by specific nitric oxide synthase (NOS) enzymes to
skeletal development is unclear. The objective of this study was to examine the effects of
inactivation of neuronal nitric oxide synthase (nNOS) on cartilage development in mice.
Mice carrying a null mutation in the nNOS gene were used in this study to address our
objectives. Histological staining, immunohistochemistry and in situ analyses were
employed along with real-time RT-PCR. nNOS-null mice show transient growth
retardation and shorter long bones. nNOS-deficient growth plates are hypocellular, with a
marked reduction in replicating cells. Reduced chondrocyte numbers may in part be due
to premature cell-cycle exit because of decreased cyclin D1 and increased p57
expressions in mutants. In addition, apoptosis was increased as shown by increased
cleaved-caspase 3 staining in terminal hypertrophic chondrocytes in mutants. Expression
of early chondrocyte markers such as Sox genes was reduced in mutant mice, while
expression of prehypertrophic markers Rorα and c-Fos was increased. Histological
sections also demonstrated thinner cortical bone and fewer trabeculae in mutant mice.
These data identify an important role of nNOS in chondrocyte proliferation and
endochondral bone growth and demonstrate that nNOS coordinates cell-cycle exit and
chondrocyte differentiation in cartilage development.
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4.2 Introduction
NO is a small signaling molecule with important regulatory effects in many tissues.
It can function as an intracellular messenger, an autacoid, a paracrine substance, or a
neurotransmitter (Murad, 1999). The versatile functions of NO stem from the chemical
properties of the compound. NO is a gaseous uncharged free radical with an unshared
electron that makes it easy to react with many molecules and proteins to regulate
biological processes (Moncada et al., 1991). Because it is uncharged, it can freely diffuse
to the surrounding cells, making it ideal as a signaling molecule (Teixeira et al., 2008). In
most processes, NO activates soluble guanylyl cyclase, resulting in increased levels of the
intracellular secondary messenger cGMP (Moncada et al., 1991; Murad, 1999), but other
modes of signaling such as protein nitrosylation also contribute to the biological effects
of NO (Ignarro, 1999; Moncada et al., 1991). Different cells and tissues have different
abilities to produce NO. In general, low levels of NO are produced from constitutive
nitric oxide synthases (endothelial NOS/eNOS and neuronal NOS/nNOS) and high levels
of NO stem from inducible nitric oxide synthase (iNOS). The ultimate effects of NO are
determined by its concentration, its source, and molecules in the microenvironment that it
can react with. Over years NO has been known to regulate bone cell metabolism, bone
remodeling and chondrocyte physiology in osteoarthritis (OA) (Abramson, 2008;
Teixeira et al., 2008; van't Hof and Ralston, 2001), but the contributions made by specific
NO synthase (NOS) enzymes to bone growth and development are unclear (CollinOsdoby et al., 1995; Teixeira et al., 2005). In light of the prevalent connections between
chondrocyte differentiation and the pathogenesis of OA (Drissi et al., 2005), and the well-
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known roles of NO in OA, the elucidation of the role of individual NOS genes in
cartilage development is of great importance.
Formation of the skeleton is achieved through two independent mechanisms:
intramembranous and endochondral ossification (Karsenty, 2003; Kronenberg, 2003).
Endochondral bone formation is a precisely regulated process and responsible for the
formation of most bones in the adult skeleton. It involves the steps of chondrogenesis,
chondrocyte proliferation, differentiation, and hypertrophy and eventually replacement of
cartilage tissue by bone tissue and bone marrow (Beier, 2005; Horton, 2003; Karsenty
and Wagner, 2002; Kronenberg, 2003; Provot and Schipani, 2005; Teixeira et al., 2008).
During postnatal development, proliferation and hypertrophy occur in a controlled
fashion in the cartilage growth plate that determines the final length of the adult bone.
Within the growth plate, chondrocytes are organized in distinguished zones (resting,
proliferating, prehypertrophic and hypertrophic zones) based on their morphologic shapes
and gene expression patterns (Beier, 2005). If any steps during this process are not
properly regulated, skeletal diseases will result, such as different types of
chondrodysplasias (Zelzer and Olsen, 2003).
We recently described cartilage development in eNOS-deficient mice that display
reduced bone growth (Yan et al., 2010). This effect appears to be due to a chondrocyteautonomous role of eNOS in chondrocyte proliferation. However, nNOS mRNA levels
were upregulated in eNOS-null chondrocytes, suggesting that nNOS partially
compensates for the loss of eNOS. nNOS KO mice have been found to be viable, have
enlarged stomachs due to pyloric muscle hypertrophy, exhibit insulin resistance and
resistance to neural damage as the result of stroke induced by middle cerebral artery
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ligation (van't Hof et al., 2004). nNOS expression has been detected during skeletal
development and fracture healing, and previous studies showed reduced bone remodeling
with a significant reduction in osteoblast and osteoclast numbers in nNOS-deficient mice
(van't Hof et al., 2004). However, the exact mechanisms and functions of nNOS in
earlier stages of skeletal development have not been described. In this study, we
investigated the effects of nNOS deficiency on cartilage development and endochondral
bone formation.
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4.3 Materials and methods
4.3.1 Antibodies and reagents
All reagent materials and general chemicals were obtained from Invitrogen, Sigma
or VWR unless otherwise stated. The following antibodies were employed in this study:
Kip2/p57 #sc8298 (rabbit antibody against human protein), RORα #sc28612 (rabbit
antibody against human protein), ATF3 #sc188 (rabbit antibody against human protein),
Sox9 #sc-17340 (goat antibody against human protein), c-Fos #sc-52 (rabbit antibody
against human protein), Goat-anti-mouse #sc2005, Goat-anti-rabbit #sc2004 (all from
Santa Cruz Biotechnology); Cyclin D1 (SP4) #9104-S1 (rabbit antibody against human,
mouse and rat proteins; NeoMarkers Inc.); PCNA #2586, (mouse antibody against
human, mouse and rat proteins; Cell Signaling Inc.).
4.3.2 Mouse breeding and genotyping
Mice with a deletion of the nNOS gene (Stock #2986) and control mice in the
C57/BL6 background were obtained from Jackson Laboratory (Bar Harbor, ME), and
exposed to a 12-hour light-dark cycle and fed tap water and regular chow at libitum (van't
Hof et al., 2004). All procedures involving animals were approved by the University of
Western Ontario Animal Care and Use Committee. For PCR genotyping, tail snips were
used to prepare DNA for PCR analysis. PCR genotyping was performed by simultaneous
amplification of the wild type and null nNOS alleles as described (Drissi et al., 2005;
van't Hof et al., 2004). PCR fragments were analyzed by agarose gel electrophoresis.
4.3.3 Histology and Immunohistochemistry
After dissection of mice, bones were rinsed with PBS, fixed in 4%
paraformaldehyde (PFA) overnight, placed in 10% formalin solution and sent for
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embedding and sectioning into 4µm sections at the Molecular Pathology Core Facility at
the Robarts Research Institute (London, Ontario, Canada). Following sectioning, bones
were stained with hematoxylin and eosin or safranin O/fast green using standard
protocols (Solomon et al., 2009; Wang et al., 2007) or used for immunohistochemistry as
described below.
For immunohistochemistry, sections unstained prior to use were dewaxed and
incubated in 3% H2O2 for 15 min at room temperature, followed by boiling for 20 min in
10 mM sodium citrate (pH 6.0) and blocking with 5% goat serum at room temperature for
30 min. Sections were incubated with primary antibody overnight at 4°C and secondary
antibodies according to the manufacturers’ recommendations. After washing, sections
were incubated for 1-10 min with DAB (3,3
′ -diaminobenzidine tetrahydrachloride)
substrate solution (Dako North America, Inc.), washed and mounted. All images were
taken at room temperature with a Retiga EX camera connected to a Leica DMRA2
microscope using OpenLab 4.0.4 software. For cell counts in sections, all cells and cells
positive for staining with primary antibody labeling were counted from three different
areas of one section. Sections from at least three mice per genotype, and at least three
sections from every mouse, were analyzed, and averages and standard deviation from all
counts/genotype are shown.
4.3.4 RNA isolation and real-time RT-PCR
Total RNA was isolated from epiphyseal cartilage of long bone from newborn mice
using TRIzol (Invitrogen), according to the manufacturer's recommendations. Taqman
real-time PCR was performed as described (Agoston et al., 2007; Woods et al., 2005)
with primers and probe sets from Applied Biosystems (Sox5 Mm00488381_m1; Sox6
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Mm00488393_m1;

Sox9

Mm00448840_m1;

P57

Mm00438170_m1;

MMP13

Mm00439495_m1; Igf1 Mm00439560_m1; Gapdh Mm99999915_g1). Data were
normalized to Gapdh mRNA levels and represent averages and SEM from direct
comparison of mutant and control littermates from three different crosses.
4.3.5 Statistical analysis
All experiments were performed with at least three independent litters. Statistical
significance was determined by a one-way ANOVA with Bonferroni post test using
GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego, California,
USA.
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4.4 Results
4.4.1 Inactivation of nNOS gene results in reduced bone length
We used nNOS-deficient mice to address the role of this gene in cartilage
development in vivo.

The knockout mice were viable and fertile, and the general

appearance of stature and gait were unremarkable, but male knockout mice appeared
more aggressive. Body weight and length were not significantly changed in nNOS-/- mice
at birth. Growth retardation developed in surviving nNOS-/- mice in the postnatal period at
day 21 to 42, as shown by reduced body weight and length (Fig. 4.1A). Body weight
showed significant reduction at postnatal day 11, before body length was reduced (Fig.
4.1A). However, analyses at 3 month and 1 year of age demonstrated similar body weight
and body length between genotypes (data not shown), suggesting that KO mice catch up
during ageing. Observation of alcian blue/alizarin red-stained skeletons showed no
obvious morphological changes in the axial and appendicular skeleton of mutants (data
not shown), but measurement of selected individual bones confirmed reduced bone length
in tibiae and humerus in mutant mice at postnatal day 21 (Fig. 4.1B).
4.4.2 nNOS deficiency results in reduced chondrocyte proliferation in the growth
plate
To elucidate the cellular basis for the skeletal phenotype, we analyzed growth plate
organization at different developmental stages. Growth plates from newborn mutant mice
displayed a similar chondrocyte arrangement in resting, proliferative and hypertrophic
zones as control mice (Fig. 4.2A). Measurement of the lengths of resting, proliferating
and hypertrophic zones did not show significant differences (data not shown) between
genotypes, and cells in the resting and hypertrophic zones of nNOS null mice did not
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Figure 4.1 Loss of nNOS results in reduced growth and bone length.
Analyses of body weight and length of wild type and nNOS homozygote null mice
showed that growth retardation developed in nNOS null mice during the first 42 days of
their life (A). Measurement of selected individual bones confirmed reduced bone length
in humerus and tibiae in postnatal day 21 mutant mice (B). Mean and standard deviation
from at least 8 mice per genotype are shown for each data point. (*P<0.05) (WT: wild
type; KO: knockout).
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Figure 4.2 Lack of nNOS causes reduced numbers of proliferating chondrocytes.
Safranin O/Fast Green staining of tibia growth plate sections from newborn mice
demonstrated similar growth plate architecture in both genotypes, however, counting of
cells revealed fewer cells in the proliferative zone of mutant growth plates (A and B).
Detailed analyses of H&E stained cells in the resting, proliferative, and hypertrophic
zones confirmed that the major differences occur in the proliferative zone (C). (RC:
resting cells; PC: proliferating cells; HC: hypertrophic cells). (Scale bar=200µm) Mean
and standard deviation from at least 6 mice per genotype are shown (*P<0.05).
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appear markedly different from controls. However, nNOS-/- growth plates were
hypocellular, especially in the proliferative zone in the center of the growth plates. Some
cells appear to be smaller in size, and the proliferative zone was disorganized with fewer
and shorter columns (Fig. 4.2A,B and C). Counts of cell numbers in the proliferative
zone of the growth plate revealed fewer cells in mutants (73% of control cell numbers per
area) (Fig. 4.2B).
Since our mutant mice showed lower cell numbers in the proliferative zone of the
growth

plate,

we

Immunohistochemical

next

examined

staining

for

chondrocyte
proliferating

proliferation
cell

nuclear

and
antigen

apoptosis.
(PCNA)

demonstrated a reduction in positive cells in mutant mice (Fig. 4.3A). Reduced cell
counts could also be due to increased cell apoptosis, which we examined by
immunohistochemical staining for cleaved (activated) caspase 3. Staining for cleaved
caspase 3 was increased in hypertrophic chondrocytes of mutant mice (Fig. 4.3B).
To elucidate the reason for reduced proliferation in nNOS-/- mice, we examined
cell cycle protein expression in growth plates. Immunohistochemical staining for cyclin
D1, which controls progression through the G1 phase of the cell cycle (Beier, 2005),
demonstrated reduced number of positive cells in mutant mice (Fig. 4.3C). The
transcription factor ATF3 acts as a repressor of cyclin D1 transcription in chondrocytes
(James et al., 2006). Immunohistochemistry demonstrated a larger number of ATF3expressing chondrocytes in nNOS-deficient growth plates (Fig. 4.3D), suggesting that
premature induction of ATF3 expression in mutant mice leads to repression of cyclin D1
transcription and chondrocyte proliferation.
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Figure 4.3 nNOS deficiency reduces chondrocyte proliferation and increases
apoptosis.
Immunohistochemical staining of newborn tibia sections for proliferating cell nuclear
antigen (PCNA; A) or cyclin D1 (C) showed a reduction in stained cells in mutant mice.
Increased staining for cleaved caspase 3 was found in hypertrophic chondrocytes in
mutant tibia sections (B). In addition, expression of ATF3 protein was increased in
growth plates from newborn mutant mice (D). (Scale bar=200µm) Representative
pictures from at least 3 independent experiments are shown. Mean and standard deviation
from at least 6 mice per genotype are shown (*P<0.05).
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4.4.3 nNOS-deficient chondrocytes differentiate prematurely
Since reduced chondrocyte proliferation is often associated with premature cell
cycle exit and maturation (Beier, 2005), we examined the expression of additional
markers of prehypertrophic chondrocytes. Expression of the cell-cycle inhibitor p57,
which promotes cell cycle exit and is required for normal chondrocyte differentiation,
was found increased by immunohistochemistry in mutant mice (Fig. 4.4A).
Immunohistochemistry also showed a similar increase in the number of cells expressing
the transcription factors c-Fos (Fig. 4.4B) and RORα (Fig. 4.4C), both of which have
been implicated in hypertrophic chondrocyte-specific gene expression (Riemer et al.,
2002; Woods et al., 2009a). In contrast, Hif-1α protein expression was not changed in
KO mice (Fig. 4.4D).
4.4.4 nNOS deficiency affects cartilage-specific gene expression
In parallel, we analyzed expression of several cartilage marker genes in the mutant
mice by real-time RT-PCR, using RNA directly extracted from cartilage. Our results
revealed decreased expression for early chondrocyte markers Sox5 and Sox6 (Fig. 4.5A,
B) while the reduction in mRNA levels for Sox9 did not reveal statistical significance
(Fig.

4.5C).

Real-time

RT-PCR

also

demonstrated

increased

expression

of

prehypertrophic and hypertrophic markers p57 and Mmp13 (Fig. 4.5D,E). Transcript
levels for Igf1, which plays an important role in regulating skeletal development and bone
remodeling (Wang et al., 1992), were also strongly decreased in the mutant mice (Fig.
4.5F). Transcript levels for several other genes did not show significant responses to
disruption of the nNOS gene in cartilage, including Ihh, aggrecan, Col 10a1, Vegfa,
Runx2, and RANKL (data not shown).
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Figure 4.4 Premature differentiation of nNOS-deficient chondrocyte
Expression of the cell-cycle inhibitor p57, which promotes cell cycle exit and is required
for normal chondrocyte differentiation, was found increased by immunohistochemical
analyses of newborn tibia sections in mutant mice (A). Immunohistochemistry also
showed a similar increase in the number of cells expressing the transcription factors cFos (B) and RORα (C), while Hif1α expression did not change in the mutant mice (D)
from newborn tibia sections. (Scale bar=200µm) Representative pictures from at least 3
independent experiments are shown.
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Figure 4.5 nNOS deficiency affects cartilage-specific gene expression.
Real-time RT-PCR revealed decreased expression for early chondrocyte markers Sox5
and Sox6 (A, B). And increased expression of the prehypertrophic and hypertrophic
markers p57 and MMP13 were also demonstrated in cartilage of KO mice (C,D).
Transcript level for Igf1 was significantly decreased in the mutant mice (E). mRNA
levels of iNOS and eNOS were also found upregulated in nNOS KO cartilage (F,G).
Mean and standard deviation from at least 4 independent experiments per genotype are
shown (*P<0.05).
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Interestingly, we also demonstrated upregulated eNOS and iNOS mRNA levels in the
nNOS KO samples (Fig. 4.5G,H).
4.4.5 Loss of nNOS results in reduced trabecular bone and calcium deposition
To analyze whether nNOS deficiency had effects on endochondral ossification, we
next examined trabecular bone formation and ossification patterns in mutant mice. Von
Kossa staining demonstrated mineralization of trabecular and cortical bone in tibia
sections from postnatal day 21 mice, which was clearly decreased in mutant mice (Fig.
4.6A). A lack of trabecular structures was seen by picrosirius red staining for fibrillar
collagen (Fig. 4.6B), suggesting that these effects are not simply due to delayed
mineralization, but to a delay or reduction in bone formation. Additionally, thinner
cortical bone was also shown in mutant mice by Safranin O/Fast green staining from
postnatal day 12 mice (Fig. 4.6C). Secondary ossification centers were advanced in
control mice at postnatal day 12, but age-matched KO mice displayed underdeveloped
ossification centers (Fig. 4.6D).
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Figure 4.6 Deficient of nNOS leads to reduced trabecular bone and calcium
deposition.
Mineralization of trabecular and cortical bone shown by VonKossa staining in tibia
sections from postnatal day 21 mice was clearly decreased in mutant mice (A). A similar
lack of trabecular structures was also seen by picrosirius red staining for fibrillar collagen
(B). Additionally, thinner cortical bone was also showed in mutant mice by Safranin O/
Fast green staining (C) from postnatal day 12 mice tibiae. Secondary ossification centers
were advanced in control mice at postnatal day 12, but displayed underdeveloped
ossification centers in mutant mice (D). (Scale bar: 200µm for A,B,D; 50µm for C)
Representative pictures from at least 3 independent experiments are shown.
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4.5 Discussion
The signaling pathways that control growth plate chondrocyte proliferation and
differentiation during endochondral ossification are incompletely understood. In this
study, we provide evidence for an important role of the nNOS gene in these processes.
Our data show that genetic ablation of nNOS results in reduced chondrocyte proliferation
and endochondral bone growth in vivo. Analyses of these changes in cellular and
molecular levels suggest that these effects are likely due to altered expression of several
cell-cycle proteins, such as cyclin D 1 and p57, as well as modulation of other genes with
known roles in cartilage differentiation, including Sox genes, RORα and c-Fos.
Although there were no obvious morphological changes in the axial and
appendicular skeleton, measurement of individual bones confirmed shorter tibiae and
femurs in postnatal day 21 mutant mice. Detailed analyses of nNOS null tissue sections
revealed several abnormalities, most notably reduced chondrocyte proliferation. nNOSdeficient growth plates resemble those we observed in mice lacking the eNOS gene (Yan
et al., 2010) and also share similarities to those in mice deficient for C-type natriuretic
peptide (CNP) (Chusho et al., 2001). Because both NO and CNP stimulate the production
of cGMP via soluble or particulate guanylyl cyclases (GC) (Chusho et al., 2001), these
similarities are not surprising and further document the importance of cGMP signaling in
endochondral bone formation. However, it should be noted that a major phenotype of
CNP null mice is a reduction in the length of the hypertrophic zone (Chusho et al., 2001)
that we did not observe here. One potential explanation for this difference is that during
hypertrophy, when all three NOS genes are expressed highly (Teixeira et al., 2005),
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eNOS and/or iNOS (or potentially CNP) can compensate for the loss of nNOS, while
they are not able to do so in the proliferating zone.
The growth plate phenotype of nNOS KO mice is strikingly similar to that of
eNOS null mice (Yan et al., 2010). Given the similar functions of eNOS and nNOS, the
similarities between the phenotypes of both KO lines are not surprising. The
compensatory upregulation of transcripts for both enzymes in the eNOS and nNOS KO
mice provides further evidence for overlapping function of the two genes. It is likely that
simultaneous inactivation of both genes would have more severe outcomes, but we have
not been able to obtain double KO mice despite extensive efforts. However, it should be
noted that mice lacking all 3 NOS genes have been described (Sabanai et al., 2008). Even
though those mice show a very high rate of lethality (85%), the surviving triple NOS
knockout mice live a surprisingly normal life (Nakata et al., 2008), suggesting that
additional compensatory mechanisms may exist.
nNOS inactivation, very similar to deletion of the eNOS gene (Yan et al., 2010),
results in reduced chondrocyte proliferation and increased apoptosis. However, increased
staining for active caspase 3 mainly located to terminally differentiated hypertrophic
chondrocytes, suggesting that apoptosis plays no or only a minor role in the
hypocellularity that we observed mainly in the proliferative zone.
One of the major reasons for the reduced proliferation appears to be the induction
of the transcription factor ATF3, which is able to suppresses cyclin D1 transcription
(James et al., 2006). Cyclin D1 expression is induced by many mitogenic stimuli and
pathways in chondrocytes (Beier, 2005). Our studies suggest that in addition to positive
regulation through transcription factors such as ATF2 and CREB (Beier et al., 2001;
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Beier et al., 1999b; Beier and LuValle, 2002), cyclin D1 transcription is also under
negative regulation by ATF3 (James et al., 2006), for example in response to reduced NO
levels. The cyclin-dependent kinase inhibitor p57 is a second cell cycle protein showing
altered expression in the absence of eNOS or nNOS. Immunohistochemsitry showed
earlier and broader expression in mutant mice, along with other prehypertrophic markers
such as RORα. At the moment, we don’t know whether NO signaling regulates cyclin D1
and p57 expression through a common pathway or through different effectors. It is also
possible that premature differentiation to prehypertrophic chondrocytes is due to the
reduced expression of Sox5, Sox6 and potentially Sox9 in nNOS KO cartilage, but the
relationship between these transcription factors and cyclin D1 expression has not been
addressed. Finally, reduced expression of Igf1 could also contribute to the dwarf
phenotype of nNOS KO mice, although the reduced growth in Igf1-deficient mice is
largely due to smaller size of hypertrophic chondrocytes, as opposed to the primary effect
on cell proliferation in our mice (Wang et al., 2006).
Loss of nNOS results in reduced von Kossa staining of cortical and trabecular
bone. Picrosirius red staining suggests that this effect is due to paucity of trabecular
structures per se, not just a delay in mineralization. At the moment, it is unclear whether
this phenotype is secondary to defects in cartilage development or due to intrinsic
functions of nNOS in osteoblasts or osteoclasts. As has been shown before (van't Hof et
al., 2004), the similar phenotypes between trabecular and cortical bone (which does not
develop from a cartilage intermediate) suggest the latter, but cell type-specific KO
models will be required to resolve this question.
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In summary, our data demonstrate a role for nNOS in chondrocyte proliferation
apoptosis and maturation. Loss of nNOS affects numerous aspects of cartilage
physiology, including chondrocyte proliferation and gene expression, as well as
mineralization of bone. It appears likely that the overall phenotype of nNOS deficient
mice is a combination of alternations in all these aspects. Further investigations into the
specific mechanisms involved will result in a better understanding of physiological and
pathological skeletal development and associated diseases, such as osteoarthritis and
osteoporosis.
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CHAPTER FIVE

GENERAL DISCUSSION AND CONCLUSIONS
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5.1 Overview of the research project
The focus of this thesis was to investigate the role of NOS/NO signaling in
endochondral bone formation. The roles of NO and NOS genes have been studied
extensively in bone remodeling and arthritis (Abramson, 2008; Scher et al., 2007; van't
Hof and Ralston, 2001). This pathway has also been implicated in chondrocyte
physiology during development. Teixeira and colleagues had shown that excess NO
promotes hypertrophic differentiation and apoptosis of chondrocytes in chicken (Teixeira
et al., 2005; Teixeira et al., 2001). However, much less is known about the specific roles
of individual NOS genes in cartilage development and endochondral ossification
(Teixeira et al., 2008).
Endochondral bone formation is a precisely regulated process, involving the steps
of chondrogenesis, chondrocyte proliferation, differentiation, hypertrophy and eventually
replacement of cartilage tissue by bone tissue and bone marrow (Beier, 2005; Horton,
2003; Karsenty and Wagner, 2002; Kronenberg, 2003; Provot and Schipani, 2005;
Teixeira et al., 2008). If any steps during this process are not properly regulated, skeletal
diseases will result, such as different types of chondrodysplasias (Zelzer and Olsen,
2003). Therefore, it is important to investigate the cellular mechanisms controlling
growth plate regulation, for a better understanding of pathophysiological processes
resulting in skeletal diseases.
The intracellular signaling pathways that control growth plate chondrocyte
proliferation and differentiation during endochondral ossification are incompletely
understood. Over the last several years, our studies in the laboratory have already
identified Rac1 gene as an important regulator of chondrocyte differentiation in vitro and
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in vivo (Wang et al., 2007; Woods et al., 2007b). In particular, mice with cartilagespecific deletion of the Rac1 gene display high mortality, profound dwarfism and
numerous skeletal defects (Wang et al., 2007). The severe dwarfism we observed upon
cartilage-specific deletion of Rac1 gene is mostly due to the profound reduction in
chondrocyte proliferation (Wang et al., 2007; Woods et al., 2007b). However, the
downstream mechanisms connecting Rac1 to chondrocyte proliferation are unknown.
Rac1 has been shown to control many cellular processes, including actin dynamics,
gene expression and generation of reactive oxygen species (ROS) (Bustelo et al., 2007;
Hordijk, 2006). The first thought during this project was to indentify whether ROS
signaling mediates Rac1 effects on chondrocyte proliferation. However, a recent study
showed that elevated ROS levels inhibit chondrocyte proliferation and induce
hypertrophy in vivo and in vitro, which did not support the notion of ROS mediating
mitogenic signaling by Rac1 (Morita et al., 2007). Indeed, we only found a moderate
reduction of ROS levels in Rac1-deficient chondrocytes. There are many interactions
between ROS and nitric oxide (NO) (Thomas et al., 2008); for example, NO can react
rapidly with superoxide and other oxygen species to form nitrite, nitrate, and
perioxynitrite (collectively called reactive nitrogen species, RNS) (Asou et al., 2002;
Feelisch, 2008; Ignarro, 1999; Moncada et al., 1991). However, NO or the enzymes
involved in its synthesis have not been identified as major mediators of Rac1 signaling.
Therefore we measured NO levels upon deletion of Rac1 in primary chondrocytes and
indeed found a significant reduction in NO levels. Interestingly, Rac1 deficiency in
primary chondrocytes resulted in reduced iNOS protein expression but no changes in
eNOS protein levels. Immunohistochemistry also showed reduced iNOS expression and
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nitrotyrosine staining, which is an indicator of intracellular NO, in Rac1 null cartilage.
Therefore we decided to examine the role of iNOS, and subsequently the other two NOS
genes, in cartilage development.
First we performed primary cell culture to investigate the effects of NOS inhibitors
and NO donors on chondrocytes. We found that inhibition of NOS by LNAME results in
reduced cell numbers, while NO donors increase chondrocyte numbers. After 6 days of
tibia organ culture, NOS inhibition resulted in a shortened proliferating zone. In addition,
we analyzed the rate of cell cycle progression by labeling growth plate chondrocytes in
the S-phase of the cell cycle with bromo-deoxyuridine (BrdU), demonstrating reduced
BrdU labeling upon NOS inhibition. Thus we demonstrated that NOS/NO signaling
regulates chondrocyte proliferation in vitro. In the next step, we started to examine this
signaling pathway in cartilage growth plate biology in vivo.
Using genetically modified mice, we examined the role of iNOS in growth plate
physiology. The physical appearances of the iNOS KO mice were not distinguishable
from WT mice. There were no obvious skeletal phenotypes in the KO mice. However,
close examination of the growth plate showed hypocellularity, especially in the center of
the growth plate. Counting of proliferating cells showed reduced cell numbers in the KO
mice. Therefore, we next analyzed cell cycle progression by using BrdU incorporation
assay which demonstrated reduced labeling in the iNOS KO mice, suggesting slower cell
proliferation in the KO mice.
Although these data established a role of iNOS in regulating chondrocyte
proliferation, we still did not know whether it mediated Rac1 effects on chondrocyte
proliferation. We used primary chondrocyte and tibia organ culture models to examine
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whether addition of exogenous NO could overcome the effects of Rac1 deficiency.
Addition of SIN-1, a NO donor, rescued the numbers of Rac1-deficient chondrocytes in
monolayer culture. In parallel, we treated cells with PMA, an inducer of ROS, and
observed no effects on chondrocyte numbers. Rac1 inhibition resulted in drastic reduction
of bone growth and shortening of the proliferative zone in the tibia organ culture system.
The NO donor SNP did not affect bone growth on its own, but completely rescued the
effects of Rac inhibition on overall tibia growth and the length of the proliferative zone.
These data demonstrate that restoration of NO levels overcomes the effects of Rac1
deficiency in the intact growth plate.
To investigate this signaling pathway further, we examined the mechanism behind
this regulation of chondrocyte proliferation by examining the expression of cell cycle
proteins. Cyclin D1 was decreased in the Rac1-deficient chondrocyte culture, and
treatment with SIN1 but not PMA restored cyclin D1 expression. In agreement with these
data, expression of the cell-cycle progression protein cyclin D1 was decreased in the
Rac1 KO mice. We had shown in our laboratory that cyclin D1 expression in
chondrocytes is repressed by ATF3 (Beier et al., 2001; Beier et al., 1999a; James et al.,
2006). Therefore, we next analyzed the expression of ATF3 in the KO mice and in our
chondrocyte monolayer culture. SIN-1 treatment reduced ATF3 protein levels both in
control

and

Rac1-depleted

chondrocytes

in

cell

culture.

Additionally,

immunohistochemistry demonstrated increased numbers of ATF3-positive cells upon loss
of Rac1 as well as in iNOS KO mice. This suggests premature induction of ATF3 which
can repress cyclin D1 transcription and result in earlier cell cycle withdrawal. We have
shown for the first time here that Rac1 activates the iNOS/NO pathway that in turn
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suppresses ATF3 expression in order to maintain cyclin D1 transcription and chondrocyte
proliferation.
After demonstrating a role of iNOS in chondrocyte proliferation, we next aimed
to examine whether other NOS genes regulate cartilage development and endochondral
bone formation. I started by characterizing the phenotype of eNOS-null mice. These mice
showed decreased viability and increased embryonic death. Examination of the genotype
distribution of newborn mice revealed that only 14% of pups are homozygote for the
mutant eNOS allele, and 40% are heterozygote, both numbers lower than the expected
Mendelian ratios. These data suggest that loss of eNOS may lead to major abnormities
during embryonic development and results in increased lethality at the prenatal or
perinatal stages. Slightly decreased body weight and length were found in eNOS-/- mice at
birth. Both of these parameters became more pronounced in surviving mutant mice as the
animals aged (to 6 weeks). However, the phenotypes of the KO mice were variable.
While the physical appearance of some KO mice was unremarkable in comparison to WT
mice, some eNOS-/- mice demonstrated a more severe delay in growth and development
and a significant reduction in size, and some were born with a kinky tail (6 out of 20 KO
mice from 9 litters). Interestingly, when this phenotype was observed, it always affected
all KO pups size in that litter.
We next examined the skeletal phenotypes of eNOS-deficient mice. There were
no obvious morphological changes in the mutant skeleton, but neonatal mutant mice
showed reduced bone length in humeri and tibiae. Appearance of primary and secondary
ossification centers was delayed in the eNOS null mice compared with control mice and
picrosirus-red staining showed fewer and shorter trabecular bones in mutant mice.
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Because our mutant mice showed skeletal phenotypes, we next analyzed the
cellular basis of this phenotype. Growth plates from newborn mutant mice displayed
similar zonal organization as control animals. Measurement of the length of the growth
plate zones did not show significant difference between genotypes. However, eNOS-/growth plates were hypocellular, especially in the center of the growth plates (similar to
iNOS null mice). Cell counts in the proliferative zone of the growth plate revealed fewer
cells per area in mutants, while cell counts in the articular cartilage did not show a
significant difference between genotypes. I next examined cell proliferation in eNOSdeficient growth plates. BrdU incorporation assay and immunohistochemical staining for
PCNA showed a marked reduction in replicating cells in mutant mice.
Because our mutant mice are whole body KO mice, we did not know whether the
skeletal phenotype was due to loss of eNOS gene in cartilage or secondary to defects in
other organ systems. Therefore, I performed organ culture and primary cell culture in
vitro. MTT assays demonstrated that mutant chondrocytes increased their numbers more
slowly than those form control littermates. In addition, tibia organ culture experiments of
E15.5 eNOS-/- and wild type mice showed that bones from KO mice grew significantly
less compared to those from control animals. These data suggest that eNOS is required
for normal chondrocyte proliferation in a cell-autonomous fashion.
Next

I

examined

cell

cycle

protein

expression

in

growth

plates.

Immunohistochemical staining of cyclin D1 demonstrated reduced numbers of positive
cells in mutant mice, while ATF3 expression was increased in eNOS-deficient growth
plates. Since reduced chondrocyte proliferation is often associated with premature cell
cycle exit and maturation (Beier, 2005), I next examined the expression of markers of
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prehypertrophic chondrocytes. Expression of the cell-cycle inhibitor p57 was found
increased by immunohistochemistry and Western blot in mutant mice. Other
prehypertrophic and hypertrophic markers, nuclear receptor RORα and Hif-1α, showed a
similar upregulation in KO mice. Their expression expanded from prehypertrophic zone
in control animals to the whole prehypertrophic and hypertrophic zone in the growth
plates of mutant mice. This phenotype is very similar to that we observed in iNOS KO
mice. This raises the questions whether there are common functions of the different NOS
genes in cartilage. By using real-time RT-PCR, I found a 3-fold increase of nNOS mRNA
level in eNOS KO cartilage, while iNOS transcript levels did not change. These data
suggest that there are compensatory effects between the two constitutively expressed
NOS genes, nNOS and eNOS.
Due to the compensatory upregulation of nNOS we found in eNOS KO mice, we
next decided to investigate the role of nNOS in cartilage development and endochondral
bone formation. nNOS knockout mice were viable and fertile, and the general appearance
of stature and gait were unremarkable. The mutant mice showed transient growth
retardation in young adulthood (2-6-week old). Other than that, there were no obvious
skeletal phenotypes. A lack of trabecular structures was seen by picrosirius red staining
and reduced mineralization of trabecular and cortical bone was demonstrated by Von
Kossa staining at postnatal day 21. Analyses of the mutant growth plate showed a very
similar phenotype to iNOS and eNOS null mice. Growth plates from nNOS KO mice
showed reduced numbers of proliferating and PCNA-positive cells. The mechanisms
behind this phenotype appeared to be premature induction of ATF3 expression, resulting
in reduced cyclin D1 expression and chondrocyte proliferation. This suggests that ATF3
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and cyclin D1 present a common pathway downstream of all three NOS genes in cartilage
biology.
Immunohistochemistry also showed increased staining for cleaved (active)
caspase-3 in cartilage of nNOS KO mice, suggesting increased apoptosis in the mutant
mice. Expression of the cell-cycle inhibitor p57 and the transcription factors c-Fos and
RORα was found significantly increased by immunohistochemistry in mutant mice. Realtime RT-PCR confirmed increased expression of the prehypertrophic and hypertrophic
markers p57 and Mmp13 in nNOS-deficient cartilage. Interestingly, transcript levels of
Igf1, which plays an important role in regulating skeletal development and bone
remodeling (Wang et al., 1992), were also significantly decreased in the mutant mice.
Moreover, eNOS and iNOS transcript levels were upregulated in nNOS KO mice, further
confirming the compensatory mechanisms among these NOS enzymes.
Collectively, these findings implicate the NOS/NO signaling pathway in
regulating chondrocyte proliferation, differentiation and apoptosis during endochondral
bone growth. Table 5.1 summarized the observed phenotypes for all three mutant mouse
lines.
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Table 5.1 Summary table of the phenotypes in the three NOS mutant mouse lines.

mice

iNOS KO

eNOS KO

nNOS KO

Bone phenotype

Reduced bone length

Reduced bone length;
delayed ossification;
fewer trabecular bone;
kinky tail

Reduced bone length;
fewer trabecular bone
and reduced
mineralization

Growth plate

Reduced proliferating
cell numbers

Reduced proliferating
cell numbers

Reduced proliferating
cell numbers

BrdU
PCNA
Cyclin D1
ATF3
Caspase-3
P57
Rorα
C-Fos
Hif1α
Sox9
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5.2 Contributions and significance
5.2.1 Contributions to the field of cartilage biology
NO has been intensively studied in bone remodeling and arthritis. I showed for the
first time that NOS/NO pathways regulate chondrocyte proliferation in vivo. Inactivation
of any NOS gene leads to reduced chondrocyte proliferation, and premature
prehypertrophic differentiation in growth plates. The significant reduction in bone length
suggests that these pathways might play an important role in the complex regulation of
growth plate physiology. NO has been implicated in controlling cell-cycle progression.
My work identified decreased cycinD1 and increased p57 expression, which could
explain the reduction in chondrocyte proliferation and bone length. We also identified,
for the first time, Rac1 as an upstream regulator of iNOS/NO signaling in chondrocytes.
Similarly, our finding that NOS genes suppress ATF3 expression in chondrocytes is
novel. This NO ATF3  Cyclin D1 pathway appears to be shared by all three NOS
genes to regulate chondrocyte proliferation and differentiation (Fig. 5.1). On the other
hand, NOS/NO signaling delays the onset of chondrocyte maturation.

Premature

hypertrophic differentiation is also a common feature of all three NOS KO mice and they
may contribute to the phenotypes observed. Most likely NO effects in chondrocytes are
differentiation stage- and concentration-dependent. For example, it is plausible to
speculate that loss of only one NOS protein has different effects as pharmacological
inhibition of all three.
NO signaling has been implied in transducing signals from various extracellular
stimuli, such as cytokines, chemokines, growth factors and hormones, for the regulation
of cell growth and metabolism. In addition to ATF3, Sox9 is another candidate
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downstream target of No signaling. Sox9 is one of the major transcription factors
regulating early chondrocyte differentiation (Asou et al., 2002; Karsenty and Wagner,
2002) and was decreased in eNOS and nNOS KO mice.
My data also implicate the NO pathway for the first time in the development of
secondary ossification centers in the epiphyseal cartilage. The formation of SOC had
been investigated in a number of studies, but not to the same extent as the development of
primary spongiosa. Therefore, additional insight into this type of regulation will help us
to understand the similarities and differences between these two components of the
endochondral bone formation process. My data show that NOS/NO signaling is required
for the normal onset and progression of secondary ossification. The most important
findings of my thesis for our understanding of cartilage development are summarized in
Table 5.1.
5.2.2 Contribution to the field of NO research
The role of NO has been intensively studied in inflammatory diseases, tissue
injury, infection and shock (Mander and Brown, 2004). Although not all details are
understood, the cytostatic action of NO, when attained at high concentrations from iNOS,
has been found essential in these processes (Akarasereenont et al., 1994; Swierkosz et al.,
1994; Tomlinson et al., 1994; Vane et al., 1994). However, the stimulatory action of
lower quantities of NO on cell physiological function, such as cell proliferation and
migration, has received less attention, although its potential physiological importance is
already apparent, such as in multiple organ development (Amin et al., 1997; Mander and
Brown, 2004; Peunova et al., 2001; Reif et al., 2004). Knowledge about the molecular
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mechanisms and signalling events that are responsible for the enhancement of cell
proliferation induced by NO is still very limited.
eNOS-deficient mice showed a significant reduction in neuronal progenitor cell
proliferation in the dentate gyrus with no difference on apoptotic cell death, suggesting
that eNOS selectively exerts its effects on the proliferation of progenitor cells. This might
be mediated by a decrease in VEGF transcripts (Reif et al., 2004). The knockout of the
nNOS gene results in decreased proliferation of neural precursors with the subsequent
depletion of immature neurons in the olfactory epithelium of newborn mice, and altered
organization of glomerular cell layers in the adult olfactory bulb, suggesting a positive
action of NO on early postnatal development (Chen et al. 2004). NO also enhances cell
proliferation in neuroepithelial cells of the developing neural tube (Traister et al. 2002;
Plachta et al. 2003). It has been demonstrated that in lung epithelial and pleural
mesothelial cells the depletion of endogenous NO by carboxy-PTIO, an NO scavenger
compound, stops cell proliferation by arresting the cell cycle (Janssen et al. 1998).
In the cardiovascular system and heart development, eNOS KO mice are
hypertensive and lack NO-mediated, endothelium-dependent vasodilation, have
suppressed smooth muscle cell proliferation and display a negative inotropic effect (Sato
et al., 2000). In a human bone marrow-derived mesenchymal stem cell culture (HBMSC),
nitroglycerin (0.1–10 μM) led to a dose-dependent increase in cell proliferation and
osteoblastic differentiation of HBMSC (Aguirre et al., 2001). Two NO donors, sodium
nitroprusside (SNP) and S-nitroso-N-acetylpenicillamine (SNAP), stimulated an increase
in myoblast cell number over a range (1-10 pM) of donor concentrations (Ulibarri et al.,
1999).
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Controversy exists about the antiproliferative role of NO in smooth muscle cells,
Drosophila and Xenopus development and a kidney cell line. One study showed that NO
is involved in controlling the size of body structures as an antiproliferative agent during
Drosophila development (Kuzin et al., 1996). And NO is an essential negative regulator
of cell proliferation in the Xenopus brain (Peunova et al., 2001). Constitutive expression
of nNOS plays an antiproliferative role in human airway smooth muscle cells (Amin et
al., 1997). eNOS gene transfer inhibited cellular proliferation in a human embryonic
kidney cell line (Maeda et al., 2000).
Collectively, the regulatory action of NO on cell proliferation is exerted in a
biphasic mode, enhancing and inhibiting the progression of the proliferative process
depending on the actual concentration of NO encountered by the cell and likely also the
specific cell type. My data will contribute to elucidate the physiological role of NO in
chondrocyte proliferation and also provide the mechanisms underlying this regulation.
The action of NO stimulating the proliferation of tumor cells has also become an
important pathophysiological issue (Yoon et al., 2004). The studies concerning the action
of NO on cancerous cells could be significant to better understand the molecular
mechanisms underlying this pathological process and its possible therapeutic control. It is
postulated that the NOS/NO pathway may be implicated in cellular proliferation and
DNA or RNA synthesis of cancer cells, apart from promoting tumor angiogenesis (Shang
et al., 2006) as well as its role in regulation in cell cycle progression in cancer cells (Holt,
2000).
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5.2.3 Contribution to the understanding and development of therapeutic strategies
in skeletal diseases
Achondroplasia, caused by activating mutations in the FGFR3 gene, is the most
common genetic form of dwarfism (Yasoda et al., 2004; Zelzer and Olsen, 2003).
Currently, there is no treatment for achondroplasia other than distraction osteogenesis. In
a mouse model of achondroplasia, systemic administration of CNP or cartilage-specific
overexpression of CNP in transgenic mice was shown to be very effective in promoting
bone growth (Yasoda et al., 2009; Yasoda et al., 2004). No side effects, including tumor
growth, were observed after intravenous administration of synthetic form of CNP, CNP22 (Yasoda et al., 2009). CNP is a promising candidate for treatment of achondroplasia
and potentially other skeletal dysplasias, but as a peptide it is relatively expensive to
generate and difficult to deliver to target cells in non-vascularized cartilage. NO and CNP
converge on the secondary messenger cGMP and thereby activate cGKII in cartilage. As
my data suggest, NOS/NO promote chondrocyte proliferation in cartilage. This may
imply a potential therapeutic target for treatment of achondroplasia, and possibly other
chondrodysplasias. Similarly such approaches might be useful in the treatment of other
skeletal diseases including trauma and osteoarthritis.
More generally, skeletal development is a well controlled, complex process, and
improved understanding of this process will help us comprehend how disturbances can
compromise the function of the entire system and how we can counteract such
disturbances.
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5.3 Limitations of research project and future directions
5.3.1 Limitations of interpretation
Reduced chondrocyte numbers in our mutant mice could also be due, in part, to
increased apoptosis (in addition to reduced proliferation). Although the observed
apoptosis, shown by cleaved caspase-3, was mainly located in terminal differentiated
hypertrophic chondrocytes, there is a chance that apoptosis or other forms of cell death
also play a role to reduce chondrocyte numbers. Therefore the decreased chondrocyte cell
numbers in KO mice could be a combination of reduced proliferation and increased
apoptosis. It would be useful to examine growth plates at different developmental stages
to elucidate this question. High concentrations of NO have long been linked to
chondrocyte apoptosis (Moncada et al., 1991), while the low level of NO from cNOS
(eNOS and nNOS) could be protective in chondrocyte survival. As we did not study this
effect in iNOS and eNOS KO mice, it would be useful to examine chondrocyte apoptosis
in these KO mice.
The regulation of Sox9 expression by the NOS/NO signaling pathway in
chondrocytes is very interesting and potentially important, but I cannot conclude whether
this is due to direct regulation by NOS/NO or secondary to other events. In addition to
our results, Sox9 nuclear translocation has been found to be regulated by cGKII in rat
chondrocytes (Chikuda et al., 2004), suggesting that regulation of Sox9 by
NO/cGMP/cGKII is complex and occurs at multiple levels. Further analysis of these
relationships is required for a more complete understanding of the downstream events of
NO signaling during cartilage development.
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We demonstrated in this project that NO suppresses the expression of ATF3 which
we expect to be responsible for reduced chondrocyte proliferation. However, I cannot
determine for sure whether suppression of ATF3 by NO is functionally important in this
context. Ultimately, one will need to look at ATF3 KO mice and potentially double KO
with NOS to address this question. Although we identified the Rac1 as an upstream
factor to stimulate iNOS expression and NO synthesis, I do not have data to examine
whether they are under direct regulation or there are intermediate pathways connecting
Rac1 to iNOS. Similar questions also exist regarding the inhibitory effects of NOS on
ATF3 expression. The signaling pathways connecting NOS to ATF3 regulation need to
be elucidated. Finally, the expression of cell cycle inhibitor p57 was clearly increased in
all three NOS KO mice. But it is not clear whether upregulation of p57 and other
prehypertrophic markers is secondary to premature cell cycle exit or independently
regulated by NOS/NO. Addressing these questions will lead to a better understanding of
cartilage biology.
5.3.2 Limitations of the experimental models
My results show that all three NOS share a common pathway in regulating
chondrocyte proliferation and differentiation. However, phenotypes are most severe in
eNOS KO mice, and minor differences between the three strains were seen (Table 5.1).
Further investigation of any double or triple NOS KO mice are required to address
redundancy and functional overlap between the three NOS genes. We have attempted
such crossings, but were not successful in obtaining double KO mice. The use of
conditional alleles that allow cartilage-specific deletion (and thus limit other phenotypes
that could contribute to lethality) would be one approach to overcome this limitation.
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Our mutant strains are conventional KO mice where the NOS genes have been
deleted in each cell of the body. Therefore, some of the observed phenotypes could be
due to primary defects in other cell types (e.g. the vasculature or endocrine organs). The
similarity of our results in organ cultures and KO mice supports that the observed effects
are due to direct effects of NO signaling in chondrocytes. However, ideally these results
should be confirmed by in vivo experiments. The generation of conditional mutants using
the Cre-lox system in combination with a cartilage-specific Cre driver line would be the
best approach to address this question.
Another major concern of this project is the variable phenotype of the KO mice,
especially in eNOS KO mice. Some KO mice (whole litters) showed a severe reduction
in size compared to other KO mice. Based on this observation, we increased the sample
size of the KO mice to at least eight litters to reach statistical difference. Growth of these
KO mice is measured by body length and weight at different stages from newborn to six
weeks to compare the difference in skeletal growth. It would be very useful to include
prenatal stages and expand this study to a longer period of time. Moreover, some of the
variance could be due to eNOS effects in other tissues; once again these could be
overcome by the generation of cartilage-specific KO mice.
My data suggest that three NOS KO mice share a common signaling pathway to
suppress cyclin D1 and inhibit chondrocyte proliferation. However, each individual NOS
may respond to different upstream regulators in controlling chondrocyte fate. For
example, we identified Rac 1 as activator of iNOS but not eNOS expression in cartilage.
We do not know now what are the other upstream signaling to regulate eNOS and nNOS
expression in cartilage. Interestingly, we found compensatory mechanisms among these
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three NOS genes in cartilage; unregulated nNOS transcript levels in eNOS-null cartilage;
and upregulated eNOS and iNOS mRNA in nNOS KO mice. This could explain the
variability of the NOS KO phenotypes and the catch up growth of the KO mice after
transient growth retardation at young age.
In this research project, we used primary chondrocyte monolayer culture and tibia
explant culture. The monolayer culture system is an economical and technically simple
model, allowing the culture of a high number of chondrocytes. Primary chondrocytes
were isolated from long bone of E15.5 tibiae. At this stage mineralization and vascular
invasion has just been initiated and a mixture of cell types is probably present (e.g. cells
from primary spongiosa, and perichondrial cells could also be present in the monolayer
cultures). However, cell types other than chondrocytes only represent a small percentage
of the entire cell population. Nevertheless, because of the heterogeneous type of cell
culture we cannot exclude that some of the observed NO effects are also due to the
interference with other cell populations. Moreover, in primary monolayer culture, loss of
chondrocyte phenotype was reported after a long period time of incubation. We limited
the culture time to 48 hours to minimize the effects of this limitation and have not
observed a changes in chondrocyte morphology. Nevertheless, three-dimensional cultures
systems such as micromass cultures (Stanton et al., 2003; Woods et al., 2007b) would be
one way to overcome this limitation.
Tibia explant culture was employed in this project for further validation the
observed effects in vitro. The intact tibia is cultured in serum-free medium and
pharmacological inhibitors can be used to alter signaling pathways in the correct threedimensional context. Cell-cell and cell-matrix interactions are preserved in this system
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and the effects of inhibitors or growth factors can be observed in a growth plate zonespecific manner. On the other hand, the organ culture system removes bone from other
organ systems, such as endocrine and biomechanical environments, and allows us to
study the effects of a single growth factor without influence of other organ systems.
Using this system, I was able to observe specific effects in certain chondrocyte
subpopulations, which would be impossible in a cell culture model.
5.3.3 Limitations of techniques and reagents
Using immunohistochemistry as a main technique in this project has certain
disadvantages, such as the potential for nonspecific signals and difficulties in quantifying
signals. Typically, sections of KO mice or organ culture from at least six independent
trials, and representative images from each trials were analyzed to draw conclusions
based on the immunostaining results (Stanton et al., 2007). Western blotting or RT-PCR
was also conducted to further verify the results of protein or gene expression in
chondrocytes in some key experiments. Controls included the omission of the primary
antibody and, in some cases, use of tissues from KO mice for the protein of interest (e.g.
the different NOS KO lines). Furthermore, expression patterns for proteins examined
corresponded to those described in the literature. Nevertheless, we have to acknowledge
the potential for lack of specificity of antibodies in IHC.
Another technical limitation in this project is that I cannot measure NO levels in
vivo. NO is known to be formed in small amounts in vivo and is rapidly transformed by
interaction with oxygen (Hashimoto et al., 1999), making measurement difficult.
However, use of the fluorescent dye (DAF-FM) provides a sensitive and accurate method
to analyze the relative quantification of NO production from chondrocytes in culture, but
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it cannot give the absolute concentration of NO levels. For in vivo studies, we had to rely
on the use of an antibody for nitrotyrosine as a substitute for measuring NO levels
indirectly.
Another limitation to our study is the reliance on a pharmacological inhibitor,
LNAME, to analyze the role of the NOS/NO in chondrocyte physiology. LNAME
demonstrates potent inhibition of all three NOS proteins (Hashimoto et al., 2006);
however, there are differences in its potency on the different enzymes, (IC50 of eNOS,
iNOS and nNOS are 0.7, 3.9 and 0.65 μM respectively). By using a relatively high
concentration, the inhibition was reported to be effective for all three NOS isoforms
(Hashimoto et al., 2005). We used different concentrations of NOS inhibitors and
measured NO production in parallel to test its effects and optimize the concentration
under our culture conditions.
NO donors gave us the possibility to observe the effects of NO on chondrocyte
without transfection. However, SNAP is a compound that is known to have peroxide
effect to cause cell membrane lipid peroxidation (Kim et al., 2005). Therefore use of
another NO donor helped us to validate the results. NOC-18 (DETA-NO) is a longlasting diazeniumdiolate compound with a half-life of 27 hours (Chikanza et al., 2000).
SIN1 is an inducer of NO and ROS. For the NO donors employed in this project, their
effects on cell proliferation, NO and ROS levels were measured before we used them in
these experiments. All donors had similar effects on the measured parameters.
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5.4 Conclusions
In conclusion, this research project has shown that the NOS/NO signaling
pathway plays important and physiological roles in multiple steps of endochondral bone
formation, in particular in the control of chondrocyte proliferation. My thesis has
identified several molecular mechanisms involved, such as NO suppression of ATF3
expression and subsequent effects on the chondrocyte cell cycle. These studies contribute
to a better understanding of physiological bone growth and may ultimately result in
improved therapeutic strategies for skeletal diseases.

179

5.5 References
Abramson, S. B. (2008). Osteoarthritis and nitric oxide. Osteoarthritis Cartilage
16 Suppl 2, S15-20.
Abramson, S. B., Attur, M., Amin, A. R. and Clancy, R. (2001). Nitric oxide
and inflammatory mediators in the perpetuation of osteoarthritis. Curr Rheumatol Rep 3,
535-41.
Agoston, H., Khan, S., James, C. G., Gillespie, J. R., Serra, R., Stanton, L. A.
and Beier, F. (2007). C-type natriuretic peptide regulates endochondral bone growth
through p38 MAP kinase-dependent and -independent pathways. BMC Dev Biol 7, 18.
Aguirre, J., Buttery, L., O'Shaughnessy, M., Afzal, F., Fernandez de
Marticorena, I., Hukkanen, M., Huang, P., MacIntyre, I. and Polak, J. (2001).
Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in
postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and
activity. Am J Pathol 158, 247-57.
Akarasereenont, P., Mitchell, J. A., Appleton, I., Thiemermann, C. and Vane,
J. R. (1994). Involvement of tyrosine kinase in the induction of cyclo-oxygenase and
nitric oxide synthase by endotoxin in cultured cells. Br J Pharmacol 113, 1522-8.
Amin, A. R. and Abramson, S. B. (1998). The role of nitric oxide in articular
cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 10, 263-8.
Amin, A. R., Attur, M., Patel, R. N., Thakker, G. D., Marshall, P. J., Rediske,
J., Stuchin, S. A., Patel, I. R. and Abramson, S. B. (1997). Superinduction of
cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric
oxide. J Clin Invest 99, 1231-7.
Appleton, C. T., Pitelka, V., Henry, J. and Beier, F. (2007). Global analyses of
gene expression in early experimental osteoarthritis. Arthritis Rheum 56, 1854-68.
Armour, K. E., Armour, K. J., Gallagher, M. E., Godecke, A., Helfrich, M.
H., Reid, D. M. and Ralston, S. H. (2001a). Defective bone formation and anabolic
response to exogenous estrogen in mice with targeted disruption of endothelial nitric
oxide synthase. Endocrinology 142, 760-6.
Armour, K. J., Armour, K. E., van't Hof, R. J., Reid, D. M., Wei, X. Q., Liew,
F. Y. and Ralston, S. H. (2001b). Activation of the inducible nitric oxide synthase
pathway contributes to inflammation-induced osteoporosis by suppressing bone
formation and causing osteoblast apoptosis. Arthritis Rheum 44, 2790-6.
Asou, Y., Nifuji, A., Tsuji, K., Shinomiya, K., Olson, E. N., Koopman, P. and
Noda, M. (2002). Coordinated expression of scleraxis and Sox9 genes during embryonic
development of tendons and cartilage. J Orthop Res 20, 827-33.
Ballock, R. T. and O'Keefe, R. J. (2003). Physiology and pathophysiology of
the growth plate. Birth Defects Res C Embryo Today 69, 123-43.
Ballock, R. T., O'Keefe, R. J. (2003). Physiology and pathophysiology of the
growth plate. Birth Defects Research, Part C, Embryo Today: Review 69, 123-143.
Bartels, C. F., Bukulmez, H., Padayatti, P., Rhee, D. K., van RavenswaaijArts, C., Pauli, R. M., Mundlos, S., Chitayat, D., Shih, L. Y., Al-Gazali, L. I. et al.
(2004). Mutations in the transmembrane natriuretic peptide receptor NPR-B impair

180

skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet
75, 27-34.
Beier, F. (2005). Cell-cycle control and the cartilage growth plate. J Cell Physiol
202, 1-8.
Beier, F., Ali, Z., Mok, D., Taylor, A. C., Leask, T., Albanese, C., Pestell, R.
G. and LuValle, P. (2001). TGFbeta and PTHrP control chondrocyte proliferation by
activating cyclin D1 expression. Mol Biol Cell 12, 3852-63.
Beier, F., Lee, R. J., Taylor, A. C., Pestell, R. G. and LuValle, P. (1999a).
Identification of the cyclin D1 gene as a target of activating transcription factor 2 in
chondrocytes. Proc Natl Acad Sci U S A 96, 1433-8.
Beier, F., Lee, R. J., Taylor, A. C., Pestell, R. G. and LuValle, P. (1999b).
Identification of the cyclin D1 gene as a target of activating transcription factor 2 in
chondrocytes. Proc Natl Acad Sci U S A 96, 1433-8.
Beier, F. and LuValle, P. (2002). The cyclin D1 and cyclin A genes are targets
of activated PTH/PTHrP receptors in Jansen's metaphyseal chondrodysplasia. Mol
Endocrinol 16, 2163-73.
Brandi, M. L., Hukkanen, M., Umeda, T., Moradi-Bidhendi, N., Bianchi, S.,
Gross, S. S., Polak, J. M. and MacIntyre, I. (1995). Bidirectional regulation of
osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci U S A 92, 29548.
Bryan, N. S., Bian, K. and Murad, F. (2009). Discovery of the nitric oxide
signaling pathway and targets for drug development. Front Biosci 14, 1-18.
Bustelo, X. R., Sauzeau, V. and Berenjeno, I. M. (2007). GTP-binding proteins
of the Rho/Rac family: regulation, effectors and functions in vivo. BioEssays 29, 356-70.
Chikuda, H., Kugimiya, F., Hoshi, K., Ikeda, T., Ogasawara, T., Shimoaka,
T., Kawano, H., Kamekura, S., Tsuchida, A., Yokoi, N. et al. (2004). Cyclic GMPdependent protein kinase II is a molecular switch from proliferation to hypertrophic
differentiation of chondrocytes. Genes Dev 18, 2418-29.
Chusho, H., Tamura, N., Ogawa, Y., Yasoda, A., Suda, M., Miyazawa, T.,
Nakamura, K., Nakao, K., Kurihara, T., Komatsu, Y. et al. (2001). Dwarfism and
early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci U S A 98,
4016-21.
Collin-Osdoby, P., Nickols, G. A. and Osdoby, P. (1995). Bone cell function,
regulation, and communication: a role for nitric oxide. J Cell Biochem 57, 399-408.
Colnot, C. (2005). Cellular and molecular interactions regulating skeletogenesis.
J Cell Biochem 95, 688-97.
Diket, A. L., Pierce, M. R., Munshi, U. K., Voelker, C. A., Eloby-Childress,
S., Greenberg, S. S., Zhang, X. J., Clark, D. A. and Miller, M. J. (1994). Nitric oxide
inhibition causes intrauterine growth retardation and hind-limb disruptions in rats. Am J
Obstet Gynecol 171, 1243-50.
Docherty, B. (2007a). Skeletal system. Part one--bone structure. Nurs Times 103,
28-9.
Docherty, B. (2007b). Skeletal system: part four--the appendicular skeleton. Nurs
Times 103, 26-7.

181

Drissi, H., Zuscik, M., Rosier, R. and O'Keefe, R. (2005). Transcriptional
regulation of chondrocyte maturation: potential involvement of transcription factors in
OA pathogenesis. Mol Aspects Med 26, 169-79.
Evans, D. M. and Ralston, S. H. (1996). Nitric oxide and bone. J Bone Miner
Res 11, 300-5.
Feelisch, M. (2008). The chemical biology of nitric oxide--an outsider's
reflections about its role in osteoarthritis. Osteoarthritis Cartilage 16 Suppl 2, S3-S13.
Finder, J. D., Petrus, J. L., Hamilton, A., Villavicencio, R. T., Pitt, B. R. and
Sebti, S. M. (2001). Signal transduction pathways of IL-1beta-mediated iNOS in
pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 281,
L816-23.
Forstermann, U. and Kleinert, H. (1995). Nitric oxide synthase: expression and
expressional control of the three isoforms. Naunyn Schmiedebergs Arch Pharmacol 352,
351-64.
Foster, M. W., Hess, D. T. and Stamler, J. S. (2009). Protein S-nitrosylation in
health and disease: a current perspective. Trends Mol Med 15, 391-404.
Furchgott, R. F. (1999). Endothelium-derived relaxing factor: discovery, early
studies, and identification as nitric oxide. Biosci Rep 19, 235-51.
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J. and Zheng, Y. (2004). Rational
design and characterization of a Rac GTPase-specific small molecule inhibitor. PNAS
101, 7618-7623.
Gauci, S. J., Golub, S. B., Tutolo, L., Little, C. B., Sims, N. A., Lee, E. R.,
Mackie, E. J. and Fosang, A. J. (2008). Modulating chondrocyte hypertrophy in growth
plate and osteoarthritic cartilage. J Musculoskelet Neuronal Interact 8, 308-10.
Goldring, M. B., Tsuchimochi, K. and Ijiri, K. (2006). The control of
chondrogenesis. J Cell Biochem 97, 33-44.
Grassi, F., Fan, X., Rahnert, J., Weitzmann, M. N., Pacifici, R., Nanes, M. S.
and Rubin, J. (2006). Bone re/modeling is more dynamic in the endothelial nitric oxide
synthase(-/-) mouse. Endocrinology 147, 4392-9.
Halawani, D., Mondeh, R., Stanton, L. A. and Beier, F. (2004). p38 MAP
kinase signaling is necessary for rat chondrosarcoma cell proliferation. Oncogene 23,
3726-31.
Harada, N., Iimuro, Y., Nitta, T., Yoshida, M., Uchinami, H., Nishio, T.,
Hatano, E., Yamamoto, N., Yamamoto, Y. and Yamaoka, Y. (2003). Inactivation of
the small GTPase Rac1 protects the liver from ischemia/reperfusion injury in the rat.
Surgery 134, 480-91.
Heasman, S. J. and Ridley, A. J. (2008). Mammalian Rho GTPases: new
insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 9, 690-701.
Hefler, L. A., Reyes, C. A., O'Brien, W. E. and Gregg, A. R. (2001). Perinatal
development of endothelial nitric oxide synthase-deficient mice. Biol Reprod 64, 666-73.
Hess, D. T., Matsumoto, A., Kim, S. O., Marshall, H. E. and Stamler, J. S.
(2005). Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 6, 15066.

182

Hirao, M., Tamai, N., Tsumaki, N., Yoshikawa, H. and Myoui, A. (2006).
Oxygen tension regulates chondrocyte differentiation and function during endochondral
ossification. J Biol Chem 281, 31079-92.
Hoffmann, A. and Gross, G. (2001). BMP signaling pathways in cartilage and
bone formation. Crit Rev Eukaryot Gene Expr 11, 23-45.
Holmbeck, K. and Szabova, L. (2006). Aspects of extracellular matrix
remodeling in development and disease. Birth Defects Res C Embryo Today 78, 11-23.
Holt, C. M. (2000). eNOS inhibition of proliferation: a role for
p21(Sdi1/Cip1/Waf1) and p27(kip1). Cardiovasc Res 47, 640-1.
Hordijk, P. L. (2006). Regulation of NADPH oxidases: the role of Rac proteins.
Circ Res 98, 453-62.
Horton, W. A. (2003). Skeletal development: insights from targeting the mouse
genome. Lancet 362, 560-9.
Hunziker, E. B. (1994). Mechanism of longitudinal bone growth and its
regulation by growth plate chondrocytes. Microsc Res Tech 28, 505-19.
Hunziker, E. B. and Schenk, R. K. (1989). Physiological mechanisms adopted
by chondrocytes in regulating longitudinal bone growth in rats. J Physiol 414, 55-71.
Hwang, P. M., Byrne, D. H. and Kitos, P. A. (1988). Effects of molecular
oxygen on chick limb bud chondrogenesis. Differentiation 37, 14-9.
Ignarro, L. J. (1999). Nitric oxide: a unique endogenous signaling molecule in
vascular biology. Biosci Rep 19, 51-71.
James, C. G., Appleton, C. T., Ulici, V., Underhill, T. M. and Beier, F. (2005).
Microarray analyses of gene expression during chondrocyte differentiation identifies
novel regulators of hypertrophy. Mol Biol Cell 16, 5316-33.
James, C. G., Woods, A., Underhill, T. M. and Beier, F. (2006). The
transcription factor ATF3 is upregulated during chondrocyte differentiation and represses
cyclin D1 and A gene transcription. BMC Mol Biol 7, 30.
Jang, D. and Murrell, G. A. (1998). Nitric oxide in arthritis. Free Radic Biol
Med 24, 1511-9.
Karp, S. J., Schipani, E., St-Jacques, B., Hunzelman, J., Kronenberg, H. and
McMahon, A. P. (2000). Indian hedgehog coordinates endochondral bone growth and
morphogenesis via parathyroid hormone related-protein-dependent and -independent
pathways. Development 127, 543-8.
Karsenty, G. (2003). The complexities of skeletal biology. Nature 423, 316-8.
Karsenty, G. and Wagner, E. F. (2002). Reaching a genetic and molecular
understanding of skeletal development. Dev Cell 2, 389-406.
Kerr, B. A., Otani, T., Koyama, E., Freeman, T. A. and Enomoto-Iwamoto,
M. (2008). Small GTPase protein Rac-1 is activated with maturation and regulates cell
morphology and function in chondrocytes. Exp Cell Res 314, 1301-12.
Kibbe, M. R., Li, J., Nie, S., Watkins, S. C., Lizonova, A., Kovesdi, I.,
Simmons, R. L., Billiar, T. R. and Tzeng, E. (2000). Inducible nitric oxide synthase
(iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation
through p42/44 mitogen-activated protein kinase activation and independent of p53 and
cyclic guanosine monophosphate. J Vasc Surg 31, 1214-28.

183

Kim, H. A., Lee, K. B. and Bae, S. C. (2005). The mechanism of lowconcentration sodium nitroprusside-mediated protection of chondrocyte death. Arthritis
Res Ther 7, R526-35.
Kirimoto, A., Takagi, Y., Ohya, K. and Shimokawa, H. (2005). Effects of
retinoic acid on the differentiation of chondrogenic progenitor cells, ATDC5. J Med Dent
Sci 52, 153-62.
Klein-Nulend, J., Helfrich, M. H., Sterck, J. G., MacPherson, H., Joldersma,
M., Ralston, S. H., Semeins, C. M. and Burger, E. H. (1998). Nitric oxide response to
shear stress by human bone cell cultures is endothelial nitric oxide synthase dependent.
Biochem Biophys Res Commun 250, 108-14.
Koshiji, M. and Huang, L. E. (2004). Dynamic balancing of the dual nature of
HIF-1alpha for cell survival. Cell Cycle 3, 853-4.
Kronenberg, H. M. (2003). Developmental regulation of the growth plate.
Nature 423, 332-6.
Kuzin, B., Roberts, I., Peunova, N. and Enikolopov, G. (1996). Nitric oxide
regulates cell proliferation during Drosophila development. Cell 87, 639-49.
Laubach, V. E., Shesely, E. G., Smithies, O. and Sherman, P. A. (1995). Mice
lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced
death. Proc Natl Acad Sci U S A 92, 10688-92.
Lefebvre, V. and Smits, P. (2005). Transcriptional control of chondrocyte fate
and differentiation. Birth Defects Res C Embryo Today 75, 200-12.
Lotz, M., Hashimoto, S. and Kuhn, K. (1999). Mechanisms of chondrocyte
apoptosis. Osteoarthritis Cartilage 7, 389-91.
Lundberg, J. O., Weitzberg, E. and Gladwin, M. T. (2008). The nitrate-nitritenitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 7, 156-67.
Mackie, E. J., Ahmed, Y. A., Tatarczuch, L., Chen, K. S. and Mirams, M.
(2008). Endochondral ossification: how cartilage is converted into bone in the developing
skeleton. Int J Biochem Cell Biol 40, 46-62.
MacPherson, H., Noble, B. S. and Ralston, S. H. (1999). Expression and
functional role of nitric oxide synthase isoforms in human osteoblast-like cells. Bone 24,
179-85.
Maeda, Y., Ikeda, U., Oya, K., Shimpo, M., Ueno, S., Okada, K., Saito, T.,
Mano, H., Ozawa, K. and Shimada, K. (2000). Endogenously generated nitric oxide by
nitric-oxide synthase gene transfer inhibits cellular proliferation. J Pharmacol Exp Ther
292, 387-93.
Mander, P. and Brown, G. C. (2004). Nitric oxide, hypoxia and brain
inflammation. Biochem Soc Trans 32, 1068-9.
Marshall, H. E., Hess, D. T. and Stamler, J. S. (2004). S-nitrosylation:
physiological regulation of NF-kappaB. Proc Natl Acad Sci U S A 101, 8841-2.
Marshall, H. E. and Stamler, J. S. (2001). Inhibition of NF-kappa B by Snitrosylation. Biochemistry 40, 1688-93.
Mericq, V., Uyeda, J. A., Barnes, K. M., De Luca, F. and Baron, J. (2000).
Regulation of fetal rat bone growth by C-type natriuretic peptide and cGMP. Pediatr Res
47, 189-93.

184

Miyazawa, T., Ogawa, Y., Chusho, H., Yasoda, A., Tamura, N., Komatsu, Y.,
Pfeifer, A., Hofmann, F. and Nakao, K. (2002). Cyclic GMP-dependent protein kinase
II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification.
Endocrinology 143, 3604-10.
Moncada, S. and Higgs, A. (1993). The L-arginine-nitric oxide pathway. N Engl
J Med 329, 2002-12.
Moncada, S., Palmer, R. M. and Higgs, E. A. (1991). Nitric oxide: physiology,
pathophysiology, and pharmacology. Pharmacol Rev 43, 109-42.
Morita, K., Miyamoto, T., Fujita, N., Kubota, Y., Ito, K., Takubo, K.,
Miyamoto, K., Ninomiya, K., Suzuki, T., Iwasaki, R. et al. (2007). Reactive oxygen
species induce chondrocyte hypertrophy in endochondral ossification. J Exp Med 204,
1613-23.
Mungrue, I. N., Bredt, D. S., Stewart, D. J. and Husain, M. (2003). From
molecules to mammals: what's NOS got to do with it? Acta Physiol Scand 179, 123-35.
Murad, F. (1999). Discovery of some of the biological effects of nitric oxide and
its role in cell signaling. Biosci Rep 19, 133-54.
Murad, F. (2006). Shattuck Lecture. Nitric oxide and cyclic GMP in cell
signaling and drug development. N Engl J Med 355, 2003-11.
Mushtaq, T., Bijman, P., Ahmed, S. F. and Farquharson, C. (2004). Insulinlike growth factor-I augments chondrocyte hypertrophy and reverses glucocorticoidmediated growth retardation in fetal mice metatarsal cultures. Endocrinology 145, 247886.
Nakata, S., Tsutsui, M., Shimokawa, H., Suda, O., Morishita, T., Shibata, K.,
Yatera, Y., Sabanai, K., Tanimoto, A., Nagasaki, M. et al. (2008). Spontaneous
myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 117,
2211-23.
Nilsson, A., Ohlsson, C., Isaksson, O. G., Lindahl, A. and Isgaard, J. (1994).
Hormonal regulation of longitudinal bone growth. Eur J Clin Nutr 48 Suppl 1, S150-8;
discussion S158-60.
Nilsson, O., Marino, R., De Luca, F., Phillip, M. and Baron, J. (2005).
Endocrine regulation of the growth plate. Horm Res 64, 157-65.
Okazaki, K. and Iwamoto, Y. (2006). [Matrix gene regulation in cartilage]. Clin
Calcium 16, 1213-19.
Olsen, B. R. (1999). Genetic regulation of skeletal patterning, differentiation, and
growth. Bone 25, 77-9.
Olsen, B. R., Reginato, A. M. and Wang, W. (2000). Bone development. Annu
Rev Cell Dev Biol 16, 191-220.
Ornitz, D. M. and Marie, P. J. (2002). FGF signaling pathways in endochondral
and intramembranous bone development and human genetic disease. Genes Dev 16,
1446-65.
Ortega, N., Behonick, D. J. and Werb, Z. (2004). Matrix remodeling during
endochondral ossification. Trends Cell Biol 14, 86-93.
Osafo, J., Wei, Y., Kenth, G. and Goodyer, C. G. (2005). Growth hormone
during development. Rev Endocr Metab Disord 6, 173-82.

185

Pejchalova, K., Krejci, P. and Wilcox, W. R. (2007). C-natriuretic peptide: an
important regulator of cartilage. Mol Genet Metab 92, 210-5.
Peunova, N., Scheinker, V., Cline, H. and Enikolopov, G. (2001). Nitric oxide
is an essential negative regulator of cell proliferation in Xenopus brain. J Neurosci 21,
8809-18.
Pfeifer, A., Aszodi, A., Seidler, U., Ruth, P., Hofmann, F. and Fassler, R.
(1996). Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent
protein kinase II. Science 274, 2082-6.
Provot, S. and Schipani, E. (2005). Molecular mechanisms of endochondral
bone development. Biochem Biophys Res Commun 328, 658-65.
Ralston, S. H. (1997). The Michael Mason Prize Essay 1997. Nitric oxide and
bone: what a gas! Br J Rheumatol 36, 831-8.
Ralston, S. H., Ho, L. P., Helfrich, M. H., Grabowski, P. S., Johnston, P. W.
and Benjamin, N. (1995). Nitric oxide: a cytokine-induced regulator of bone resorption.
J Bone Miner Res 10, 1040-9.
Reif, A., Schmitt, A., Fritzen, S., Chourbaji, S., Bartsch, C., Urani, A.,
Wycislo, M., Mossner, R., Sommer, C., Gass, P. et al. (2004). Differential effect of
endothelial nitric oxide synthase (NOS-III) on the regulation of adult neurogenesis and
behaviour. Eur J Neurosci 20, 885-95.
Riemer, S., Gebhard, S., Beier, F., Poschl, E. and von der Mark, K. (2002).
Role of c-fos in the regulation of type X collagen gene expression by PTH and PTHrP:
localization of a PTH/PTHrP-responsive region in the human COL10A1 enhancer. J Cell
Biochem 86, 688-99.
Rosa, S. C., Judas, F., Lopes, M. C. and Mendes, A. F. (2008). Nitric oxide
synthase isoforms and NF-kappaB activity in normal and osteoarthritic human
chondrocytes: regulation by inducible nitric oxide. Nitric Oxide 19, 276-83.
Sabanai, K., Tsutsui, M., Sakai, A., Hirasawa, H., Tanaka, S., Nakamura, E.,
Tanimoto, A., Sasaguri, Y., Ito, M., Shimokawa, H. et al. (2008). Genetic disruption of
all NO synthase isoforms enhances BMD and bone turnover in mice in vivo: involvement
of the renin-angiotensin system. J Bone Miner Res 23, 633-43.
Sato, J., Nair, K., Hiddinga, J., Eberhardt, N. L., Fitzpatrick, L. A., Katusic,
Z. S. and O'Brien, T. (2000). eNOS gene transfer to vascular smooth muscle cells
inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis. Cardiovasc
Res 47, 697-706.
Sawada, N., Salomone, S., Kim, H.-H., Kwiatkowski, D. J. and Liao, J. K.
(2008). Regulation of Endothelial Nitric Oxide Synthase and Postnatal Angiogenesis by
Rac1. Circ Res 103, 360-368.
Scher, J. U., Pillinger, M. H. and Abramson, S. B. (2007). Nitric oxide
synthases and osteoarthritis. Curr Rheumatol Rep 9, 9-15.
Schipani, E., Ryan, H. E., Didrickson, S., Kobayashi, T., Knight, M. and
Johnson, R. S. (2001). Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte
growth arrest and survival. Genes Dev 15, 2865-76.
Shang, Z. J., Li, Z. B. and Li, J. R. (2006). In vitro effects of nitric oxide
synthase inhibitor L-NAME on oral squamous cell carcinoma: a preliminary study. Int J
Oral Maxillofac Surg 35, 539-43.

186

Shesely, E. G., Maeda, N., Kim, H. S., Desai, K. M., Krege, J. H., Laubach, V.
E., Sherman, P. A., Sessa, W. C. and Smithies, O. (1996). Elevated blood pressures in
mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 93, 13176-81.
Shum, L. and Nuckolls, G. (2002). The life cycle of chondrocytes in the
developing skeleton. Arthritis Res 4, 94-106.
Silvestrini, G., Ballanti, P., Patacchioli, F. R., Mocetti, P., Di Grezia, R.,
Wedard, B. M., Angelucci, L. and Bonucci, E. (2000). Evaluation of apoptosis and the
glucocorticoid receptor in the cartilage growth plate and metaphyseal bone cells of rats
after high-dose treatment with corticosterone. Bone 26, 33-42.
Solomon, L. A., Li, J. R., Berube, N. G. and Beier, F. (2009). Loss of ATRX in
chondrocytes has minimal effects on skeletal development. PLoS One 4, e7106.
Stamler, J. S., Lamas, S. and Fang, F. C. (2001). Nitrosylation. the prototypic
redox-based signaling mechanism. Cell 106, 675-83.
Stanton, L. A., Underhill, T. M. and Beier, F. (2003). MAP kinases in
chondrocyte differentiation. Dev Biol 263, 165-75.
Stevens, D. A., Hasserjian, R. P., Robson, H., Siebler, T., Shalet, S. M. and
Williams, G. R. (2000). Thyroid hormones regulate hypertrophic chondrocyte
differentiation and expression of parathyroid hormone-related peptide and its receptor
during endochondral bone formation. J Bone Miner Res 15, 2431-42.
Swierkosz, T. A., Mitchell, J. A., Tomlinson, A., Botting, R. M., Warner, T.
D. and Vane, J. R. (1994). Relationship between different isoforms of nitric oxide
synthase and cyclooxygenase in various cell types. Pol J Pharmacol 46, 587-92.
Teixeira, C. C., Agoston, H. and Beier, F. (2008). Nitric oxide, C-type
natriuretic peptide and cGMP as regulators of endochondral ossification. Dev Biol 319,
171-8.
Teixeira, C. C., Ischiropoulos, H., Leboy, P. S., Adams, S. L. and Shapiro, I.
M. (2005). Nitric oxide-nitric oxide synthase regulates key maturational events during
chondrocyte terminal differentiation. Bone 37, 37-45.
Teixeira, C. C., Mansfield, K., Hertkorn, C., Ischiropoulos, H. and Shapiro,
I. M. (2001). Phosphate-induced chondrocyte apoptosis is linked to nitric oxide
generation. Am J Physiol Cell Physiol 281, C833-9.
Thomas, D. D., Ridnour, L. A., Isenberg, J. S., Flores-Santana, W., Switzer,
C. H., Donzelli, S., Hussain, P., Vecoli, C., Paolocci, N., Ambs, S. et al. (2008). The
chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med
45, 18-31.
Tomlinson, A., Appleton, I., Moore, A. R., Gilroy, D. W., Willis, D., Mitchell,
J. A. and Willoughby, D. A. (1994). Cyclo-oxygenase and nitric oxide synthase
isoforms in rat carrageenin-induced pleurisy. Br J Pharmacol 113, 693-8.
Tranguch, S. and Huet-Hudson, Y. (2003). Decreased viability of nitric oxide
synthase double knockout mice. Mol Reprod Dev 65, 175-9.
Ulibarri, J. A., Mozdziak, P. E., Schultz, E., Cook, C. and Best, T. M. (1999).
Nitric oxide donors, sodium nitroprusside and S-nitroso-N-acetylpencillamine, stimulate
myoblast proliferation in vitro. In Vitro Cell Dev Biol Anim 35, 215-8.

187

van't Hof, R. J., Macphee, J., Libouban, H., Helfrich, M. H. and Ralston, S.
H. (2004). Regulation of bone mass and bone turnover by neuronal nitric oxide synthase.
Endocrinology 145, 5068-74.
van't Hof, R. J. and Ralston, S. H. (1997). Cytokine-induced nitric oxide
inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing
osteoclast activity. J Bone Miner Res 12, 1797-804.
van't Hof, R. J. and Ralston, S. H. (2001). Nitric oxide and bone. Immunology
103, 255-61.
van den Berg, W. B. (2001). Lessons from animal models of osteoarthritis. Curr
Opin Rheumatol 13, 452-6.
van der Eerden, B. C., Karperien, M. and Wit, J. M. (2003). Systemic and
local regulation of the growth plate. Endocr Rev 24, 782-801.
Vane, J. R., Mitchell, J. A., Appleton, I., Tomlinson, A., Bishop-Bailey, D.,
Croxtall, J. and Willoughby, D. A. (1994). Inducible isoforms of cyclooxygenase and
nitric-oxide synthase in inflammation. Proc Natl Acad Sci U S A 91, 2046-50.
Vega, F. M. and Ridley, A. J. (2007). SnapShot: Rho family GTPases. Cell 129,
1430.
Vega, F. M. and Ridley, A. J. (2008). Rho GTPases in cancer cell biology. FEBS
Lett 582, 2093-101.
Wagner, E. F. and Karsenty, G. (2001). Genetic control of skeletal
development. Curr Opin Genet Dev 11, 527-32.
Wang, G. and Beier, F. (2005). Rac1/Cdc42 and RhoA GTPases antagonistically
regulate chondrocyte proliferation, hypertrophy, and apoptosis. J Bone Miner Res 20,
1022-31.
Wang, G., Woods, A., Agoston, H., Ulici, V., Glogauer, M. and Beier, F.
(2007). Genetic ablation of Rac1 in cartilage results in chondrodysplasia. Dev Biol 306,
612-23.
Wang, G., Woods, A., Sabari, S., Pagnotta, L., Stanton, L. A. and Beier, F.
(2004). RhoA/ROCK signaling suppresses hypertrophic chondrocyte differentiation. J
Biol Chem 279, 13205-14.
Wang, Y., Nishida, S., Sakata, T., Elalieh, H. Z., Chang, W., Halloran, B. P.,
Doty, S. B. and Bikle, D. D. (2006). Insulin-like growth factor-I is essential for
embryonic bone development. Endocrinology 147, 4753-61.
Wang, Z. Q., Ovitt, C., Grigoriadis, A. E., Mohle-Steinlein, U., Ruther, U.
and Wagner, E. F. (1992). Bone and haematopoietic defects in mice lacking c-fos.
Nature 360, 741-5.
Woods, A., James, C. G., Wang, G., Dupuis, H. and Beier, F. (2009a). Control
of chondrocyte gene expression by actin dynamics: a novel role of cholesterol/Ror-alpha
signalling in endochondral bone growth. J Cell Mol Med 13, 3497-516.
Woods, A., James, C. G., Wang, G., Dupuis, H. and Beier, F. (2009b). Control
of Chondrocyte Gene Expression by Actin Dynamics: A Novel Role of
Cholesterol/Roralpha Signaling in Endochondral Bone Growth. J Cell Mol Med.
Woods, A., James, C. G., Wang, G., Dupuis, H. and Beier, F. (2009c). Control
of Chondrocyte Gene Expression by Actin Dynamics: A Novel Role of

188

Cholesterol/Roralpha Signaling in Endochondral Bone Growth. J Cell Mol Med 13,
3497-3516.
Woods, A., Wang, G. and Beier, F. (2005). RhoA/ROCK signaling regulates
Sox9 expression and actin organization during chondrogenesis. J Biol Chem 280, 1162634.
Woods, A., Wang, G., Dupuis, H., Shao, Z. and Beier, F. (2007a). Rac1
Signaling Stimulates N-cadherin Expression, Mesenchymal Condensation, and
Chondrogenesis. J. Biol. Chem. 282, 23500-23508.
Woods, A., Wang, G., Dupuis, H., Shao, Z. and Beier, F. (2007b). Rac1
signaling stimulates N-cadherin expression, mesenchymal condensation, and
chondrogenesis. J Biol Chem 282, 23500-8.
Yan, Q., Feng, Q. and Beier, F. (2010). Endothelial nitric oxide synthase
deficiency in mice results in reduced chondrocyte proliferation and endochondral bone
growth. Arthritis Rheum 62, 2013-22.
Yasoda, A., Kitamura, H., Fujii, T., Kondo, E., Murao, N., Miura, M.,
Kanamoto, N., Komatsu, Y., Arai, H. and Nakao, K. (2009). Systemic administration
of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias.
Endocrinology 150, 3138-44.
Yasoda, A., Komatsu, Y., Chusho, H., Miyazawa, T., Ozasa, A., Miura, M.,
Kurihara, T., Rogi, T., Tanaka, S., Suda, M. et al. (2004). Overexpression of CNP in
chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 10,
80-6.
Yasoda, A. and Nakao, K. (2009). [Hormones and osteoporosis update. Effects
of natriuretic peptides on endochondral bone growth]. Clin Calcium 19, 1003-8.
Yoon, W. H., Jung, Y. J., Kim, T. D., Li, G., Park, B. J., Kim, J. Y., Lee, Y.
C., Kim, J. M., Park, J. I., Park, H. D. et al. (2004). Gabexate mesilate inhibits colon
cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and
angiogenesis. Clin Cancer Res 10, 4517-26.
Zelzer, E. and Olsen, B. R. (2003). The genetic basis for skeletal diseases.
Nature 423, 343-8.

189
APPENDIX A

JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS
Aug 06, 2010

This is a License Agreement between Qian Yan ("You") and John Wiley and Sons ("John
Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license consists
of your order details, the terms and conditions provided by John Wiley and Sons, and the
payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
License Number

2483310496524

License date

Aug 06, 2010

Licensed content publisher

John Wiley and Sons

Licensed content publication

Arthritis & Rheumatism

Licensed content title
Endothelial nitric oxide synthase deficiency in mice
results in reduced chondrocyte proliferation and endochondral bone growth
Licensed content author

Yan Qian, Feng Qingping, Beier Frank

Licensed content date

Mar 30, 2010

Start page

2013

End page

2022

Type of use

Dissertation/Thesis

Requestor type

Author of this Wiley article

Format

Print and electronic

Portion

Full article

Will you be translating?

No

190
Order reference number
Total

0.00 USD

Terms and Conditions
TERMS AND CONDITIONS
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc.
or one if its group companies (each a “Wiley Company”) or a society for whom a Wiley
Company has exclusive publishing rights in relation to a particular journal (collectively
“WILEY”). By clicking “accept” in connection with completing this licensing
transaction, you agree that the following terms and conditions apply to this transaction
(along with the billing and payment terms and conditions established by the Copyright
Clearance Center Inc., (“CCC’s Billing and Payment terms and conditions”), at the time
that you opened your Rightslink account (these are available at any time at
http://myaccount.copyright.com).
Terms and Conditions
1. The materials you have requested permission to reproduce (the "Materials") are
protected by copyright.
2. You are hereby granted a personal, non-exclusive, non-sublicensable, non-transferable,
worldwide, limited license to reproduce the Materials for the purpose specified in the
licensing process. This license is for a one-time use only with a maximum distribution
equal to the number that you identified in the licensing process. Any form of
republication granted by this licence must be completed within two years of the date of
the grant of this licence (although copies prepared before may be distributed thereafter).
Any electronic posting of the Materials is limited to one year from the date permission is
granted and is on the condition that a link is placed to the journal homepage on Wiley’s
online journals publication platform at www.interscience.wiley.com. The Materials shall
not be used in any other manner or for any other purpose. Permission is granted subject to
an appropriate acknowledgement given to the author, title of the material/book/journal
and the publisher and on the understanding that nowhere in the text is a previously
published source acknowledged for all or part of this Material. Any third party material is
expressly excluded from this permission.
3. With respect to the Materials, all rights are reserved. No part of the Materials may be
copied, modified, adapted, translated, reproduced, transferred or distributed, in any form
or by any means, and no derivative works may be made based on the Materials without
the prior permission of the respective copyright owner. You may not alter, remove or
suppress in any manner any copyright, trademark or other notices displayed by the
Materials. You may not license, rent, sell, loan, lease, pledge, offer as security, transfer or
assign the Materials, or any of the rights granted to you hereunder to any other person.

191
4. The Materials and all of the intellectual property rights therein shall at all times remain
the exclusive property of John Wiley & Sons Inc or one of its related companies
(WILEY) or their respective licensors, and your interest therein is only that of having
possession of and the right to reproduce the Materials pursuant to Section 2 herein during
the continuance of this Agreement. You agree that you own no right, title or interest in or
to the Materials or any of the intellectual property rights therein. You shall have no rights
hereunder other than the license as provided for above in Section 2. No right, license or
interest to any trademark, trade name, service mark or other branding ("Marks") of
WILEY or its licensors is granted hereunder, and you agree that you shall not assert any
such right, license or interest with respect thereto.
5. WILEY DOES NOT MAKE ANY WARRANTY OR REPRESENTATION OF ANY
KIND TO YOU OR ANY THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY,
WITH RESPECT TO THE MATERIALS OR THE ACCURACY OF ANY
INFORMATION CONTAINED IN THE MATERIALS, INCLUDING, WITHOUT
LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY,
ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR
PURPOSE, USABILITY, INTEGRATION OR NON-INFRINGEMENT AND ALL
SUCH WARRANTIES ARE HEREBY EXCLUDED BY WILEY AND WAIVED BY
YOU.
6. WILEY shall have the right to terminate this Agreement immediately upon breach of
this Agreement by you.
7. You shall indemnify, defend and hold harmless WILEY, its directors, officers, agents
and employees, from and against any actual or threatened claims, demands, causes of
action or proceedings arising from any breach of this Agreement by you.
8. IN NO EVENT SHALL WILEY BE LIABLE TO YOU OR ANY OTHER PARTY
OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL,
INCIDENTAL, INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER
CAUSED, ARISING OUT OF OR IN CONNECTION WITH THE DOWNLOADING,
PROVISIONING, VIEWING OR USE OF THE MATERIALS REGARDLESS OF THE
FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, BREACH OF
WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE
(INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF
PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD
PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY
LIMITED REMEDY PROVIDED HEREIN.
9. Should any provision of this Agreement be held by a court of competent jurisdiction to
be illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve
as nearly as possible the same economic effect as the original provision, and the legality,
validity and enforceability of the remaining provisions of this Agreement shall not be

192
affected or impaired thereby.
10. The failure of either party to enforce any term or condition of this Agreement shall
not constitute a waiver of either party's right to enforce each and every term and
condition of this Agreement. No breach under this agreement shall be deemed waived or
excused by either party unless such waiver or consent is in writing signed by the party
granting such waiver or consent. The waiver by or consent of a party to a breach of any
provision of this Agreement shall not operate or be construed as a waiver of or consent to
any other or subsequent breach by such other party.
11. This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
12. These terms and conditions together with CCC’s Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes all
prior agreements and representations of the parties, oral or written. This Agreement may
not be amended except in a writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives, and
authorized assigns.
13. In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC’s Billing and Payment terms and conditions,
these terms and conditions shall prevail.
14. WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC’s Billing and Payment terms
and conditions.
15. This Agreement shall be governed by and construed in accordance with the laws of
England and you agree to submit to the exclusive jurisdiction of the English courts.
16. Other Terms and Conditions:
BY CLICKING ON THE "I ACCEPT" BUTTON, YOU ACKNOWLEDGE THAT
YOU HAVE READ AND FULLY UNDERSTAND EACH OF THE SECTIONS OF
AND PROVISIONS SET FORTH IN THIS AGREEMENT AND THAT YOU ARE IN
AGREEMENT WITH AND ARE WILLING TO ACCEPT ALL OF YOUR
OBLIGATIONS AS SET FORTH IN THIS AGREEMENT.
V1.2
Gratis licenses (referencing $0 in the Total field) are free. Please retain this
printable license for your reference. No payment is required.

193
If you would like to pay for this license now, please remit this license along with
your payment made payable to "COPYRIGHT CLEARANCE CENTER"
otherwise you will be invoiced within 48 hours of the license date. Payment should
be in the form of a check or money order referencing your account number and this
invoice number RLNK10827948.
Once you receive your invoice for this order, you may pay your invoice by credit
card. Please follow instructions provided at that time.
Make Payment To:
Copyright Clearance Center
Dept 001
P.O. Box 843006
Boston, MA 02284-3006
If you find copyrighted material related to this license will not be used and wish to
cancel, please contact us referencing this license number 2483310496524 and noting
the reason for cancellation.
Questions? customercare@copyright.com or +1-877-622-5543 (toll free in the US) or
+1-978-646-2777.

194
APPENDIX B

195
CURRICULUM VITAE

Qian Yan
Department of Physiology & Pharmacology
Schulich School of Medicine & Dentistry
University of Western Ontario
London, ON, Canada
N6A 5C1

University Education
University

Year Received
or Expected

Degree

Discipline

China Pharmaceutical
University

HBSc

Pharmacy

2000

The University of
Western Ontario

MSc

Pharmacology&
Toxicology

2006

The University of
Western Ontario

PhD

Physiology&
Dev. Biology

2010

Awards & Scholarships
•
•
•
•

•
•
•

Schulich Scholarship for Medical Research, Schulich School of Medicine &
Dentistry, The University of Western Ontario, 2007-2010, $795 each year
Western Graduate Research Scholarship, The University of Western Ontario,
2007-2010, $1,366 each year
Western Graduate Research Scholarship, The University of Western Ontario,
2004-2007, $6,600 each year
Academic Scholarships for Undergraduate Studies, Faculty of Pharmacy, China
Pharmaceutical University, 1996-2000, $2000 each year

Travel Award – Gordon Research Conference, Bone & Teeth, Maine,
Massachusetts, 2009, $500
Travel Award – Gordon Research Seminar, Bone & Teeth, Maine, Massachusetts
2009, $500
Best Poster – Margaret Moffat Research Day, Schulich School of Medicine &
Dentistry, The University of Western Ontario, 2008, $500

196
•

Best Poster -- The International Conference on Chinese Medicinal Use, CHIR,
Vancouver, Canada, 2005, $500

Teaching Experience
•
•
•
•

Graduate Teaching Assistant, Physiology 465, Regulatory and Integrative
Neurophysiology. The University of Western Ontario, 2007-2009
Graduate Teaching Assistant, Pharmacology & Toxicology 443, The University of
Western Ontario, 2007-2008
Graduate Teaching Assistant, Pharmcology & Toxicology 358, Principles of Drug
Action, The University of Western Ontario, 2006-2007
Graduate Teaching Assistant, BMSc 400 Medical Sciences Laboratory, The
University of Western Ontario, 2004-2006

Academic Service
•

Program Volunteer, Let’s Talk Science Program, The University of Western
Ontario, 2005-2006

Peer-Reviewed Publications
•
•
•
•
•
•
•

Yan Q., Feng Q., Beier F. (2010). Endothelial nitric oxide synthase deficiency in
mice results in reduced chondrocyte proliferation and endochondral bone growth.
Arthritis & Rheum 62(7):2013-2022.
Wang, G.*, Yan, Q. *, Woods, A., Feng, Q. and Beier, F. iNOS/nitric oxide
signaling mediates the mitogenic activity of Rac1 during endochondral bone
growth. (*contributed equally). Revision will be submitted to J. of Cell Science.
Yan, Q., Feng, Q. and Beier, F. Reduced chondrocyte proliferation, increased
apoptosis and premature differentiation in neuronal nitric oxide synthase-deficient
mice. Submitted to Arthritis Res Ther.
Liu, H., Yan, Q., (2002) Protective Effects of Baicalin on Myocardial Injury
induced by Ischemia and Reperfusion in Rats. Journal of Railway Medical
Science. 18(2)198-208
Yan, Q., Li, Y., (2001) The Immune Effect of Chinese Drug Fengshikang-1.
Journal of Railway Medical Science. 29(6).33-386
Liu, H., Xu, D., Yan, Q., et al. (1999) Pharmacokinetic study on Colonic -coated
Oral Thymopeptidin 1&2. Journal of Biochemistry. 26(11). 369-375
Liu, H., Wang, H., Pu, P., Pu, J., Xu, D., Yan, Q., et al. (1998) Chemical and
Pharmacological research of Chinese Drug Mohanlian. Journal of Chinese
Drugs. 23(11) 680

197
Manuscript in Preparation:
•
•

Yan, Q., Beier, F. Nitric oxide and Bone. (Review, in preparation),
Yan, Q., E.M.K. Lui Protective effects of an aqueous extract of Salviae
miltiorrhizae (Danshen) against homocysteine-induced loss of vascular reactivity
in rats. Life Science. (In preparation)

Textbooks
•

Zhao, L., Yan, Q., (2000) Instruction of pharmacological experiments for
continual education students. Press of Medical School, Southeast University.

Abstracts & Presentations
•
•
•
•
•
•
•
•
•
•

Abstract: Yan, Q., Feng, Q., Beier, F. Reduced chondrocyte proliferation and
endochondral bone formation in endothelial nitric oxide synthase deficient mice.
Osteoarthritis & Cartilage (2009) S1.
Abstract: Wang, G., Yan, Q. Rac1/iNOS/nitric oxide signalling is required for
chondrocyte proliferation and endochondral bone growth. OR18. Bone 43(2008)
S32
Oral presentation: Endothelial nitric oxide synthase deficiency results in reduced
chondrocyte proliferation and endochondral bone growth. 6th Canadian Nitric
Oxide Society Conference. London, Canada. 2010.
Oral presentation: Reduced chondrocyte proliferation and bone formation in
endothelial nitric oxide synthase dificent mice. Gordon Research Seminar &
Conference. Massachusetts, US. 2009.
Oral presentation: Reduced chondrocyte proliferation and bone formation in
endothelial nitric oxide synthase deficient mice. Great Lakes Mammalian
Development Meeting, Toronto, Canada. 2009.
Poster presentation; Endothelial nitric oxide synthase deficiency results in
reduced chondrocyte proliferation and endochondral bone growth. Developmental
biology Research Day, London, Canada, 2010.
Poster presentation: Endothelial nitric oxide synthase deficiency results in
reduced chondrocyte proliferation and endochondral bone growth. 16th Canadian
Connective Tissue Conference, Toronto, Canada. 2010.
Poster presentation: Endothelial nitric oxide synthase deficiency results in
reduced chondrocyte proliferation and endochondral bone growth. Great Lakes
Mammalian Development Meeting, Toronto, Canada. 2010.
Poster presentation: Reduced chondrocyte proliferation and bone formation in
endothelial nitric oxide synthase deficient mice. Gordon Research Conference.
Massachusetts, US. 2009.
Poster presentation: Reduced chondrocyte proliferation and bone formation in
endothelial nitric oxide synthase deficient mice. Great Lakes Mammalian

198

•
•

•
•
•
•
•
•

Development Meeting, Toronto, Canada. 2009.
Poster presentation: Reduced chondrocyte proliferation and bone formation in
endothelial nitric oxide synthase deficient mice. Margaret Moffat Research Day,
The University of Western Ontario, London, Canada. 2009.
Poster presentation: Reduced chondrocyte proliferation and bone formation in
endothelial nitric oxide synthase deficient mice. Department of Physiology &
Pharmacology Research Day, The University of Western Ontario, London,
Canada. 2009.
Poster presentation: iNOS/nitric oxide signaling is required for chondrocyte
proliferation during endochondral bone growth. 14th Canadian Connective Tissue
Conference, Montreal, Canada. 2008.
Poster presentation: Loss of endothelial nitric oxide synthase (eNos) leads to
reduced chondrocyte proliferation and endochondral bone formation. Great Lakes
Mammalian Development Meeting, Toronto, Canada. 2008.
Poster presentation: NOS/NO signaling in endochondral bone formation.
Margaret Moffat Research Day, The University of Western Ontario, London,
Canada. 2008.
Poster presentation: NOS/NO signaling in endochondral bone formation.
Department of Physiology & Pharmacology Research Day, The University of
Western Ontario, London, Canada. 2008.
Poster presentation: Inhibition of NOS/NO pathway regulates differentiation of
chondrocyte. 13th Canadian Connective Tissue Conference, Toronto, Canada,
2007.
Poster presentation: Inhibition of NOS/NO signaling in chondrocyte. Margaret
Moffat Research Day, The University of Western Ontario, London, Canada. 2007.

Academic Contracts
•
•
•

Graduate Research Assistant, Department of Physiology and Pharmacology,
University of Western Ontario, London, Canada, 2004-2010
Research Assistant, Middlesex-London Health Unit, London, Canada, 2004-2006
Assistant Professor, Clinical Pharmaceutical Lab, Medical School, Southeast
University, Nanjing, China, 2000--2003

